Biocracked

DHA ga Kwakwalwa: Watanni 12 na Rage Raguwa a Hippocampus a MCI

Nova Chen — Sat, 17 Oct 2026 07:31:31 GMT

# DHA ga Kwakwalwa: Watanni 12 na Rage Raguwa a Hippocampus a MCI Hippocampus, tunawa‑mashigin da yake a ƙasa da tsakiyar kwakwalwa, yana ƙara raguwa da sauri a cikin waɗanda ke da Matsakaicin Nakasa na Tunani (MCI). Shekaru da dama, shawarwarin da aka ba da su suna nuni da a tsaya a jira. Sai dai yanzu wani gwaji mai ƙau‑kare, mai ƙauracewa da dub dub, a cikin manya masu MCI ya nuna cewa, shan DHA (omega‑3 da ke ƙunshe sosai a ƙwayoyin kwakwalwa) kowace rana na tsawon shekara guda na iya rage wannan raguwar a hoto na MRI kuma ya haɓaka wasu maki na tunani. Sai dai, bayanin cikakke da kuma ƙayyadaddun sharuɗɗa su ma suna da muhimmanci. ## Gwajin: Wanene, Mene ne, da Tsawon Lokaci - **Masu halarta:** manya 240 masu shekaru 65 ko sama da haka, duka suna da MCI; an raba su da ƙa'ida cikin ƙungiyoyi biyu – ɗaya da DHA, ɗaya da placebo. - **Masu kammala:** 219 sun kammala gwajin (110 a ƙungiyar DHA, 109 a placebo). - **Kayan ƙara:** 2 g na DHA a rana, an haɗa da man masara a matsayin placebo. - **Tsawon lokaci:** watanni 12; an auna tunani da MRI a farkon gwaji, a watanni 6 da watanni 12. - **Tsari:** gwajin ƙau‑kare, dub dub, tare da placebo. Adadin 2 g/kwana yana nufin ƙimar ƙara. Bisa ga abin da ke cikin takardar, adadin nan ya samar da kusan 900 mg (0.9 g) na DHA na ainihi a kowace rana – bambanci tsakanin adadin DHA da adadin “man kifi” ko “man algae” da ake sayarwa. Wannan bambanci ya kamata a lura da shi idan aka kwatanta kayayyakin kasuwa. Rukunin DHA ya samu karin serum DHA na kashi 3.85 % yayin da rukunin placebo ya samu kashi 1.06 % kawai. ## Sakamakon MRI: Rage Atrophy a Hippocampus Bayanan hoto su ne maɓallin wannan binciken. A cikin watanni 12, rukunin da ya karɓi DHA ya sha bamban sosai da placebo a cikin: - **Hippocampus hagu** (p = 0.016) - **Hippocampus dama** (p = 0.008) - **Jimillar hippocampus** (p = 0.023) - **Jimillar girman kwakwalwa** (p = 0.032) Abin da aka samu shi ne raguwar atrophy – ba ƙaruwa ba – a dukkan sassan hippocampus. A MCI, ana sa ran asarar wani kashi na sararin hippocampus a kowace shekara, don haka DHA ya rage wannan asara idan aka kwatanta da placebo. Marubutan sun kammala da cewa DHA "ya rage ci gaban atrophy na hippocampus." Duk da haka, takardar ta ba da girman tasiri (η²) mai yawa, kamar 0.757 ga hippocampus dama. A nan ya kamata a yi hankali har sai ƙungiyoyi masu zaman kansu sun maimaita sakamakon. ## Sakamakon Tunani: IQ, Bayani da Digit Span An auna ƙwarewar tunani da tsarin Wechsler. Idan aka kwatanta da placebo, rukunin DHA ya nuna ci gaba mai ma'ana a: - **IQ duka‑duka** (p = 0.039) - **Gwajin Bayani** (ƙwaƙwalwar kalmomi da ilimin gama gari) (p < 0.001) - **Digit Span** (ƙwaƙwalwar aiki) (p < 0.001) Wannan ya nufin ƙaruwa da kimanin maki 10 a IQ, kusan 33 % a Bayani, da kusan 48 % a Digit Span. Waɗannan ƙididdiga sun fito ne daga cikakken bayanin takardar, ba daga taƙaitaccen takaitaccen ba. Suna nuna cewa DHA na iya ƙara aikin tunani a matakan da suka dace. ## Dalilin da ya Sa DHA Zai Iya Kare Kwakwalwa DHA na ɗaya daga cikin manyan kitse masu mahimmanci a kwakwalwa, musamman a membrane ɗin ƙwayoyin ƙanƙara da synapses. Akwai hanyoyi biyu da aka fi danganta su da kariya: 1. **Inganta membrane da aikin receptor.** DHA da ke cikin membrane na ƙwayoyin ƙanƙara na iya sanya membrane ya zama laushi, ya inganta hanyoyin receptors da sinadaran alama, wanda ke tallafawa sadarwar synaptic da juriya ga tsufa. 2. **Tallafa wa BDNF.** Brain‑Derived Neurotrophic Factor (BDNF) yana ƙarfafa ƙwayoyin ƙanƙara su tsira, su girma, su haɗa. Ana tunanin DHA na ƙarfafa siginar BDNF, wanda zai iya taimakawa kiyaye yankunan kamar hippocampus. Waɗannan su ne ra'ayoyin da ake da su, amma wannan gwaji ba a tsara shi ne don tabbatar da su ba. Binciken lura ya haɗa cin DHA da rage haɗarin Alzheimer, kuma wannan RCT ya ƙara ƙarfafa ra'ayin tsoma DHA a cikin rukunin da ke da babban haɗari. ## Yadda Wannan Ke Daidaita Da Gwaje‑Gwajen Omega‑3 Masu Bambanci Idan omega‑3 na da fa'ida ga kwakwalwa, me ya sa manyan gwaje‑gwaje a cikin manya masu lafiya suka gaza? Nazarin kamar VITAL da sashen tunani na DO‑HEALTH sun ba da sakamako marasa daidaito ko babu sakamako kwata‑kwata. Dalilai da yawa na iya haifar da wannan gibin: - **Ƙungiyar mutane:** Masu lafiya ba su da raguwar tunani da yawa don a rage, don haka fa'ida ba ta bayyana ba. Mutanen da ke da MCI suna a kan matakin da zai nuna tasirin DHA. - **Matsayin asali:** Mutanen da ke cin kifi akai‑akai na iya riga sun samu matakin DHA mai girma, haka kuma ba su da bukatar ƙara. - **Nau'in da adadi:** Yawancin gwaje‑gwaje sun yi amfani da haɗin EPA/DHA a ƙananan adadin DHA. - **Tsawon lokaci da manufa:** Gwaje‑gwajen a cikin mutane masu lafiya na iya zama gajere don a ga tasiri. Gwajin Tianjin ya nuna cewa fa'idar DHA na iya iyakantuwa ga waɗanda suka nuna alamar matsalolin tunani tun da wuri. ## Abubuwan Da Za A Iya Amfani Da Su - **Adadi:** Gwajin ya yi amfani da 2 g/kwana (kusan 0.9 g na DHA). Duba alamar “DHA” a kowane serva, ba kawai “man kifi” ba. - **DHA vs EPA:** Wannan gwajin ya gwada DHA kai tsaye. EPA yana da amfani ga lafiyar zuciya, amma hujjar gina kwakwalwa ta fi mayar da hankali ga DHA. Idan burinka shi ne ƙara ƙwaƙwalwar tunawa, nemi samfurin da ke da yawa DHA. - **Man algae vs man kifi:** Duka na samar da DHA. Man algae ya fi dacewa ga masu cin ganyayyaki da vegans, kuma yana samuwa daga tushen DHA kai tsaye. Man kifi ma yana aiki, amma za ka iya buƙatar ƙarin kwayoyi don kai daidai adadin DHA. - **Lokaci:** Shanya da abinci mai mai don ƙara narkewa da rage wari. - **Wa ya kamata ya yi amfani da shi:** Manyan da ke da korafin tunawa ko an tantance su da MCI – su tattauna da likita kafin fara. - **Tsaro:** Omega‑3 na iya sanya ƙaramin tasirin narkewar jini a manyan adadi. Idan kana shan warfarin, antiplatelet, ko wasu magungunan da ke shafar jini, ko kana shirin tiyata, ka tattauna da likita. ## Iyakokin Bayani - **Gwaji guda, wuri guda.** Wannan bincike na cibiyar guda a Sin, sakamakonsa na iya rashin dacewa da al'ummomi, abinci, ko yanayin kiwon lafiya daban‑daban. - **MCI kawai.** Ba za a iya fitar da sakamakon ga mutane masu lafiya ko waɗanda suka riga sun sami dementia ba. - **Placebo.** Man masara yana da amfani a matsayin placebo, amma kowane man placebo na iya haifar da tambayoyi game da inganci. - **MRI da maki ba su daidai da hana dementia.** Suna nuna raguwar atrophy da inganta maki, amma ba su nufin cikakken kariya daga cutar dementia ba. - **Bukatar maimaitawa.** Marubutan sun jaddada buƙatar ƙarin gwaje‑gwaje na dogon lokaci da manyan ƙungiyoyi. ## Kammalawa A cikin manya 219 da suka kammala gwaji, DHA 2 g/kwana (kusan 0.9 g na DHA a zahiri) na tsawon watanni 12 ya rage raguwar hippocampus kuma ya haɓaka maki masu alaƙa da IQ idan aka kwatanta da placebo. Sakamakon alƙawari ne, yana da tushe a ilimin halitta, amma yana fitowa ne daga gwaji guda. Don manya da ke da damuwar tunawa, ƙara DHA na iya zama zaɓi mai ma'ana a tattaunawa da likita, ba zai maye gurbin cikakken kimantawa da sauran al'adun kariya ga kwakwalwa ba.

Anserine, Dipeptide Daga Nonon Kaza, Ya Ƙara Ƙarfi Ga Masu MCI a Ƙwaƙwalwa

Nova Chen — Sat, 17 Oct 2026 07:26:45 GMT

# Anserine, Dipeptide Daga Nonon Kaza, Ya Ƙara Ƙarfi Ga Masu MCI a Ƙwaƙwalwa ## Takaitaccen Bayani Anserine, wani dipeptide da ake samu a nonon kaza, ya ba da sakamako mai ɗimbin tasiri a cikin mutanen da ke da **mild cognitive impairment** (MCI). A cikin gwajin bazuwar da ya ɗauki makonni 12, shan miligram 500 a kowace rana ya haɓaka maki **1.9** a gwajin **Mini‑Mental State Examination (MMSE)**, yayin da ƙungiyar placebo ba ta samu wani canji ba (p = 0.036). An yi zaton yadda anserine ke aiki ne ta hanyar tsarewa ko ɗaukar sinadarin **hypochlorous acid (HClO)** – wani kwayoyin da ke ƙara kumburin kwakwalwa. Sakamakon ya dace da binciken haɗin *carnosine* da kuma nazarin meta na 2024 da ya nuna ingantaccen **delayed recall**. Duk da haka, an gudanar da wannan bincike kan mutane **30** kacal, kuma an yi amfani da gwaji guda ɗaya, don haka abin da aka gano yana buƙatar ƙarin tantancewa. ## Bayanin Gwaji Wani ƙaramar gwaji a Japan ya ba da sakamako mai sha'awa: mutane masu **MCI** sun sha miligram 500 na anserine – dipeptide da ake samu a nonon kaza da kuma kifi – a kowace rana. Bayan makonni 12, maki a gwajin MMSE sun tashi kusan maki **2**, yayin da rukunin placebo ba su sami wani sauyi ba. **Anserine** ba shi da suna a manyan shagunan ƙari, amma yana da tarihin bincike da ke girma a hankali. Wannan gwajin bazuwar da aka wallafa a shekarar 2021 a mujallar *Aging* shi ne ɗaya daga cikin muhimman abubuwan da suka fito, kuma yana bukatar a karanta shi da hankali. ## Menene Anserine? Anserine (**beta‑alanyl‑3‑methyl‑L‑histidine**) shi ne **dipeptide**, wato haɗin amino acid biyu. Yana da alaka sosai da **carnosine**, wani sinadari da aka fi sani da tasirin antioxidant da anti‑glycation. Dukansu suna cikin rukunin **histidine‑containing dipeptides**. Anserine yana da yawa a tsokokin tsuntsaye da kifi. Nonon kaza na daga cikin manyan tushen sa, haka kuma tuna da sauran kifi. Shi ya sa ake samun sa a binciken “chicken breast peptide brain”. An sayar da shi a matsayin ƙarin gina jiki, galibi an samo shi daga ƙwayoyin kaza ko kifi, kuma yana yawan haɗuwa da carnosine a samfuran haɗe‑haɗe. ## Tsarin Gwaji: Wanene, Menene, Da Tsawon Lokaci Binciken da **Tatsuhiro Hisatsune** da tawagarsa suka jagoranta a Japan ya kasance gwajin bazuwar da aka yi a tsakanin masu **MCI**. - **Masu Gwajin:** Mutane 58 masu manyan shekaru - **Raba Gwaji:** Mutane 36 da ke da MCI – an ba su 500 mg anserine a rana ko placebo - **Tsawon Lokaci:** Makonni 12 - **Masu Kammala:** Mutane 30 – 15 a kowanne rukuni - **Abubuwan da aka auna:** Mini‑Mental State Examination (MMSE) a farkon gwaji da bayan shan magani ## Sakamako Rukunin da aka ba da anserine ya samu ƙaruwa a MMSE da **+1.9 maki (SD = 2.0)**. Rukunin placebo ya tsaya a **0 maki (SD = 2.8)**. Bambancin ya kasance da muhimmanci a matakin **p = 0.036**. Masana sun ƙara la’akari da yawan anserine da kowane mutum ke samu daga abincin yau da kullum (mutanen da ke cin kaza da kifi suna samun ɗan ƙari). Bayan yin wannan gyara, sakamakon ya ƙara ƙarfi zuwa **p = 0.0176**. MMSE na da maki 30, don haka ƙaruwa maki 1.9 ba babba ba ce, amma a rukunin da ake sa ran za su tsaya ko su yi ƙasa‑kasa a hankali, ganin rukunin placebo yana tsaya yayin da na maganin ke tashi, shine abin da masana ke nema a farkon alamar tasiri. ## Tsarin Aiki A Sauƙaƙe Alzheimer ana ɗauka a matsayin cuta mai sashi na kumburi, ba kawai plaques da tangles ba. Marubutan sun mai da hankali kan sarkar abubuwa masu zuwa: 1. **Neutrophils** (ƙwayoyin garkuwar jiki) suna fitar da enzyme **myeloperoxidase (MPO)**. 2. MPO yana samar da **hypochlorous acid (HClO)** – irin sinadarin da yake cikin bleach na gida – wanda ke kashe kwayoyin cuta. 3. A kwakwalwa, yawaitar HClO na iya lalata ƙwayoyin da haifar da kumburi, wanda aka danganta da cigaban Alzheimer. Anserine ana tsammanin yana aiki a matsayin **mai tsare HClO**. Yana ɗaukar wannan sinadari mai ƙarfi, wanda ke rage ɗigon kumburi da MPO ke haifarwa. A takaice, manufar ita ce rage wutar sinadarai a cikin kwakwalwa kafin su haifar da mummunan illa. Don tabbatar da wannan tsari, binciken ya auna tunani ne kawai, ba alamomin kumburi a kwakwalwa ba. Tsarin aiki yana da ma’ana, amma ba a tabbatar da shi a wannan gwaji ba. ## Alaka Da Carnosine Da Sauran Shaida Anserine ba shi kaɗai ba ne. Wasu gwaje‑gwajen Japan da suka gabata sun yi amfani da **hadadden anserine/carnosine**, galibi ratio 4:1 da kusan **gram 1 a rana**, kuma sun ga fa’ida a wasu bangarorin tunawa da jini zuwa kwakwalwa a tsofaffi. A kwanan nan, **nazarin meta na 2024** a *Nutrition Reviews* ya haɗa bincike kan **histidine‑containing dipeptides** kuma ya gano ingantaccen **delayed recall** – iya tuna abu bayan ɗan jinkiri. Wannan muhimmin ne, domin **delayed recall** na ɗaya daga cikin abubuwan da suka fara ƙasa a cutar Alzheimer. Gwajin da ake tattaunawa a nan ya ƙara wani abu daban: sakamako na anserine **kai‑tsaye**, a ƙananan adadi, a mutanen da suka riga suna da MCI. ## Abubuwan Amfani Na Gaskiya - **Kima:** Gwajin ya yi amfani da **500 mg a rana** na anserine. Samfuran da aka yi amfani da su a bincike na baya sun ba da kusan **gram 1 a rana** na dipeptides haɗe‑haɗe. - **Tushen abinci:** Nonon kaza da kifi kamar tuna su ne manyan hanyoyin samun sa. Masana sun yi la’akari da cin abinci domin yana ƙara yawan sinadarin gaba ɗaya. Samun adadi mai ma’ana daga abinci kaɗai na iya zama wuya, shi ya sa ƙari ke da amfani. - **Nau’in samfuri:** A kasuwa za ku ga nau’i biyu – anserine kai‑tsaye da haɗadden anserine/carnosine. Shaidar da ke kan kowane samfur na da bambanci, don haka ku duba alamar don sanin milligram na ainihi a kowane ciyawa. - **Wanda zai iya sha’awa:** Mutanen da ke da damuwa kan tunawa ko da aka ba su **diagnosis** na MCI su tattauna da likita. Anserine ba magani ne ga **dementia** ba, kuma ba zai maye gurbin kulawar likita, motsa jiki, barci, sarrafa hawan jini, ko sauran halayen da aka nuna suna da fa’ida ba. ## Iyakoki Na Gaskiya Sakon yana da alƙawari, amma hujjojin har yanzu suna da iyaka: - **Ƙananan samfur:** Mutane **30** kawai aka nazarta, 15 a kowanne rukuni. Ƙananan gwaje‑gwaje kan ƙara girman tasiri. - **Lokaci ƙanƙanta:** Makonni 12 ba su ba da wata alama game da tasirin dogon lokaci ko ko fa’idar zata ci gaba. - **Gwaji guda ɗaya:** Babban sakamakon shine MMSE, wanda ke da sauƙin canzawa da koyo ko yanayin mutum. - **Ƙasa guda:** Dukkan mahalarta sun fito daga Japan, inda tsarin abinci da al’adu ke iya bambanta da sauran ƙasashe. - **Raguwar mahalarta:** Daga 36 da aka yi randomisation, an nazarta 30 kawai, wanda zai iya shafar ƙimar sakamakon. - **Matsakaicin mahimmanci:** p‑value na 0.036 ya ƙasa ƙa’ida ta al’ada, amma ba da nisa ba; don haka buƙatar maimaitawa. Wannan ba yana nufin anserine ba ya aiki ba; yana nufin za a buƙaci manyan gwaje‑gwaje masu tsawo, wurare da yawa, tare da gwaje‑gwajen kwakwalwa da biomarker don tabbatar da fa’ida da kuma ingancin tsarin HClO. ## Ƙarshe Anserine wani dipeptide ne da ake samu daga abinci, mai yiwuwa yana da tasirin anti‑kumburi, kuma yana da gwajin mutum ƙanana da ke ci gaba. Shaidar **500 mg a rana** ta nuna kusan **maki 2** na ƙaruwa a MMSE a makonni 12 yayin da placebo ya tsaya. Idan an haɗa da binciken haɗadden samfura da nazarin meta na 2024 da ya nuna ingantaccen **delayed recall**, anserine na ɗaya daga cikin ƙarin da ake ɗauka a matsayin mai tallafawa lafiyar kwakwalwa. Har yanzu ba a tabbatar da ita a matsayin magani ba. Idan kuna tunanin amfani da ita, ku tattauna da likitan ku, musamman idan kuna da damuwa kan tunawa da ke buƙatar cikakken bincike.

Peptid na Salmon da Whey: +13 % Ferritin Cikin Mako 8 (Gwajin Farko kan Mutane 14)

Nova Chen — Sat, 17 Oct 2026 07:25:34 GMT

# Menene Peptid na Salmon (Hydrolysate na Furotin na Salmon)? **Hydrolysate** na furotin na kifi ana samar da shi ne ta hanyar ƙaƙa furotin na kifi – a nan Atlantic salmon – zuwa ƙananan sassa ta amfani da enzymes. Wannan aikin, da ake kira *enzymatic hydrolysis*, yana haifar da aminos ɗin da ba su da haɗin kai, ƙananan peptide (yawanci 2‑20 amino acid) da wasu manyan ɓangarorin. Manufar **bioactive peptides** ita ce wasu ɓangarorin su wuce samar da amino acid kawai; da zarar an saki su, za su iya haɗawa da masu karɓa, enzymes ko hanyoyin tantance ƙwayoyin halitta. Masana suna nazarin waɗannan peptide‑din abinci don tasirin su kan hawan jini, sarrafa sukari, aikin anti‑oxidant da kuma garkuwar jiki. Aikin da peptide yake yi ya dogara sosai da asalin furotin da enzymes da aka yi amfani da su, don haka ba za a iya ɗauka cewa hydrolysate ɗaya zai yi kama da wani ba. **ProGo®** shine hydrolysate na salmon da aka ƙera a Norway ta kamfanin **Hofseth BioCare**. Nazarin da aka yi a kan wannan sinadari ya nuna alamu na tasiri kan metabolism na ƙarfe, kumburi da lafiyar metabolic, kuma ƙaruwa a aikin *FTH1* – wani kwayar halitta da ke samar da ɓangaren ferritin. Samfurin na da takardar shaidar **Health Canada** da ke haɗa shi da ferritin da hemoglobin. ## Gwajin: Gram 12 a Rana vs Whey tsawon Kwanaki 56 An wallafa sakamakon a *Biomedicines* (2026) ta Currie, Myklebust, Bjerknes da Framroze. Gwajin **randomized, double‑blind, active‑controlled pilot** ne da aka gudanar a Norway tare da haɗin gwiwar Hofseth BioCare da **Møre og Romsdal Hospital Trust**. - **Masu halarta:** Mutane 14 da ke da nauyi daban‑daban - **Hanyar gwaji:** Gram 12 a rana na ProGo® hydrolysate na furotin na salmon - **Ma’aunin kwatanta:** Gram 12 a rana na whey protein isolate, daidai da nitrogen (iso‑nitrogenous) - **Tsawon lokaci:** Kwanaki 56 (mako 8) - **Manyan sakamako:** Alamar jini da haɗin gashi, ƙwai da fata (integumentary) tare da gyaran Holm‑Bonferroni don gwaje‑gwaje da yawa - **Sakamakon biyu‑biyu:** Tsarin jiki, cytokine na kumburi da metabolism na sukari Mahimmancin ma’aunin shine: saboda whey yana ba da adadin nitrogen daidai, duk wani bambanci ba zai kasance kawai “ƙarin furotin” ba. ## Sakamako: Menene Ya Canza? ### Alamar Jini Idan aka kwatanta da whey, ƙungiyar da ta sha salmon ta samu ƙaruwa mai ma’ana a hemoglobin (kimanin **4 %**), ƙidayar ƙwayoyin jini ja (kimanin **7 %**) da ferritin (kimanin **13 %**). Ferritin alama ce ta adana ƙarfe a jiki, yayin da hemoglobin da ƙwayoyin jini ja ke nuna iyawar ɗaukar iskar oxygen. Waɗannan sune manyan sakamakon da aka tsara da gyaran yawan gwaje‑gwaje. ### Gashi, Fata da Kwiya Matsakaicin haɗin **integumentary** ya tashi a ƙungiyar salmon. Sakamakon ba shi da ƙarfi sosai, don haka a yi taka tsantsan, duk da cewa an ƙara shi a matsayin manufa tun farko. ### Tsarin Jiki Nazarin biyu‑biyu ya nuna raguwar kaso na kitse a jiki da BMI, yayin da **lean body mass** ya kasance a matakin da ya kasance. Rage kitse tare da kiyaye lean mass fa’idar ne ga manya, domin rasa ƙashi da tsoka na iya haifar da rauni. ### Kumburi da Sukari Cytokine masu haifar da kumburi sun ragu, haka nan **HbA1c** da glucose a lokacin azumi sun ƙasa. Whey bai haifar da irin wannan tasiri ba. > **Lura:** Alamar jini da na fata sune manyan manufa; tsarin jiki, kumburi da sukari su ne sakamako na biyu‑biyu waɗanda za a yi musu ƙarin bincike. ## Me Ya Sa Peptid na Salmon Zai Iya Yin Fiye da Furotin na Al'ada? Masu binciken sun ce sakamakon ya fi dacewa da **bioactive effect** maimakon tasirin gina jiki kawai. Dalilin su kai tsaye: duka ƙungiyoyin sun samu nitrogen daidai, amma kawai ƙungiyar salmon ce ta haifar da wannan tasiri. Manya‑manya masu yiwuwa, kodayake har yanzu ba a tabbatar da su ba, sun haɗa da: - **Sarrafawar ƙarfe:** Tasirin ƙididdigar *FTH1* na iya canza yadda jiki ke adana ko sakin ƙarfe. - **Siginar kumburi:** Kumburi yana ƙara **hepcidin**, wanda ke hana shigar da ƙarfe da fitar da shi. Rage cytokine na iya inganta samun ƙarfe da ƙirƙirar ƙwayoyin jini. - **Siginar metabolic:** Ƙananan peptide na iya tasiri kan hormones na hanji da hanyoyin insulin. Binciken bai tabbatarda waɗannan hanyoyin ba kai tsaye. Haka kuma, hydrolysate na salmon na iya ƙunsar ƙananan ma'adanai ko wasu sinadaran da ba a san tasirinsu ba. ## Yadda Ake Amfani Da Shi - **Matsakaicin amfani:** Gram 12 a rana na tsawon kwanaki 56. Wannan shi ne tsarin da aka gwada; ba a san ko ƙara adadi zai ƙara tasiri ba. - **Waɗanda za su iya amfana:** - Mutanen da ke da **ferritin ƙasa** ko a matsakaicin iyaka – ko da yake ba a zaɓi masu fama da ƙarancin ƙarfe a wannan gwaji ba, don haka ba a san ko zai yi aiki a gare su ba. Ferritin ƙasa na bukatar a bincika da likita don gano dalili. - Manyan mutane masu shekaru **25–65** da ke damuwa da yiwuwar anemia, kumburi da rasa tsoka. - Masu cin kifi ko waɗanda ke neman madadin furotin na teku. - **Banbanci da collagen peptides:** **Collagen peptides** ana hydrolyze su daga collagen (kamar fata na shanu, fata ko kashi na kifi) kuma galibi ana amfani da su don ƙara elasticity na fata, gwiwa da ƙashi. Samfurin salmon na nufin hydrolysate na furotin na kifi wanda ya bambanta da collagen, kuma binciken sa ya fi mayar da hankali kan alamar ƙarfe, kumburi da metabolism. Ba za a iya musanya su da juna ba. - **Gargadi:** Mutanen da ke da **alergi ga kifi** ko daɗewa a gurasar teku su guje su sha. Mutanen da ke da matsalar yawaitar ƙarfe kamar **hemochromatosis**, masu shan magungunan jini, ko masu kula da cutar sukari su tattauna da likita kafin su fara, domin alamar sukari da ƙarfe na iya canzawa. ## Ƙuntatawa: Abubuwan Da Ya Kamata Ka Kula Da Su Kafin Ka Saya 1. **Karamin samfur:** Mutane 14 kacal ba su iya ba da tabbacin ainihin tasiri ko ƙaddamar da shi ba, musamman ga sakamakon biyu‑biyu. 2. **Hadin gwiwar masana'anta:** Kamfanin da ya samar da samfurin ne ya tallafa wa binciken. Wannan ba ya kawar da sakamakon, amma ana buƙatar maimaita bincike da masu zaman kansu. 3. **Tsawon lokaci kaɗan:** Mako takwas ba su ba da shaidar aminci ko ɗorewa na dogon lokaci ba. 4. **Alamomin wucin gadi:** Canjin ferritin, cytokine da HbA1c ba su nufin ingantacciyar lafiya kai tsaye ba. 5. **Rukuni mai iyaka:** Ba ya wakiltar masu kiba, tsofaffi ko wadanda ke da ƙarancin ƙarfe sosai. 6. **Manufa mai ra'ayi:** Makin gashi, fata da ƙwai na iya yin tasiri ta hanyar tunani, ko da akwai ɓoyayyen gwaji. 7. **Babu tabbataccen tsarin:** “Bioactive” ƙira ce, ba hujja ba. Masu binciken sun bayyana sakamakon a matsayin **“hypothesis‑generating”** kuma suna roƙon a tabbatar da su a manyan gwaje‑gwaje na masu zaman kansu. ## Karshe Hydrolysate na furotin na salmon yana da ban sha'awa a fannin bioactive peptide, kuma kwatanta shi da whey ya ba da alamar da ta fi na kawai furotin‑vs‑placebo ƙarfi. Amma da mutum 14 kacal da kamfanin da ya tallafa masa, wannan na daya ne kawai farawa don manyan gwaje‑gwaje, ba hujja ba don ɗaukar peptid na salmon a matsayin hanyar da ta tabbatar da ƙara ferritin ko tsawaita yawan rai. Idan kana damuwa da ƙarfe ko lafiyar jini, ka fara da gwaje‑gwajen dakin gwaje‑gwaje daga likita, sannan ka jira manyan gwaje‑gwaje masu zaman kansu su ba da amsa.

Magnesium L‑Threonate Ya Kara Mafi Kyawun Bacci Mai Zurfi da REM a Kan Oura Bayan Kwanaki 21

Nova Chen — Sat, 17 Oct 2026 07:24:41 GMT

# Magnesium L‑Threonate Ya Kara Mafi Kyawun Bacci Mai Zurfi da REM a Kan Oura Bayan Kwanaki 21 Magnesium ana sayar da shi a nau’uka da dama, kuma kusan dukkan lakabi suna yi wa mai amfani alƙawarin samun barci mafi kyau. Wani gwaji na bazuwar da aka buga a 2024 a *Sleep Medicine* ya gwada ɗaya daga cikinsu – magnesium L‑threonate (MgT, wanda ake sayar da shi a ƙarƙashin suna **Magtein**). Bayan kawai kwanaki **21**, mahalarta da suka sha wannan sinadarin sun samu maki mafi girma a bacci mai zurfi da REM a kan zoben Oura suƙa da waɗanda suka ci placebo. Sakamakon ya burge, amma dole ne mu fahimci cikakken bayani da ƙalubalen da ke tattare da shi. ## Me Ya Sa Nau’in Magnesium Ya Zama Muhimmanci? Magnesium yana zuwa da haɗe‑haɗe daban‑daban (citrate, glycinate, oxide, threonate, da sauransu). Wannan haɗe‑haɗe na iya shafar yadda jiki ke shan magnesium, yadda yake shigowa cikin hanji, da inda ƙarshe yake taruwa a jiki. **MgT** an ƙirƙira shi ne bisa ga binciken da aka yi kan berayen (Slutsky et al., *Neuron*, 2010) wanda ya nuna cewa threonate na iya ƙara matakin magnesium a kwakwalwa. Masu gudanar da sabon gwaji sun nuna MgT a matsayin abin da ke da sauƙin shiga kwakwalwa, kuma yana da alaka da tunani, ƙwaƙwalwa da yanayi. Wannan ya sa aka yanke shawarar gwada shi akan barci, amma ba ya nufin cewa zai ba da ingantaccen barci a kowane mutum ba – wannan shine ainihin manufar binciken. ## Gwajin: Wa, Me, da Tsawon Lokaci - **Mahalarta:** manyan mutane 80, shekaru 35‑55, waɗanda suka ba da rahoton matsalolin barci da kansu. - **Kuma:** gram 1 a rana na MgT (Magtein) ko placebo. - **Lokacin gwaji:** kwanaki 21. - **Kima ta ƙwarai‑kwarai (subjective):** Insomnia Severity Index, Leeds Sleep Evaluation Questionnaire, Restorative Sleep Questionnaire, Profile of Mood States, da wakilin yini na yau da kullum. - **Kima ta zahiri (objective):** zoben Oura. Haɗa tambayoyi na kimiyya da na’urar da ake sakawa a wuyan mutum hanya ce mai kyau don tantance yadda mutum ke ji da abin da na’ura ta rubuta. Sau da yawa waɗannan su biyun ba su jituwa ba, don haka samun sahihan sakamako daga duka biyun ya fi ƙarfin ɗaya kawai. ## Sakamakon Oura Idan aka kwatanta da placebo, rukunin **MgT** ya nuna haɓaka mai ma’ana a kima (p < 0.05) a: - Bacci mai zurfi (deep sleep) - Bacci REM - Lokacin bacci mai haske (light sleep) - Maki na aiki da motsi na yini - Maki na shiri, daidaito tsakanin aiki da barci Wannan ba yana nufin an ƙara mintuna a kowanne mataki ba – suna nuni ne da ƙaruwa a ƙididdigar zobe na Oura. Haka kuma, a ƙarshen binciken an lura cewa rukunin MgT ya *riƙe* ingantaccen barci da ƙarfin aiki, yayin da rukunin placebo ya *rasa* waɗannan. Saboda haka, wani ɓangare na bambancin ya samo ne daga raguwar placebo, ba daga ci gaban MgT kawai ba. ## Yanayi, Ƙarfi, da Aikin Yini Tambayoyin kima na yanayi sun nuna irin wannan hanya. Idan aka kwatanta da placebo, **MgT** ya haɓaka halayen farkawa, ƙarfi, aiki a rana, fushi, yanayi da kuma faɗakarwa. Kamar yadda ake kimanta ƙarfin barci ne da yadda mutum ya ji a gobe, wannan gwaji ya ba da alamu masu ƙarfi akan tasirin gaba ɗaya. Masu binciken sun jaddada cewa waɗannan sakamako sun dace da abin da aka sani game da MgT a dabbobi, amma ba su nufin cewa wannan gwaji ya tabbatar da amfanin sa ga kowa ba. Wannan shi ne matakin farko, kuma yana bukatar ƙarin bincike masu zaman kansu. ## Magnesium Threonate vs Glycinate vs Citrate Wannan tambaya ce da yawancin masu neman “magnesium mafi kyau don barci” ke tambaya, amma gwajin da aka tattauna ba ya kwatanta MgT da glycinate ko citrate. Ya kwatanta **MgT** ne kawai da placebo, don haka duk wani ƙuduri game da yadda zai kasance idan aka kwatanta da sauran nau’uka har yanzu yana cikin zato. - **Threonate:** yana da hujja cewa yana iya shiga kwakwalwa, amma yawancin shaidar kimiyya na dabbobi ne; kasuwanci ne kuma ya fi tsada. - **Glycinate:** an fi amfani da shi don barci saboda sauƙin hanji da yiwuwar amfanin glycine; babu hujja da ke nuna ya fi threonate. - **Citrate:** yana shafar jiki sosai kuma yakan haifar da laxative idan an sha a manyan adadi. Masu binciken sun nuna cewa sakamakon magnesium da barci ya bambanta gwargwadon asalin haɗin, don haka babu dalilin ɗaukar cewa duk nau’in magnesium suna aiki iri ɗaya. ## Abubuwan Da Za A Iya Amfani Da Su **Kima.** Gwajin ya yi amfani da gram 1 a rana na MgT. Wannan sinadari ne gaba ɗaya, ba magnesium na ainihi ba. A kusan kashi 7‑8 na nauyin sa, gram 1 yana ba da mg 72‑80 na magnesium na ainihi – ƙasa da 300‑400 mg da mutane da yawa ke ɗauka a matsayin “kudin magnesium”. Duba alamar samfur, domin wasu na iya nuna rabo daban. **Lokaci.** Binciken bai fayyace lokacin da mahalarta suka sha MgT ba. Yawanci mutane suna sha da yammaci don taimakon barci, amma wannan al’ada ce kawai, ba wani ɓangare na gwaji ba. **Wanda zai iya amfana.** Kawance ne ga manyan mutane masu shekaru 35‑55 da ke da matsalolin barci da suka bayyana da kansu. Ba ya wakiltar magance insomnia mai tsanani, apnea na barci, ko wasu cututtukan barci. **Matsalolin gefe.** MgT ya kasance lafiya a lokacin gwaji, amma magnesium gaba ɗaya na iya haifar da saukin bayan gida ko kumburin ciki. Mutanen da ke da matsalar koda ko waɗanda ke shan magunguna masu hulɗa da magnesium (kamar wasu antibiotics da bisphosphonates) su nemi shawarar likita. ## Iyakokin Gwajin - **Tsawon lokaci.** Kwanaki 21 ba su ba da bayani kan tasirin dogon lokaci ba. - **Na’urar auna barci.** Zoben Oura na ƙididdige matakan barci, amma ba ya maye gurbin polysomnography – ma’aunin dakin bincike na asibiti. - **Binciken cuta.** Mahalarta ba su wuce ganewar cuta ba, don haka ba a san ko wasu cututtuka ne suka shafi sakamakon ba. - **Adadin mahalarta.** Mutane 80 ya isa don gano alama, amma ba don ƙarfafa ƙarshe ba. - **Albarkatun kasuwanci.** Magtein samfurin kamfani ne; masu karatu su duba takardar bayanan da ba a bayar da tallafi ba don tantance sha’anin haɗin kai. - **Kwanan gwaje‑gwaje da yawa.** Yawan gwaje‑gwajen da aka yi na iya haifar da sakamakon “p < 0.05” da aka samu ba da gangan ba – don haka akwai buƙatar sake nazari. ## Gabaɗaya Gwajin ya ba da alamar farko mai kyau cewa MgT na iya ƙara maki a bacci mai zurfi da REM, da inganta yanayi da ƙarfin aiki a yini, a cikin makonni uku. Ba ya nuna cewa threonate ya fi glycinate ko citrate ba, kuma ba ya warware batun kimar da lokacin ɗauka ko tasirin dogon lokaci. Ka ɗauki wannan a matsayin ƙarfafa don ƙarin gwaje‑gwaje masu zaman kansu, masu tsawo, kuma ka tuntuɓi likita idan kana tunanin gwadawa.

Mushroom “Vitamin ɗin Dogon Rayuwa” Ya ƙara NAD+ a Berayen Tsohuwa Ta Hanyar H2S

Helix Ward — Sat, 17 Oct 2026 07:23:42 GMT

## Menene ergothioneine, kuma me ya sa ake kiransa "vitamin ɗin dogon rayuwa"? Ergothioneine (ET) sinadarin amino acid ne mai dauke da sulfur (thione) wanda jikin mutum ba ya iya ƙirƙirarsa. Sai dai ana samun sa ta abinci, kuma **ƙwaro ne daga cikin manyan abincin da ke ɗauke da shi**. Jikinmu na da ƙwayar karɓar wannan sinadari ta musamman, shi ya sa masana suka yi masa lakabi da "vitamin ɗin dogon rayuwa." Ba a yarda a kirkiro “vitamin” don abu da ba ya da tasiri ba – amma kasancewar ET yana da matuƙar amfani a jiki ya sa aka ɗauke shi a matsayin muhimmin nutrient. Har yanzu ana nazarin ET a matsayin anti‑oxidant da mai kare ƙwayoyin, amma aikin da muka samu a cikin wannan bincike ya nuna cewa ET ba wai kawai “mai tsarkakewa” ba ne, har ma yana **kafa siginar kwayoyin** – wani ɓangare da masu sha'awar bio‑hacking za su iya kulawa da shi. ## Sakamakon a ciyawar *C. elegans*: tsawon rai da motsi mafi inganci Masana suka fara gwada ET a *Caenorhabditis elegans*, ƙwanƙolin da aka fi amfani da shi wajen binciken tsufa. * ET ta tsawaita rayuwar ciyawar kuma ta inganta motsin su lokacin da suka tsufa. * Ciyawar da aka ba da magani sun nuna ƙarin juriya ga damuwa da rage alamun da ke bayyana da tsufa. Wannan sakamako yana daga cikin matakan farko da ake samu a ciyawar, amma ba koyaushe ne ke haifar da canji iri ɗaya a dabbobi masu girma kamar beraye ba. Saboda haka an ɗauki ET a matsayin abin da za a yi ƙoƙarin gwadawa a berayen. ## Sakamakon a berayen tsofu: juriya, ƙarfi a tsoka, da NAD+ Berayen da suka tsufa (kimanin watanni bakwai) aka ba su ET tsawon makonni huɗu, ƙungiyar ta lura da waɗannan canje‑canje: - **Ƙara juriya a treadmill** – berayen sun yi tafiya mai nisa a kan treadmill fiye da wadanda ba a ba su ET ba. - **Ƙara ƙarfin tsoka** – an ga ƙaruwa a ƙarfin da tsokoki ke nuna a gwajin igiya. - **Ƙara yawan jijiyoyin jini a cikin tsoka** – wato ƙaruwar cibiyoyin jini da ke ba da iskar oxygen da abinci ga tsoka. - **Ƙaruwa a matakin NAD+ a tsoka** – NAD+ na raguwa da tsufa, kuma yana da mahimmanci ga aikin mitochondria. Haihuwa a cikin tsoka na nuni da tasiri kan sarcopenia (raƙumin ƙarfi a tsokoki). ## Mabudin dabarar: yadda ET ke haɓaka NAD+ ta hanyar H₂S Marubutan sun gano cewa ba kawai ET ke ƙara NAD+ kai tsaye ba; yana aiki ne a cikin wani tsari na kwayoyin da ke ƙara samar da hydrogen sulfide (H₂S). Ga matakan da suka bayyana: 1. **CSE (cystathionine γ‑lyase) na ƙara samar da H₂S** – ET na ba da ƙarin ƙarfin CSE, ko a ce yana “madadin sinadari” wanda ke ƙara fitar da H₂S. 2. **H₂S na bai wa proteins alamar persulfidation** – wannan canjin kimiyya na ƙara sulfide a kan cysteine residues, yana sauya yadda protein ke aiki. An gano fiye da ƙwayoyin 300 da aka persulfidate. 3. **cGPDH (cytosolic glycerol‑3‑phosphate dehydrogenase) na kunnawa** – ɗayan waɗannan target, cGPDH, an kunna shi ta persulfidation. cGPDH yana cikin hanyoyin shuttle da ke taimakawa sake samar da NAD⁺ daga NADH a cytoplasm. 4. **NAD⁺ na tashi** – kunna cGPDH shi ne tushen haɓakar NAD⁺ da ET ta haifar. **Hujojinsa** an nuna ta gwajin knockout: **Idan aka cire CSE ko cGPDH, tasirin ET ya Ɂoyan gaba ɗaya**. Wannan yana tabbatar da cewa hanyar da aka gano ba wani abu ne da ba a sarrafa ba, sai dai wata hanya mai mahimmanci. ## Yaya wannan ke kwatanta da NMN da NR? NMN da NR su ne **precursors** na hanyar NAD⁺ salvage – suna ba da kayan gini ga sel don sake ƙirƙirar NAD⁺. A gefe guda, ET ba yana ba da kayan gini ba; yana **kafa siginar redox** wadda ke kunna enzyme (cGPDH) don samar da NAD⁺ daga NADH. Hanyoyin biyu na iya cika juna, amma har yanzu ba a yi ƙididdigar haɗin kai a cikin gwaje‑gwaje ba. Takardar ba ta ƙunshi gwajin kai tsaye tsakanin NMN/NR da ET ba, don haka kowanne iƙirari na “ET ya fi” ko “ya fi haɗi da su” ya rage ga tunani. ## Abubuwan da za a iya amfani da su ga masu sha'awa - **Abincin da ke da yawa ET** – ƙwaro ne mafi yawan ET, musamman **shiitake, king oyster, shiitake, da porcini**. A ƙananan adadi ana samun ET a wasu wake, oat bran, da nama. Dafa abinci ba ya lalata ET sosai. - **Kayan kari (supplement) na ET** – yawanci suna ba da **5 – 25 mg a kowace rana**. Wannan shine adadin da ake amfani da shi a gwaje‑gwajen kan mutane. - **Adadin da aka yi amfani da shi a beraye** – a cikin gwajin, berayen sun karɓi kusan **200 – 260 mg a kowace rana** idan aka fassara zuwa mutum, wato kusan sau goma na adadin da ake ba da shi a ƙwayoyin ƙaruwa. Ko wannan adadi yana da aminci ko kuma yana da tasiri a mutane ba a tabbatar ba. Takardar ba ta nuna cewa kashi 5‑25 mg na ƙwallon zai iya haɓaka NAD⁺ a tsoka ga mutum ba. ## Babban gargadi: dabbobi kawai, ba a samu hujja a mutane ba tukuna Ku kasance masu shakku game da duk wani tsammani da aka yi na ƙwarai ga mutane: - **Babu bayanan mutum** – Binciken ya ƙunshi ciyawa, beraye, da ƙwayoyin sel. - **Bambancin adadi** – Adadin da ya haifar da tasiri a beraye, idan aka juya zuwa matsakaicin mutum, ya ninka sau goma adadin da ake amfani da shi a yau da kullum. - **Tsawon lokaci ba a sani ba** – Ba a tabbatar da sakamakon dogon lokaci, amincin adadi mai yawa, ko tasirin a rayuwar mutane ba. - **NAD⁺ a tsoka ba alamar kiwon lafiya kai tsaye ba** – Ƙara NAD⁺ a tsoka da ƙara ƙarfi a treadmill alamu ne masu kyau a beraye, amma ba hujja ce ta tsawon rai ko lafiyar gabaɗaya a mutane ba. - **Hujja tana buƙatar gwajin mutum** – Hanya kimiyya ce mai kyau don gudanar da gwaji, ba madadin gwajin mutum ba. ## Kammalawa Wannan takarda ta fayyace ainihin hanyar da ergothioneine ke amfani da ita: haɗin CSE → H₂S → persulfidation → cGPDH → NAC⁺. Wannan mataki ne da ya wuce tunanin “anti‑oxidant kawai.” Cin ƙwaro ko shan kari na ET wata hanya ce mai sauƙi, amma har yanzu ba mu da hujjar da ta tabbatar da cewa zai ƙara NAD⁺ ko rage alamar tsufa a mutane. Wannan zai kasance a kan gwaje‑gwajen mutane da za su zo nan gaba.

Peptide GHK‑Cu Na Iya Daidaita Hanyoyin Kwayoyin Halitta Don Gyaran Fata

Nova Chen — Fri, 16 Oct 2026 07:23:39 GMT

# Peptide GHK‑Cu: Kwayar Ƙurfe da Ke Daidaita Hanyoyin Kwayoyin Halitta Don Gyaran Fata Idan ka taba ganin GHK‑Cu a cikin serum, tabbas ka ga manyan alkawuran da ake danganta masa. Binciken da aka wallafa a shekarar 2018 a *International Journal of Molecular Sciences* ta Loren Pickart da Anna Margolina ya bayyana dalilin da ya sa masu bincike ke ci gaba da nazarin wannan peptide mai ɗauke da ƙarfe. Babban hujjar su ita ce, bayanan fitar da kwayoyin halitta (gene expression) sun nuna yadda wannan ƙwayar ƙanana ke haifar da tasirin kariya da sabunta jiki da dama. ## Menene GHK‑Cu? GHK peptide ne da ke kunshe da amino acid uku – glycyl‑L‑histidyl‑L‑lysine – wanda ke samuwa a jikin ɗan adam. Yana haɗa ƙarfe sosai, don haka ake kiran sa "copper peptide" ko GHK‑Cu. Ana samun sa a cikin kayan kwalliya da yawa. Masu bincike sun bayyana ayyukansa a matsayin, gwargwadon ilimin da ake da shi a yanzu, suna da fa'ida ga lafiya. Wannan bayanin ba gwaji ne na ƙarshe ba, amma sharhi ne kan adabin da ake da shi. ## Manyan Sakamako a Taƙaitaccen Bayani A cewar binciken, GHK‑Cu: - **Yana ƙarfafa haɓakar ƙananan jijiyoyi da ƙashi**, muhimman sassa na warkar da rauni. - **Yana ƙara samar da ƙolajen, elastin, da glycosaminoglycan**, waɗanda suke gina tsarin fata, ba su ba da tsari ba, kuma su ne ke riƙe danshi. - **Yana tallafawa aikin fibroblast** – sel ɗin da ke gina da kula da ƙwanƙolin fata. - **Yana inganta gyaran sel a cikin fata, huhu, ƙashi, hanta, da sauran sassan jiki**. Ga masu sha'awar tsufar fata, waɗannan abubuwan – ƙolajen, elastin, glycosaminoglycan, da fibroblast – su ne suka fi shafar siffar fata, laushi, da ƙarfi. ## Ba kawai fata ba: Tasirin Kariya Binciken ya kuma tabo wasu tasirin da suka wuce fannin kayan shafawa, kamar: - Aiki anti‑inflammatory (rage kumburi) - Ayyukan anti‑cancer da dama - Kariya ga huhu da farfadowar fibroblast a cutar COPD (chronic obstructive pulmonary disease) - Rage NFκB, wani siginar da ke da alaƙa da kumburi da cututtukan tsufa - Tasirin anti‑anxiety, anti‑pain, da anti‑aggression - Gyaran DNA - Kafa proteasome, wato tsarin "tsabtace" da sake amfani da furotin a cikin sel Wannan jerin tasiri yana nuna faɗin abin da sinadari guda ɗaya zai iya yi. ## Hanyar Aikin Gene Expression Manufar ita ce, GHK ba ya aiki ta hanya ɗaya kawai, sai dai yana shafar hanyoyi da dama a cikin kwayoyin halitta. Sabbin bayanan fitar da kwayoyin halitta sun nuna cewa GHK ke sarrafa manyan hanyoyi da suka shafi gyara, rage kumburi, da kula da sel. Idan peptide ya canza ayyukan sel da dama, za a ga amfaninsa a sassa daban‑daban na jiki – daga fata har zuwa huhu. ## Abubuwan da Ya Kamata Ka Kulawa da Su Binciken yana da amfani, amma yana da iyaka. Ga wasu abubuwan da ya kamata mai karatu ya lura da su: 1. **Binciken ne na labarai (review), ba sabon gwaji ba.** Ya haɗa da sakamakon gwaje‑gwaje a dakin gwaje‑gwaje, dabbobi, da bayanan gene expression. Ba ya bayar da sabbin sakamakon likita, kuma ba ya ikirarin hakan. 2. **Bayanan gene expression na nuna alaka, ba tabbacin fa'ida ba.** Idan alamar sel ta motsa a hanya mai kyau a cikin bayanai, ba lallai ne hakan ya nufin za a samu irin wannan sakamako a jikin mutum ba. 3. **Sakamakon gyaran sel sun fito ne daga samfura daban‑daban.** Shaidar da ke nuna inganci ga huhu, hanta, ko ƙashi ba ta nufin cewa za a samu tasirin daidai a fuskantar kurajen fata. 4. **Masu rubutun su ma su ne masu nazarin GHK na dogon lokaci.** Kodayake suna da ƙwarewa, masu karatu ya kamata su nemi ƙarin hujjojin daga wasu masana. ## Yadda Ake Amfani da Peptide a Jiki da a Fata Idan kana tunanin sayen samfuran GHK‑Cu, ga wasu ka'idoji masu amfani: - **Manufar samfurin ya dace da amfani a kan fata.** Ƙolajen, elastin, glycosaminoglycans, da tallafin fibroblast su ne manyan abubuwan da ke da alaƙa da kayan shafawa, kodayake binciken ba ya gwada takamaiman samfur ko adadi. - **Mahimmancin haɗin sinadarai.** Tsayayyen peptide, yadda ƙarfe ke haɗuwa da shi, da yadda peptide ke wucewa ta fata suna bambanta tsakanin samfura, kuma binciken bai warware su ba. - **Kada a ɗauki ikirarin da ya shafi jiki baki ɗaya a matsayin tabbatacce.** Sakamakon anti‑cancer, kariyar huhu, da tasirin anti‑anxiety sun fito ne daga yanayin bincike – ba daga amfani da samfurin da aka amince da shi ba. - **Yi shawara da likita** idan kana da wata matsala ta lafiya, kana da ciki, ko kuma kana son ƙara sinadari fiye da kayan shafa. ## Takaitaccen Bayani Babban hujjar da wannan bincike ya gabatar ita ce, GHK‑Cu na da faɗin tasirin gyara da kariya saboda yana shafar hanyoyi da dama na sarrafa kwayoyin halitta maimakon wani sinadari guda ɗaya. Wannan ra'ayi na da amfani ga fahimtar tsufar fata da gyaran sel, kuma ya bayyana dalilin da ya sa peptide ke ci gaba da kasancewa a cikin manufofin masu bincike. Sai dai, ba a samu hujja da ke nuna sakamakon da ba za a iya gani ba a jikin mutum daga kowanne samfur a kasuwa. Don haka, shawarar mu ita ce: ka kasance mai sha'awa amma ka yi taka tsantsan – GHK‑Cu na da alƙawarin kimiyya, matakin gaba kuma shi ne samun sahihin bayanin da ya shafi mutum da kansa. *Wannan labarin na nufin ba da bayanai ne kawai, ba maganar likita ba.*

Fisetin, Senolytic, Ya Tsawaita Rayuwar Beraye—Babu Shaida a Kan Dan Adam

Helix Ward — Fri, 16 Oct 2026 07:22:41 GMT

**Karanta wannan da farko:** duk abin da ke ƙasa ya samo asali ne daga gwaje‑gwajen berayen, sel, da samfuran nama na ɗan adam a faranti. Ba ya da alaƙa da kammala wani gwajin tsawon rai na ɗan adam da aka gudanar a ƙungiyoyin gwaji. Ba a nuna cewa fisetin yana da ikon tsawaita rayuwar ɗan adam ko inganta lafiyarsa ba. A cewar haka, takardar *EBioMedicine* ta 2018 da Yousefzadeh da abokan aikinsa suka wallafa ce ta ɗaya daga cikin manyan dalilan da suka sa fisetin ya zama shahara a al’amuran tsawon rai. ## Takaitaccen bayani: flavonoid daga strawberries da ke kawar da “kwayoyin zombie” Fisetin flavonoid ne na halitta, wani **polyphenol** da ke cikin tsirrai a ƙananan adadi a abinci kamar strawberries. Masu binciken sun yi masa sha’awa a matsayin **senotherapeutic** – wato magani da ke magance kwayoyin da suka shiga *senescence*. Kwayoyin da suka shiga senescence suna daina rabuwa, galibi sakamakon damuwa ko lalacewar DNA. Ba su mutuwa ba; suna cigaba da wanzuwa a ƙashi tare da fitar da sinadarai masu haifar da kumburi, kuma an danganta su da tsufa da cututtuka masu alaka da tsufa. Kwayoyin da ke kawar da irin wadannan su ne ake kira **senolytics**. Ƙungiyar ta riga ta nuna cewa dasatinib da quercetin (D+Q) suna aiki a matsayin senolytic. Wannan binciken na tambayar ko flavonoid guda ɗaya – wato fisetin – zai iya yin fiye da haka. ## Abin da masu binciken suka yi - **Sun gwada flavonoids guda 10** a kan fibroblasts na berayen da na ɗan adam da suka shiga senescence sakamakon damuwar oxidative da genotoxic. - **Fisetin ta fice** a matsayin senolytic mafi ƙarfi a cikin wannan rukuni. - **An gwada a cikin samfurin berayen biyu:** berayen progeroid (samfurin tsufa mai sauri) da ke ɗauke da alamar *p16INK4a‑luciferase*, da kuma berayen da suka tsufa ba tare da ƙari ba. - **An duba ƙashin ɗan adam:** an yi amfani da ƙashin mai (adipose) da aka fitar don ganin ko sakamakon zai ci gaba. ## Muhimman sakamakon da aka samu **1. Ƙananan alamun senescence a ƙashi da dama.** Maganin fisetin – na gaggawa ko na lokaci‑lokaci – ya rage alamun senescence a berayen progeroid da tsofaffi. Tsarin ya kama da dabarar *hit‑and‑run*: kwanaki kaɗan na magani na kawar da kwayoyin, don haka ba lallai ne a ci gaba da ba da magani kullum ba. **2. Aiki mai zaɓi, ba na kowane iri ba.** Fisetin ta rage senescence a *wani ɓangare* kawai na kwayoyin a ƙashin berayen da na ɗan adam. Masu rubutun sun nuna wannan a matsayin takamaiman ƙwayoyin, wato ba magani ne da ke kawar da kowane ƙwaya ba. **3. Amfani ga lafiya da tsawon rai a beraye.** Lokacin da aka ba berayen farfesa *a ƙarshen rayuwarsu*, fisetin ta dawo da daidaiton ƙashi, ta rage cututtukan da suka danganci tsufa, kuma ta tsawaita **tsawon rayuwar matsakaici da iyaka**. Ba a buƙatar farawa da wuri; ba da maganin a ƙarshen rayuwa yana da mahimmanci. ## Halin ƙimar magani: abin da takarda ke faɗi da abin da ba ta faɗa ba Taƙaitaccen bayanin ba ya nuna ƙimar, kuma dole ne a duba cikakken takarda don sanin ainihin jadawalin. Abubuwa biyu ne suka fi muhimmanci: - **Ƙimar ta danganta da nauyin berayen**, an ba su a lokuta na ɗan gajeren lokaci ko a lokaci‑lokaci maimakon a matsayin ƙarin abinci na yau da kullum. Ba ta daidaita da ƙimar da ta dace da ɗan adam ba. - **Canjin daga beraye zuwa ɗan adam ba shi da sauƙi.** Bambance‑bambancen metabolism, shaƙa, da yawan fatar jiki na nufin ba za a iya mayar da miligram/kilogram na beraye zuwa yawan miligram/kilogram na ɗan adam ba. Fisetin ma na da ƙarancin **bioavailability** a baki, wani al’amari da ke ƙara wahalar fassara. Duk wanda ya yi “ƙimar ɗan adam” daga wannan takarda yana yin ƙiyasin. Masu rubutun sun ce sakamakon yana nuna yana *yiwuwa* a kai ga gwaje‑gwajen ɗan adam. ## Dalilin da ya sa ta jawo hankali Jawo hankalin ya fito ne daga haɗin waɗannan siffofi: - **Samfurin halitta** da ake samu a abinci na tsawon lokaci. - **Siffofin *hit‑and‑run***, wato amfani a kai‑kai ba kullum ba. - **Tasiri a ƙarshen rayuwa** a beraye. - **Wani fassarar zuwa ƙashin ɗan adam**, ko da yake a cikin ƙashi ne kawai. Aiki ya samu tallafi daga manyan ƙuran NIH da ƙungiyoyin da ke kula da tsufa, ciki har da **Glenn/AFAR**, don haka ya fito ne daga manyan dakunan bincike na geroscience. ## Manyan ƙuntatawa da suka kamata a sani - **Beraye ba su daidai da mutane.** Yawancin matakai da suka tsawaita rayuwar beraye ba su kai ga mutane ba. - **Bayanan ƙashin ɗan adam sun iyakance.** Kashi na ƙashi na nuna cewa fisetin na iya rage senescence a ƙashin ɗan adam a faranti, amma ba su nuna fa'idar klinik ba. - **Senescence abu ne mai tsari.** Kwayoyin senescent na iya zama masu amfani wajen warkar da rauni da hana cutar kansa; don haka bukatar nazari mai zurfi kan sakamakon kawar da su. - **Babu cikakken RCT na tsawon rai a ɗan adam.** Masu rubutun sun nuna yiwuwar fassara zuwa ƙwararrun gwaje‑gwaje, ba su da'awar an tabbatar da sakamakon. ## Wa zai kamata ya damu - **Masu binciken tsawon rai da likitoci** da ke bibiyar fannin senolytic, waɗanda za su iya amfani da wannan takarda a matsayin madaidaicin matakin pre‑clinical. - **Masu sha'awar ƙarin abubuwa**, waɗanda ya kamata su ɗauki wannan sakamako a matsayin tunanin farko, ba shawara da za su ɗauki wani abu ba. - **Mutanen da ke da cututtuka ko ke amfani da magunguna**, ciki har da masu shan anticoagulants ko magungunan cutar kansa, su nemi shawarar ƙwararren likita kafin su sha kwayoyin flavonoid da yawa. - **Masu bibiyar labaran gwaje‑gwajen likita**, su dinga sa ido kan rijistar gwaje‑gwajen ɗan adam na fisetin, domin su ne za su zama gwajin gaskiya. ## Gaba ɗaya Takardar ta nuna cewa fisetin ce mafi ƙarfi a tsakanin flavonoids goma wajen kawar da kwayoyin senescent, ta rage alamun senescence a beraye da ƙashin ɗan adam, kuma ta tsawaita matsakaicin da iyakar rayuwar berayen da suka tsufa. Wannan sakamako ne mai ƙarfi a matakin pre‑clinical. Ba sakamakon tsawon rai na ɗan adam ba, kuma tazara tsakanin su shi ne inda yawancin kwayoyi masu alƙawari suka makale. Har sai an samu gwaje‑gwajen ɗan adam da aka sarrafa, fisetin zai ci gaba da kasancewa abin da ake gani a dakin gwaje‑gwaje, ba wani kayan anti‑aging da aka tabbatar ba.

Epithalon Na Kunnawa Telomerase a Kwayoyin—Ba a Mutane

Helix Ward — Fri, 16 Oct 2026 07:21:30 GMT

# Epithalon Na Kunnawa Telomerase a Kwayoyin—Ba a Mutane **Gajeren bayani:** Epithalon peptide ne mai ƙwayoyin amino huɗu da ake cẽwa yana kunna telomerase – wani enzyme da yawancin ƙwayoyin manya ke rasa – sannan ya tsawaita telomeres a ƙwayoyin ɗan adam. Wannan bincike ne ya haifar da sha’awar “tsawon rai” da ake yiwa Epithalon suna. Amma an yi gwajin ne a kan fibroblasts na jariri a cikin tukunya, ba a kan mutane ba; kuma zato game da tsawaita rayuwa ba shi da tushe a wannan takarda. Anan za ku ga abin da nazarin 2003 ya nuna, abin da ba ya nuna, da kuma yadda za ku tantance shi kafin ku yanke shawarar siyan wani abu. Peptide ɗin da ke ƙunshi amino acid huɗu ne, wato Ala‑Glu‑Asp‑Gly, kuma an ƙirƙira shi a rukunin bincike na Rasha da Vladimir Khavinson ke jagoranta. An fi saninsa da suna *Epithalon* (ko *Epitalon*). A mafi yawan wallafa, an danganta sakamakonsa da wannan ƙungiya, don haka yana da muhimmanci mu fahimci iyakokin da ke cikinsa. ## Takaitaccen Bayani A wani takarda da aka buga a 2003 a *Bulletin of Experimental Biology and Medicine*, Khavinson, Bondarev, da Butyugov sun rubuta cewa ƙara Epithalon zuwa **human fetal fibroblasts* (fibroblasts ɗin jariri da ba su da telomerase a yanayi na al'ada) ya haifar da abubuwa guda uku: - Bayyanar **sashen catalytic** na enzyme telomerase (hTERT). - Samuwar **aikin telomerase** da za a iya auna shi. - **Tsawaitar telomere** a waɗannan ƙwayoyin. Masu rubutun sun yi nuni da cewa wannan yana nuna “yiwuwar” farfarar telomerase a ƙwayoyin somatic, kuma suna ganin hakan na iya nuni da yiwuwar tsawaita rayuwar ƙwayoyin da dukan mutum. Sai dai wannan kuskuren fassara ne kawai; takardar ba ta ƙunshi wani hujja na tsawaita rayuwa ba, kuma ta tsaya a gwajin al'ada ne. ## Me Ya Sa Telomerase Ke Jan Hankali? Telomeres sune *ƙusurwar* DNA da ke a ƙarshe na kowanne chromosome. A mafi yawan ƙwayoyin somatic, telomeres suna ragowa a kowane rabon kwaya. Idan sun yi gajarta ƙwarai, ƙwayoyin na daina rabuwa ko su shiga yanayin ɗaukar tsufa. Telomerase enzyme ne da ke ƙara sassa na telomere; sashen catalytic ɗinsa, hTERT, yana iyakantacce a ƙwayoyin manya. Saboda haka, wani sinadari da ke kunna hTERT kuma ya tsawaita telomeres a ƙwayoyin da ba su da telomerase a al'ada yana da matuƙar sha’awa. Amma “kunna telomerase” na da fuskoki biyu: a cikin wani yanayi, hakan na iya haifar da ciwon daji, domin ƙwayoyin da ke da telomerase mai ƙarfi suna iya ci gaba da rabuwa ba tare da iyaka ba. Don haka, muhimmin tambaya ita ce: shin peptide ɗin na iya yin wannan a jikin ɗan adam ba tare da haifar da matsala ba? ## Menene Epithalon? Epithalon peptide ne da aka fi sani da Ala‑Glu‑Asp‑Gly. An ƙirƙire shi a ƙungiyar bincike ta Rasha, inda aka kwatanta shi da epithalamin – wani sinadari da pineal gland ke fitarwa. Duk da cewa mafi yawan binciken da aka wallafa sun fito ne daga wannan ƙungiya, wannan ba yana nufin sakamakon ba su da inganci ba; aƙalla buƙatar gwaje‑gwajen da ba su da alaka da kamfanin talla akwai. ## Iyakokin Da Ke Gaskiya ### 1. Gwaji ne na kwayoyin al'ada An yi amfani da fibroblasts na jariri, wato ƙwayoyin da suka fi matasa kuma an girka su a cikin yanayin dakin gwaje‑gwaje. Waɗannan ƙwayoyin ba su da tsarin garkuwar jiki, hormones, tsarin ƙashi, metabolism, ko kuma hanyoyin sadarwa na jiki. Saboda haka, sakamakon da aka samu a cikin tukunya ba lallai ne ya wuce zuwa ga jikin mutum ba. ### 2. Ba a yi gwajin kan mutum ba Takardar ba ta kunshi wani ɗan adam da aka ba da Epithalon ba, kuma ba ta ba da bayanai kan ƙuduri, amincin, hanyar bayarwa, ko tasirin a kan kwayoyin ɗan adam. ### 3. Ba ta nuna tsawaitar rayuwa ba Kalmar “yiwuwar tsawaitar rayuwa” da ke cikin takardar na nufin *yiwuwa* a matakin ƙwaya ne, ba a ma'anar tsawon lokaci na lafiya ko tsawon rayuwa a mutum ba. Tsufa na da hanyoyi da dama – ciki har da oxidative stress da gajartawar DNA – waɗanda ba su da alaka kai tsaye da telomeres kawai. ### 4. Takarda ɗaya ce a farkon bincike Sakamakon yana fitowa ne daga gwaji guda. Don samun sahihiyar hujja, ana buƙatar gwaje‑gwaje da yawa – daga laboratori masu zaman kansu, ƙwayoyi daban‑daban, bayanai kan amsa da ƙuduri, har zuwa gwaje‑gwajen klinik na mutane. ### 5. Hadarin daji ba a magance ba Kunna telomerase na iya ƙara haɗarin ciwon daji. Wannan takarda ba ta tabo wannan haɗari ba, kuma ba za a iya ɗaukar ta a matsayin shaida ta amincin lafiyar ɗan adam ba. ## Menene Wannan Ke Nufi Ga Masu Son Saya? Idan ka na tunanin sayen Epithalon, ga wasu abubuwan da ya kamata ka duba kafin ka kashe kuɗi: **Abin da takardar ke tallafawa:** - Epithalon na iya “kunna” hTERT, samar da aikin telomerase, da tsawaita telomere a fibroblasts na jariri a cikin tukunya. - Wannan ya sa peptide ɗin ya zama wani abu mai ban sha’awa a fannin binciken dakin gwaje‑gwaje. **Abin da takardar ba ta tallafawa ba:** - Cewa Epithalon zai tsawaita telomere a mutane da suka sha shi. - Cewa yana rage ko maido da tsufar ɗan adam. - Cewa akwai ƙuduri, zagaye, ko hanyar amfani da ke da inganci da aminci a jiki. - Cewa kayayyakin da ake sayarwa a layi suna ɗauke da ainihin Epithalon kamar yadda aka rubuta a takardar. **Tambayoyi muhimmai kafin siye:** 1. Shin mai sayarwa yana gabatar da Epithalon a matsayin “kimiyyar bincike” amma yana mai da hankali kan fa’idar ɗan adam? Wannan alamar gargaɗi ce. 2. Shin an yi gwajin inganci daga ɓangare na uku don tantance tsabta da sahihancin samfur? 3. Shin Epithalon an amince da shi a matsayin magani a ƙasarka? A yawancin ƙasashe ba a amince da shi ba don amfani a kan ɗan adam. 4. Ka tattauna da likita, musamman idan kana da tarihin cutar daji ko na iyali. ## Kammalawa Binciken 2003 na da matuƙar ban sha’awa: peptide ƙanƙani da ke nuna alamar farfarar telomerase a fibroblasts na jariri a cikin tukunya. Wannan shi ne matakin farko, ba amsa ba. Yin gagarumin tashi daga “telomere da aka tsawaita a cikin tukunya” zuwa “kayan da zai tsawaita rayuwarka” yana buƙatar shaidar da ta wuce gwaje‑gwajen ɗan adam. Don haka, a yanzu, Epithalon yana nan a matsayin wani abu mai ban sha’awa a dakin gwaje‑gwaje. Sai dai har sai an samu ƙarin bincike da aka gudanar a kan mutane, ƙara da’awar cewa zai tsawaita rayuwar ɗan adam ba ta da tushe. *Wannan rubutu yana nufin ilimi kawai, ba shawarwarin kiwon lafiya ba.*

NR + Pterostilbene na ƙara NAD+ kusan 40–90 % a Gwajin Dan Adam

Nova Chen — Fri, 16 Oct 2026 07:20:28 GMT

## Lambar da ta fi daukar hankali: NAD+ ya tashi ~40 % zuwa ~90 % **NAD+** coenzyme ne da ƙwayoyin halittar mu ke amfani da shi wajen sarrafa makamashi da gyaran DNA. Ana yawan cewa matakan NAD+ kan ragu yayin da mutum ke ƙara tsufa, don haka masu kayan ƙari suna mai da hankali kan *precursors* na NAD+. Daya daga cikin shahararrun haɗaɗɗun kayayyaki, **NRPT**, yana haɗa **nicotinamide riboside (NR)** da **pterostilbene (PT)**, kuma ana sayarsa da sunan *Basis*. Binciken da aka wallafa a 2017 a *npj Aging and Mechanisms of Disease* shine **gwajin farko akan ɗan adam da aka yi sau da yawa da wannan haɗin**. Muhimman sakamakon su sune: - **~40 % ƙaruwa** a matakin NAD+ na jini a ƙimar da ake ba da shawara (NRPT 1X). - **~90 % ƙaruwa** a ƙimar da ta ninka (NRPT 2X). - **Babu ƙaruwa** a rukunin placebo. - **Babu wani haɗari mai tsanani** da aka ruwaito. An auna wannan ƙaruwa bayan makonni huɗu, kuma an bi sawun ta har zuwa ƙarshen makonni takwas. ## Waɗanda aka yi wa gwaji da yadda aka yi shi An haɗa **mutane 120 masu lafiya, masu shekaru 60–80**. An raba su gida uku: 1. **Placebo** – babu wani abu a ciki. 2. **NRPT 1X** – ƙimar da ake ba da shawara. 3. **NRPT 2X** – ƙimar da ta ninka (ninki biyu). Kowane mahalarta ya sha ƙarin da aka ɓoye **kullum na tsawon mako takwas**. Masu binciken sun auna NAD+ a jini a matakai daban‑daban, tare da lura da alamar lafiyar su. ## Dalilin da ya sa wannan haɗin ke da mahimmanci: NR da pterostilbene - **NR** sinadarin B3 ne da ke cikin madara da wasu abinci a ƙananan matakai; ƙwayoyin jiki na iya mayar da shi kai tsaye zuwa NAD+. - **Pterostilbene** polyphenol ne da aka fi samu a blueberries, yana da ɗan alaka da resveratrol. Manufar haɗin ita ce sinadaran biyu su cika juna, amma gwajin ya kwatanta haɗin *duka* ne da placebo kawai; ba a kwatanta shi da NR ba tare da PT ko PT ba tare da NR ba. Saboda haka **ba za a iya tantancewa ainihin tasirin kowane sinadari ba**. ## Abubuwan da za a iya ɗauka daga sakamakon - **Martani mai alaƙa da ƙima.** Ninkawa ƙimar ya ninka kusan adadin ƙaruwa a NAD+, daga ~40 % zuwa ~90 %. Wannan yana nuna cewa tasirin yana haɓaka tare da ƙarin sinadari. - **Fara da sauri.** Babbar ƙaruwa ta bayyana a makonni huɗu. - **Ci gaba, ba tsalle‑tsalle ba.** NAD+ ya ci gaba da kasancewa a sama har tsawon mako takwas, ba tare da saukowa ba. - **Placebo ba ya canzawa.** Wannan ya rage yiwuwar canjin da ya samo asali daga yanayi ko kuskuren gwaji. Rukuni 1X ya ƙunshi **250 mg NR da 50 mg pterostilbene a kullum**, yayin da rukuni 2X ya ninka duka biyun. Duba takardar asali don ƙarin bayani kafin yanke shawara kan amfani. ## Lafiya: abin da binciken ya nuna da abin da bai nuna ba Masu binciken sun ruwaito **babu wani haɗari mai tsanani** a cikin makonni takwas. Wannan alƙawari ne mai kyau ga gwaji na farko a kan ɗan adam, har da rukunin da ke samun ninkawa. ### Iyakoki - **Ƙarancin lokaci.** Makonni takwas ba su ba da cikakken haske kan tasirin dogon lokaci ba. - **Masu lafiya kawai.** Sakamakon ba su shafi mutanen da ke da cututtuka masu tsanani ko masu shan magunguna da yawa ba. - **Ƙaramin yawan mahalarta.** Mutane 120 a rukunin uku na iya rasa ƙarfin gano matsaloli masu saurin tasowa. ## Abubuwan da wannan bincike ba ya ikirarin su Wannan shi ne wurin da ake samu **overhype**. Manufar gwajin ita ce **duba lafiyar jini da matakin NAD+**. Binciken ba ya ba da hujja cewa NRPT: - Yana tsawaita rayuwa ko rage tsufa. - Yana inganta ƙarfi, tunani, ko makamashi. - Yana warkar da wata cuta ko yanayi na musamman. Ɗaga NAD+ sakamakon sinadarai ne kawai. Shin wannan zai haifar da lafiyar dogon lokaci, har yanzu ana buƙatar ƙarin gwaje‑gwaje masu tsawo da suka haɗa da al'amuran kiwon lafiya daban‑daban. Duk wanda ke yin talla da cewa NAD+ **tabbatar da tsawon rai** yana wuce gona da iri bisa ga abin da takardar ta nuna. ## Karanta sakamakon da hankali - **NAD+ na jini wakili ne na shigowar precursors.** Yana nuna an sha su, amma ba ya nuna abin da ke faruwa a cikin tsoka, kwakwalwa, ko sauran gabobi. - **Masana'antu na shiga.** Gwaje‑gwajen kayan ƙari yawanci suna da alaƙa da kamfanonin da ke samar da kayayyakin, don haka a duba ko an samu **conflict of interest** a takardar. - **Yawan mahalarta na da tasiri.** Sakamakon da aka samu a cikin manya masu lafiya ba lallai su shafi ƙuruciya ko masu cuta ba. ## Kammalawa Gwajin NRPT ya tabbatar da abu guda: a cikin manya masu lafiya, **sha NR da pterostilbene a kowace rana na ɗaga matakin NAD+ na jini a hanya mai alaƙa da ƙima**, kusan 40 % a ƙimar da ake ba da shawara da kuma kusan 90 % a ƙimar da ta ninka. NAD+ ya kasance a sama tsawon makonni takwas ba tare da wani haɗari mai tsanani ba. Amma **abinda waɗannan matakan NAD+ ke nufi ga lafiyar dogon lokaci har yanzu ba a sani ba**. Idan kana tunanin ƙara wani precursor na NAD+, musamman a ƙima mai girma ko tare da wasu magunguna, ka tattauna da likita kafin ka fara.

Rapamycin Sau Daya a Kowane Mako na Shekara: Lafiya, Amma Shin Kitse na Ciki Ya Sauya?

Rex Meridian — Fri, 16 Oct 2026 07:19:38 GMT

**Sakamakon da ke kan taken zai iya ba wa masu sa ran rapamycin jin baɗin rai idan suna tunanin zai ƙone kitse a ciki. Sauran bayanai su ne waɗanda suka fi jan hankali.** Gwajin **PEARL** (wanda aka buga a *Aging*, 2025) na daga cikin ƙuruciyoyin farko da aka yi da tsarin gwaji mai duhu, an kwatanta da placebo, kuma an bai wa manya masu lafiya ƙananan ƙuduri na rapamycin a kai a kai. Tambayar bai kasance ko rapamycin zai tsawaita rayuwar ɗan adam ba, sai ko shan sa sau ɗaya a mako, kusan shekara guda, na da aminci kuma ko yana motsa wasu alamu na tsawon lokacin lafiya. ## Siffar Gwajin - **Tsari:** gwajin da ba a san waninsa ba (double‑blind), duhu, rarrabe, placebo‑controlled (NCT04488601). - **Lokaci:** makonni 48. - **Rukuni:** placebo, 5 mg rapamycin a mako, 10 mg rapamycin a mako. - **Babban sakamako:** kitse na ciki da aka auna ta DXA. - **Aminci:** adadin abubuwan da suka faru marasa kyau da masu tsanani ya yi daidai a dukkan rukuni. - **Kitse na ciki:** ba a sami canjin da ya kai mahimmanci ba (ηp² = 0.001, p = 0.942). - **Alamomin jini:** canje‑canje sun tsaya a cikin iyakokin al’ada. - **Alamomin biyu:** ƙaruwa a ƙwayar ƙiba da rage jin zafi a mata masu sha 10 mg; jin daɗi na tunani da lafiyar gaba ɗaya sun inganta a rukunin 5 mg. ## Babban Sakamako: Kitse Na Ciki Bai Sauya Ba Sakamakon da aka fi mai da hankali a kai – kitse na ciki – bai nuna wani gagarumin canji ba. ƙimar **p = 0.942** da ƙananan **ηp² = 0.001** na nuni da babu alama a nan. Idan buri shine rage kitse a ciki, wannan gwaji ba ya tallafa wa wannan tunani. Ko da yake ba a sami tasiri a babban sakamako ba, sakamakon na da amfani: yana nuna mana iyakokin abin da rapamycin ba zai iya yi ba a wannan ƙungiya da tsawon lokaci. ## Aminci: Tabbas, Amma Da Sharudda Rapamycin (sirolimus) sanannen magani ne da ake amfani da shi wajen hana ƙwanƙolin ƙwayoyin da ke haifar da ƙiba. A PEARL, adadin abubuwan da suka faru marasa kyau da masu tsanani ya yi daidai tsakanin rukuni‑rukuni, kuma alamomin jini sun tsaya a cikin iyakokin da ake tsammani. Marubutan sun ƙare da cewa shan rapamycin a ƙananan ƙuduri sau ɗaya a mako tsawon makonni 48 "kusan amintacce" ga manya masu lafiya. Wannan kalma na nufin: - mahalarta su ne mutanen da ba su da cuta mai tsanani ko hulɗar magunguna; - shan 5 mg ko 10 mg sau ɗaya a mako, ba kullum ba; - kusan shekara guda, ba shekaru goma ba. Bayanan shekara ɗaya ba su ba da cikakken haske kan haɗarin dogon lokaci ba. ## Sakamakon Ƙananan Rukuni: Sha’awa Amma Ba Shaida Ba Alamomin biyu da suka fi jan hankali sun fito ne daga nazarin ƙananan rukuni: - **Mata masu sha 10 mg:** ƙaruwa a ƙwayar ƙiba (ηp² = 0.202, p = 0.013) da raguwar jin zafi (ηp² = 0.168, p = 0.015). - **Rukuni 5 mg:** ingantaccen jin daɗin tunani (ηp² = 0.108, p = 0.023) da lafiyar gaba ɗaya (ηp² = 0.166, p = 0.004). - **Sauran alamu:** ba a ga tasiri mai mahimmanci ba. Wadannan bayanai sun yadu a intanet, don haka a karɓe su da hankali. Sun samo asali ne daga nazarin ƙananan rukuni da tambayoyi masu zaman kansu, ba daga babban manufar gwajin ba. Suna iya zama alamar da ake buƙatar tantancewa a nan gaba. ## Magani da Aka Yi Amfani Da Shi A PEARL **rapamycin an haɗa**. Samfurin da aka haɗa na iya bambanta da maganin kasuwanci a fannin ƙwayar kwaya, narkewa, da daidaito. Saboda haka, sakamakon gwajin ya shafi takamaiman samfurin da aka yi amfani da shi, ba zai iya auna kai tsaye ga wasu samfura ba. Idan kana son kwatanta shirin ka da gwajin, ka lura da nau’in maganin da yadda aka haɗa shi. ## Bayanin Tsarin Gwaji (Ba Shawara Ta Kiwon Lafiya Ba) Idan kana karanta wannan bincike, ga abubuwan da yake nuna da wadanda ba ya nuna: 1. **Tsarin shan magani:** PEARL ya yi amfani da shan sau ɗaya a mako na 5 mg ko 10 mg. Wannan shine tsarin da aka gwada – ba a tabbatar da wani ƙarfin dogon lokaci ba. 2. **Kulawa da aminci:** an bi diddigin abubuwan da suka faru marasa kyau da alamomin jini a ko da yaushe. Duk wanda ke tunanin amfani da rapamycin ba tare da izini ba ya kamata ya tattauna da likita kuma ya yi gwaje‑gwajen jini yadda ya dace. 3. **Matsayi na auna:** an yi amfani da DXA don auna kitse na ciki kuma an yi tambayoyi don tantance jin daɗi da radadi. Ma’aunin ainihi yafi tunani. 4. **Sanya tsammani a madaidaici:** babban sakamakon – kitse na ciki – bai canza ba. 5. **Yanayin mahalarta:** su ne mutanen da ke da lafiya. Sakamakon ba su shafi masu cuta, masu matsalar garkuwar jiki, ko waɗanda ke amfani da magunguna masu hulɗa ba. ## Abinda Gwajin BA YA NUNA A takaitaccen: **PEARL ba ya tabbatar da cewa rapamycin yana tsawaita rayuwar ɗan adam ko yana rage tsufa.** Gwajin ba a tsara shi don haka ba. ## Gabaɗaya Saƙon da PEARL ya fi ƙarfafa shine game da **aminci**: shan rapamycin a ƙananan ƙuduri sau ɗaya a mako tsawon shekara guda ba ya haifar da mummunan sakamako fiye da placebo a manya masu lafiya. Babban sakamako – babu canji a kitse na ciki – ya nuna cewa rapamycin ba ya yi tasiri a wannan fanni. Ƙaruwa a ƙwayar ƙiba, rage radadi, da ingantaccen jin daɗi na tunani suna da ban sha'awa, amma su ne sakamakon ƙananan rukuni kuma ba su tabbatar da fa’ida ga kowa ba. Marubutan suna shirin gudanar da ƙarin gwaje‑gwaje da ƙuduri daban‑daban don auna tasirin rapamycin da kyau. Har sai an kammala waɗannan, rapamycin a matsayin maganin tsawaita rai har yanzu ra'ayi ne mai alƙawari, yayin da amincin shekara guda ya nuna rashin haɗari mai tsanani amma ba ya nufin an samu fa’ida tabbatacciya.

Berberine da Metformin: Gwajin Farko da ya rage HbA1c daga 9.5% zuwa 7.5%

Helix Ward — Thu, 15 Oct 2026 09:52:02 GMT

# Kun taɓa jin ƙarar da ake yadawa: ƙara abinci mai rahusa da ake cewa tana daidai da maganin farko na cutar suga Wani ƙaramar gwaji na farko da aka wallafa a 2008 a *Metabolism* ya zama tushen wannan hayaniya, kuma lissafin ainihi ya cancanci a karanta da kyau, har da sassan da ƙarar ba ta taɓa ambata ba. **Sakamakon da aka fi maida hankali a kai:** a cikin mutane masu sabuwar ganewar cutar suga nau’in 2, **tasirin berberine wajen rage suga ya yi daidai da na metformin**, kuma HbA1c a ƙungiyar berberine ya sauka daga **9.5 % zuwa 7.5 %** cikin watanni uku. Wannan abu ne mai ban mamaki, amma har yanzu gwaji ne ƙanana a cikin masu cutar suga, ba a cikin masu lafiya da ke neman “bio‑hack” ba. *Madogara: Yin J, Xing H, Ye J. "Efficacy of berberine in patients with type 2 diabetes mellitus." Metabolism. 2008 May;57(5):712‑7. [PubMed record](https://pubmed.ncbi.nlm.nih.gov/18442638/) | [DOI](https://doi.org/10.1016/j.metabol.2008.01.013)* ## Menene ainihin gwajin ya ƙunsa? Takardar tana ba da rahoton gwaje‑gwaje biyu masu zaman kansu, kowannensu ya ɗauki watanni uku. - **Gwaji A:** mutane 36 da aka sabunta ganowarsu da cutar suga nau’in 2 an raba su zuwa rukuni‑ruƙuni biyu; an ba su **berberine** ko **metformin** a daidai gwargwado. An ba su **0.5 g sau uku a rana**. - **Gwaji B:** mutane 48 da ke da cutar suga ba a sarrafa ba, suka sha berberine **a gefe da maganin da suke riga suna amfani da shi**, har na tsawon watanni uku. Gwaji A shine gwajin kai‑da‑kai (placebo‑controlled). Gwaji B ba shi da rukuni‑na‑kwatanta a cikin takaitaccen bayani; yana tambayar ko berberine na ƙara wani tasiri a kan maganin da marasa lafiya ke sha. ## Sakamakon Gwaji A: berberine vs. metformin Masu bincike sun kammala da cewa tasirin berberine na rage suga yana kama da na metformin. A ƙungiyar berberine an samu waɗannan canje‑canje: | Alamar | Kafin | Bayan | Mahimmanci | |---|---|---|---| | HbA1c | 9.5 % ± 0.5 % | 7.5 % ± 0.4 % | P < 0.01 | | Glukos na safe | 10.6 ± 0.9 mmol/L | 6.9 ± 0.5 mmol/L | P < 0.01 | | Glukos bayan cin abinci | 19.8 ± 1.7 mmol/L | 11.1 ± 0.9 mmol/L | P < 0.01 | | Triglycerides | 1.13 ± 0.13 mmol/L | 0.89 ± 0.03 mmol/L | P < 0.05 | Takaitaccen bayani ba ya ba da lambobin rukunin metformin, don haka “kama” ya dogara ne kacokam a kan bayanin marubuta. ## Sakamakon Gwaji B: berberine a matsayin ƙari A cikin mutanen 48 da ke da cutar suga marasa sarrafa, berberine ya rage glukos na safe da na bayan cin abinci **daga mako na ɗaya har zuwa ƙarshen gwajin**. Wasu muhimman bayanai: - **HbA1c:** 8.1 % ± 0.2 % zuwa 7.3 % ± 0.3 % (P < 0.001) - **Insulin na plasma a safe:** raguwar 28.1 % (P < 0.001) - **HOMA‑IR (ma’aunin rashin amincin insulin):** raguwar 44.7 % (P < 0.001) - **Cholesterol gaba ɗaya da LDL:** duk sun ragu sosai (ba a bayar da adadi a takaitaccen bayani ba) Raguwar insulin da HOMA‑IR su ne abubuwan da masu sha’awar lafiyar metabolism za su kamata su lura da su, domin suna nuna ingantaccen amincin insulin maimakon sauƙaƙan matakan glukos kawai. ## Yaya berberine ke aiki? (Ta hanyar AMPK) Takardar ta yi nuni da cewa an nuna berberine yana sarrafa glukos da ƙwayoyin kitse a cikin dakin gwaje‑gwaje da a jikin dabbobi. Ba a tantance wani salon aiki ba. A mafi yawancin adabi, an ce berberine yana kunna **AMPK**, wani enzyme a cikin ƙwayoyin da ke ƙara cin glukos da ƙone kitse, tare da rage adanar kitse da samar da glukos a hanta. Metformin ma ana ɗauka yana shiga hanyoyin da suka shafi AMPK, shi ya sa kwatantawar ke da ban sha’awa. A nan, ku ɗauki wannan a matsayin bayani na asali, ba sakamakon gwaji ba. Gwajin ya auna sakamako, ba aikin AMPK ba. ## Karamin rubutu: iyakoki Kafin ku canza ƙarin abincinku, ku yi la’akari da waɗannan: - **Ƙananan gwaje‑gwaje na farko.** Mutane 36 da 48 ba su isa su tabbatar da wata hujja ba; su ne kaɗan don ba da shawarar yin ƙarin bincike. - **Masu cutar suga ne kawai.** Gwaji A ya kunshi sabbin marasa lafiya, yayin da Gwaji B ya ƙunshi marasa lafiya masu sarrafa da ba daidai ba. Ba ya nuna abin da berberine zai yi a cikin mutane masu lafiya ko waɗanda ke da matsalolin metabolism na ƙanana. - **Gwaji B yana da ƙari‑ƙari.** Ba tare da rukuni‑na‑kuma‑ba a takaitaccen bayani ba, ba za a iya tabbatar da cewa berberine kaɗai ne ya haifar da canjin ba. - **Lokaci ɗan gajeren.** Watanni uku ba su ba da alamar aminci na dogon lokaci ko tabbacin tsawon amfani ba. - **Illolin hanji sun kasance da yawa.** **Masu cuta 20 (34.5 %)** sun fuskanci rashin jin daɗin hanji na ɗan lokaci. Takaitaccen bayani ba ya fayyace adadin ainihi, kuma 20 na daga cikin 58 ba su dace da ƙungiyoyin da aka ambata ba, don haka ba a fayyace ba. - **Alamomin aminci sun iyakance ga abin da aka duba.** Marubutan sun ce ba su ga wata matsalar hanta ko koda ba, amma wannan yana nuni da ƙaramin binciken aminci. Kila kun taɓa ganin berberine ana kiransa “Ozempic na halitta”. Wannan ƙarar ne daga intanet, kuma wannan gwaji ba ya gwada wani abu makamancin haka. Ba a yi gwajin rage kiba ba, kuma ba a kwatanta da magungunan GLP‑1. ## Abin da yake nufi a gare ku: muhimman abubuwa - **Matsakaicin da aka yi amfani da shi a gwaji:** 0.5 g sau uku a rana, kamar yadda aka ambata a rukuni na metformin (gwaji A). Takaitaccen bayani ba ya bayyana lokacin cin abinci, amma a mafi yawan lokuta, a ci tare da abinci yana taimakawa rage rashin jin daɗin hanji. - **Waɗanda wannan hujja ta shafi:** manya masu cutar suga nau’in 2, tare da likita da ke bibiyar matakan sukari da HbA1c. Idan kana da lafiya sosai, wannan bincike ba ya nuna amfanin kai. - **Waɗanda ya kamata su guje shi ko su yi hankali kwarai:** - Duk wanda ke kan maganin suga, domin ƙara wani abu mai rage sukari na iya haifar da ƙarancin sukari (hypoglycemia). - Duk wanda ke amfani da magunguna da iyaka mai ƙanƙanta na aminci. Berberine na iya hulɗa da wasu magunguna ta hanyar canza yadda jiki ke metabolizawa, don haka a duba da likita ko ƙwararren magani. - Mata masu juna biyu, masu shayarwa, ko masu fama da cutar hanta ko koda. A tuntubi kwararre kafin a fara. - **Illolin da za a iya fuskanta:** A wannan gwaji, matsalolin hanji ne mafi yawa kuma na ɗan lokaci. Idan kun gwada berberine tare da kulawar likita, ku shirya cewa zai ɗauki wani lokaci kafin jikinku ya saba. - **Gaba ɗaya:** Berberine **ba zai maye gurbin maganin suga da aka rubuta maka ba**, sai dai idan likita ya yanke shawarar hakan. Wannan gwajin na 2008 alama ce mai kyau wadda ke buƙatar manyan gwaje‑gwaje masu tsawo da kyakkyawan kulawa. Ba shine izinin canza metformin zuwa ƙarin abinci ba. *Wannan rubutun yana nufin bayar da bayanai kawai, ba shawarwarin likita ba.*

Vitamin D3 Ya Dakile Raguwar Telomere da 140 Base Pairs a Gwajin RCT na Shekaru 4

Dr. Synapse — Thu, 15 Oct 2026 09:50:47 GMT

# Vitamin D3 Ya Dakile Raguwar Telomere da 140 Base Pairs a Gwajin RCT na Shekaru 4 **Sakamako:** Wani babban gwaji mai kulawa da placebo ya gano cewa shan vitamin D3 tsawon shekaru hudu ya rage raguwar telomere da kusan **140 base pairs**. Bayanai sun samo asali daga binciken VITAL da aka gudanar a kan manyan 'yan Amurka masu shan **2,000 IU** a kowace rana. Tasirin ya kasance kanana (p = 0.039), kuma tsawon telomere alama ce kawai, ba hujjar tsawon rai ba. Omega‑3 kuwa a wannan gwaji ba ta nuna wani tasiri kan telomere. ## Yawancin Ikirarin Anti‑aging Sun Dogara ne a kan Beraye Ko Ƙananan Nazari Mafi yawan maganganun anti‑aging sun fito ne daga gwaje‑gwajen beraye, ƙwayoyin da aka girka a faranti, ko ƙananan nazarin da ba su da ƙarfi. Wannan sakamakon kuwa ya fito ne daga babban gwaji mai kulawa da placebo, an yi shi a matsayin gwajin **2 × 2 factorial**. A cikin shekaru hudu, shan vitamin D3 ya dakile raguwar telomere da kusan **140 base pairs** idan aka kwatanta da placebo. Tasirin ya wanzu a ma’anar ƙididdiga, amma ƙanana ne. Ga abin da binciken ya gano da abin da ba a tabbatar ba. ## Me Gwajin Ya Yi Da Gaske? Aikin ya fito ne daga **VITamin D and OmegA‑3 TriaL (VITAL)**, wani gwaji da ya haɗa **25,871** manyan 'yan Amurka: mata masu shekaru **55 da sama** da maza masu shekaru **50 da sama**. VITAL ta yi amfani da tsarin **2 × 2 factorial**, don haka mahalarta an raba su zuwa: - **Vitamin D3 2,000 IU/ rana** ko placebo - **Omega‑3 na teku 1 g/ rana** ko placebo An gudanar da shirin na tsawon **5 shekara**. Nazarin telomere wani ɓangare ne na ƙananan ƙungiya (NCT04386577) wanda ya tara **1,054** mahalarta, waɗanda aka duba a Cibiyar Kimiyyar Kwayoyin Halitta ta Harvard. An auna tsawon telomere na sel ɗin fararen jini (leukocyte) ta hanyar **qPCR** a **lokacin farawa, shekara ta 2, da shekara ta 4**. Jimillar samfuran da aka nazarta su **2,571** daga mahalarta **1,031** an gudanar da su tare da ƙirar haɗa‑haɗɗen tasirin layi. Masu binciken, a jagorancin **Zhu H., Manson J.E., Dong Y.** da ƙungiyarsu, ba su da wata ƙaura (conflict of interest). Sakamakon an wallafa a *American Journal of Clinical Nutrition* a 2025. ## Muhimman Sakamako: Lambobin Daidaitattu - **Vitamin D3 vs. placebo:** raguwar telomere ta tsaya da **0.14 kb (140 base pairs)** a tsawon shekaru 4 (95 % CI: 0.007 – 0.27; **p = 0.039**). - **Tsawon telomere a kowace shekara:** ƙungiyar da ta karɓi vitamin D3 ta kasance **0.035 kb** mafi tsawo a kowace shekara idan aka kwatanta da placebo (95 % CI: 0.002 – 0.07; p = 0.037). - **Omega‑3 na teku:** **babu tasiri mai mahimmanci** a sarari a shekara ta 2 ko shekara ta 4. Vitamin D3 ba ta tsawaita telomere daga farko ba, amma ta rage saurin raguwar su idan aka kwatanta da placebo. Omega‑3 da ake tallata tare da vitamin D don “kariya daga tsufa” ba ta nuna wani fa’ida ga telomere a wannan gwaji ba. ## Dalilin Da Telomere Ke Da Muhimmanci (Kuma Me Ya Sa Ba Ya Nuni Da Cikakken Lafiya) Telomere suna kama da murfin kariya a ƙarshen kwayoyin halitta. Suna gajarta yayin da ƙwayoyin ke rabuwa; idan suka yi gajarta ƙwarai, kwayoyin na shiga yanayin **senescence** – wato daina rabuwa kuma su fitar da sinadarai masu haifar da damuwa. Saboda haka, tsawon telomere na daga cikin manyan alamu da ake bi a binciken tsufa. Amma ai alamu ba su zama sakamako ba. Telomere alama ce **ta maye gurbi**; wannan gwaji ba ya nuna cewa rage raguwar telomere zai sa mutum ya rayu tsawon rai, ya kasance lafiya, ko ya kauce wa cuta. Marubutan sun ce vitamin D3 "na iya taka rawa wajen rage raguwar telomere ko senescence na kwayoyin". Wannan kalmar na nuni da wata alama, ba da tabbacin canji ba – dole ne masu karatu su yi taka tsantsan. ## Iyakoki: Karanta Wannan Kafin Ka Yi Murna - **Tasirin ƙanƙanta kuma a ɓangaren iyaka.** Kima **p = 0.039** ya ƙanƙanta kaɗan da ƙa’ida ta 0.05. Bawul (confidence interval) ya fara daga **0.007 kb** zuwa **0.27 kb**, don haka tasirin zai iya zama ƙanana ko ma fi girma. Dole ne a sake tantance wannan sakamako a wasu gwaje‑gwaje. - **Alamar maye gurbi ce.** Tsawon telomere a sel ɗin jini ba ya nufin tsawon rai ko kariya daga cuta kai tsaye. - **Ƙungiyar da aka yi wa gwaji takamaimai.** Mahalarta manyan 'yan Amurka ne (mata 55+, maza 50+). Sakamakon na iya ba su dacewa da matasa, sauran al’ummomi, ko mutanen da ke da matakan vitamin D daban‑daban. - **Leukocyte telomere wakili ne.** Sun nuna tsawon telomere a sel ɗin fararen jini ne, ba a dukkan sassan jiki ba. - **Omega‑3 ba ta da tasiri.** Ko da yake mai kifi na iya bayar da wasu fa’idodi ga lafiya, a wannan gwaji da **1 g/ rana** ba ta kare telomere ba. ## Me Wannan Ke Nufi Ga Kai? Wannan bincike yana ba masu sha’awar tsawon rai wani dalili mai ma’ana don ɗaukar vitamin D, amma ba yana nufin ƙara shi a matsayin maganin anti‑aging ba. Ka ɗauke shi a matsayin ƙarin hujja ga kariya da ake da ita, wadda ba ta da tsada kuma an tantance ta sosai. ## Abubuwan Da Za Ka Iya Aiwatar Da Su - **Matsakaicin da aka yi amfani da shi a gwaji:** **2,000 IU/ rana** na vitamin D3 (cholecalciferol). Wannan shine kawai adadin da ke da hujja a cikin sakamakon; ba mu da dalili a ƙara yawan. - **Lokacin shan:** Vitamin D yana narkewa a mai, don haka sha shi tare da abinci mai ɗan mai na taimakawa wajen shigar da shi. Daidaiton shan a kowace rana yafi muhimmanci fiye da lokacin da ake sha. - **Gwada, kar ka yi hanzari:** Ka auna matakin **25(OH)D** a jini – alamar da ake amfani da ita don tantance matakin vitamin D. Idan matakin naka ƙasa ne, ka yi la’akari da ƙara a hankali maimakon ƙara yawan ba tare da sanin halin ka ba. - **Kada ka wuce ma’aunin da aka gwada:** Gwajin ya yi amfani da ƙima mai tsaka‑tsaki, kuma ba a tabbatar da cewa ƙarin yawan vitamin D zai haifar da ƙarin tasiri ga telomere ba. Manyan ƙima na iya ƙara yawan calcium a jini kuma su jawo matsaloli. - **Waɗanda za su amfana:** Manyan 'yan Amurka (50 shekara da sama) da ke neman kariya da aka tabbatar da ita, a ƙarƙashin ƙima mai yau da kullum, musamman idan an duba matakin vitamin D a jini. - **Waɗanda ya kamata su tattauna da likita kafin su fara:** - Mutanen da ke da tarihin **hypercalcemia**, **kashi**, ko **cutar ƙoda** - Masu cutar **sarcoidosis** da sauran cututtuka da ke shafar metabolin calcium ko vitamin D - Duk wanda ke shan magunguna da ke hulɗa da vitamin D ko calcium - Matan da ke cikin ciki ko shayarwa, da kuma waɗanda ke tunanin ɗaukar ƙima sama da na gwaji - **Lafiya:** A 2,000 IU/ rana a babban gwaji mai tsari, vitamin D3 an ɗauka mafi aminci. Duk da haka, tarihin lafiyar mutum yana da muhimmanci; don haka ka nemi shawara daga ƙwararren likita idan ba ka da tabbas. - **Kada ka saya omega‑3 don telomere.** Mai kifi na iya da wasu amfani ga lafiyarka, amma wannan gwaji bai nuna wani tasiri ga telomere ba. ## Gabaɗaya A babban gwaji mai kulawa da placebo, **2,000 IU/ rana** na vitamin D3 na tsawon shekaru hudu ya danganta da kusan **140 base pairs** ƙananan raguwar telomere idan aka kwatanta da placebo. Tasirin ya kasance kanana (p = 0.039) kuma alama ce kawai, ba hujjar tsawon rai ba. Wannan sakamako yana ƙarfafa ci gaba da bincike kuma yana ba da hanya mai araha don daidaita matakin vitamin D. Ba ya tabbatar da cewa vitamin D na tsawaita rai. **Madaidaici:** Zhu H, Manson JE, Cook NR, Bekele BB, Chen L, Kane KJ, Huang Y, Li W, Christen W, Lee IM, Dong Y. "Vitamin D3 and marine ω‑3 fatty acids supplementation and leukocyte telomere length: 4‑year findings from the VITamin D and OmegA‑3 TriaL (VITAL) randomized controlled trial." *Am J Clin Nutr.* 2025 Jul;122(1):39‑47. [PubMed: 40409468](https://pubmed.ncbi.nlm.nih.gov/40409468/) | [DOI: 10.1016/j.ajcnut.2025.05.003](https://doi.org/10.1016/j.ajcnut.2025.05.003) *Wannan labarin yana ba da bayanin ilimi ne kawai, ba shawarar likita ba.*

Gram 2.5 na Peptide Collagen Ya Rage Tabon Idanu da Kashi 20% Cikin Makonni 8

Nova Chen — Thu, 15 Oct 2026 09:46:38 GMT

# Gram 2.5 na Peptide Collagen Ya Rage Tabon Idanu da Kashi 20% Cikin Makonni 8 **Taƙaitaccen Bayani**: Collagen ɗaya daga manyan abubuwan da ake nema a fannin kwalliya da tsawon rai, amma mafi yawan samfuran suna da takardun placebo ne kawai. A wani gwaji da mata 114 masu shekaru 45‑65 suka halarta, gram 2.5 na takamaiman peptide mai aiki Verisol ya rage ƙyallin tabon idanu da kashi 20 % idan aka kwatanta da placebo bayan makonni 8. Biopsies sun nuna ƙaruwa a procollagen I da kashi 65 % da elastin da kashi 18 %, yayin da ƙaruwa a fibrillin (6 %) ba ta da muhimmanci. Tasirin ya ci gaba da bayyana har makonni 4 bayan shan ƙarshe, amma sakamakon ya shafi peptide ɗaya ne kawai a ƙungiyar mata, ba kowanne foda na collagen ba. **Abun Ciki** Collagen powders suna ko'ina, amma mafi yawansu suna ɗauke da alkawura marasa tabbas da kuma ƙananan takardun kimiyya. Wannan rafin gwaji double‑blind, placebo‑controlled ne. A cikinsa, **gram 2.5 a rana na takamaiman peptide collagen mai aiki ya rage ƙyallin tabon idanu da kashi 20 % idan aka kwatanta da placebo bayan makonni 8**. Biopsies suma sun nuna ƙaruwar procollagen I a fata. Matsalar ita ce, sakamakon ya shafi peptide ɗaya mai alama **Verisol**, wadda aka gwada a ƙungiyar mata kawai. Ba ya nufin kowanne foda na collagen da ke kan tebur ba. Waɗannan rubutun na bayyana abin da binciken ya yi, abin da ya gano, da iyakokin sakamakonsa. ## Abin da Binciken Ya Yi Takardar da aka rubuta *Oral intake of specific bioactive collagen peptides reduces skin wrinkles and increases dermal matrix synthesis* ta ƙunshi Proksch E, Schunck M, Zague V, Segger D, Degwert J da Oesser S, kuma an wallafa ta a *Skin Pharmacology and Physiology* a shekarar 2014 (27(3):113‑119). Cikakken bayanin takardar yana a kan [PubMed](https://pubmed.ncbi.nlm.nih.gov/24401291/). **Tsarin Binciken** - **Mata 114 masu shekaru 45‑65**, an raba su daidai (57 a kowanne rukuni) - **Gram 2.5 na peptide collagen mai aiki Verisol, ko placebo, sau ɗaya a rana tsawon makonni 8** - Double‑blind da placebo‑controlled - An auna ƙyallin tabo a matakin farko, makonni 4 da makonni 8, sannan an ƙara **makonni 4 na lokaci na dawowa** bayan ƙarshe ƙarin magani - **Ƙungiyar ƙanana** ta sami biopsy na suction blister a matakin farko da makonni 8. An auna procollagen I, elastin da fibrillin a fata. Auna ƙyallin tabo da biopsies ne suka bambanta wannan gwaji da yawancin ƙarin kayan abinci da suka dogara da tambayoyin “fata na ji daɗi”. ## Peptide Collagen Mai Aiki vs. Collagen Na Kowa Collagen wani protein ne na gina jiki. “Collagen supplements” na iya nufin abubuwa dabam‑dabam, daga gelatin zuwa powders da ba a fayyace ba. *Peptide collagen mai aiki* (BCP) shi ne takamaiman tsari na ƙwayoyin peptide da aka tantance. Manufar takardar Verisol ita ce masu binciken sun gwada **peptide ɗaya takamaimai**, ba collagen gaba ɗaya ba. Masu rubutu sun bayyana hakan a fili: “takamaiman peptide collagen mai aiki (Verisol®).” Idan ka sayi wani samfurin collagen daban, wannan gwaji ba ya ba da wani tabbaci ko zai yi aiki ba. Wataƙila zai yi, amma ba a tabbatar da hakan a wannan binciken ba. ## Muhimman Sakamako, Tare da Lissafi **Ƙyallin Tabon Idanu** - Ƙyallin tabo ya ragu sosai (p < 0.05) idan aka kwatanta da placebo a makonni 4 da 8. Rage a makonni 8 ya kai **kashi 20 %**. - **Tasiri mai ɗorewa** har ma ya kasance mai muhimmanci (p < 0.05) **makonni 4 bayan ƙarshe ƙarin magani**. **Matrix na Fata (bayanan biopsy, makonni 8 vs. placebo)** - **Procollagen I: +65 %** - **Elastin: +18 %** - **Fibrillin: +6 %**, wanda **bai kai ga samun ƙididdiga mai mahimmanci ba** Sakamakon fibrillin abu ne da za a iya warewa a kan taken labarai; ba shi da ƙarfi na kimiyya don a kirga shi nasara. ## Tsarin Da Aka Bayyana Taken takardar yana danganta raguwar ƙyallin tabo da “ƙaruwa a samar da matrix na dermal.” Proccollagen I shi ne farkon collagen nau’in I, babban collagen na gina fata. Elastin na ba fata lankwasa. Hawan matakan duka a rukuni da aka yi magani ya dace da raguwar ƙyallin da aka gani. Amma, bayanin da ke cikin takardar yana nuna alaka ce da aka auna a cikin gwaji guda. Ba ya nuna cewa canjin matrix ne ya haifar da raguwar tabo. Haka kuma, ba a fayyace yadda peptide ɗin ke aika saƙon zuwa sel‑fata ba. Ka ɗauki wannan tsarin a matsayin mai yuwuwa kuma an tallafa shi da bayanan biopsy, ba a matsayin cikakken bayani ba. ## Takaitattun Iyakoki: Karanta Wannan Kafin Ka Saya Sakamakon suna da ƙarfafa, amma ƙuntatawa suna da mahimmanci kamar su: - **Mata masu shekaru 45‑65 kawai.** Maza da mata ƙasa ko manya ba a gwada su ba. - **Makonni 8 na shan magani** da kuma makonni 4 na bi‑biyan. Ba a san tasiri ko haɗari na amfani na shekara guda ko fiye ba. - **Peptide ɗaya mai alama.** Ba a iya amfani da sakamakon ga sauran kayayyakin collagen ba. - **Manufa ɗaya kawai: tabon idanu.** Ba a ba da rahoto kan sauran wuraren fuska ko jiki ba. - **Biopsies daga ƙungiyar ƙanana**, ba dukan mahalarta 114 ba. - **Fibrillin bai kai ga samun ma’ana ba.** - Takardar **ba ta ba da rahoton illa**; don haka ba za a iya yin ƙirari kan aminci ba. Masu rubutu sun lura da cewa ƙarancin binciken klinikal da ke tallafawa ikirarin cewa ƙarin abinci na inganta tsufar fata. Wannan gwaji yana ƙara bayanai, amma a matsayin nazari guda kaɗai; maimaita da ƙwararrun masu bincike zai ƙara gamsuwa. ## Abinda Yake Nufi Ga Kai: Ka'idojin Amfani **Abin Da Aka Yi Amfani Da Shi** - **Kima:** gram 2.5 na peptide collagen mai aiki Verisol - **Sauƙi:** sau ɗaya a rana - **Tsawon Lokaci:** makonni 8 – wannan ne lokacin da aka gwada kuma tasiri ya riga ya bayyana a mako na 4. - **Lokaci:** takardar tana cewa sau ɗaya a rana ne. Ba a gwada safiya ko maraice, ko tare da abinci ko ba tare da abinci ba, don haka babu “lokaci mafi kyau” da aka tabbatar da shi. **Wanda Ya Fi Daɗa** - Mata tsakanin shekaru 45‑65 da ke son rage layukan ƙarƙasasshe a kusa da idanu, wadda ta yi daidai da ƙungiyar da aka yi gwaji a kai. - Mutanen da ke son samfurin da ke da takardun kimiyya, an gwada da placebo. **Wanda Ya Kamata Ya Yi Caution Ko Ya Guje Shi** - Kowa **wanda ba shi cikin rukuni da aka gwada** ya kamata ya ɗauki fa’idar a matsayin ba a tabbatar ba. - Mutanen da ke da matsalolin abinci ko iyakoki suna buƙatar duba tushen collagen da abubuwan da ke ciki. Takardar ba ta bayyana tushen ba. - Matan da ke da ciki, masu shayar da yara, da waɗanda ke da cuta ko ke shan magani su nemi shawarwarin likita. Wannan gwaji ba ya magana kan waɗannan ƙungiyoyi. - Idan samfurin da kake amfani da shi ba Verisol ba ne, kada ka ɗauka adadin 20 % ya shafe shi. **Lafiya** Takardar ba ta tattauna illa ko ƙarfafa juriya ba, don haka ba za a iya fitar da wani ƙuduri na aminci ba. Kada ka ɗauka wannan a matsayin garanti na rashin illa. **Sa ran gaske** Kashi 20 % na raguwar ƙyallin tabo a idanun idan aka kwatanta da placebo abu ne mai auna, amma ba babbar canji ba. Ba zai maye gurbin facelift ba, ko ma maye gurbin kariyar rana. Tasirin ya ci gaba da kasancewa a kalla har makonni 4 bayan an daina, wanda ke nuna ba kawai na ɗan lokaci ba. Babu bayanin yadda zai ɗore fiye da haka. ## Kammalawa Wannan gwaji na ɗaya daga cikin mafi ƙarfi na takardun ɗan adam a bangaren collagen. Gram 2.5 a rana na Verisol na tsawon makonni 8 ya rage ƙyallin tabon idanu da kashi 20 % idan aka kwatanta da placebo, kuma biopsies sun nuna ƙaruwar procollagen I da kashi 65 % da elastin da kashi 18 %. Shaidar ta takaita ne ga mata 45‑65, tsawon lokaci kaɗan, da peptide ɗaya mai alama. Idan kana son maimaitawa, ka nemi wannan takamaiman peptide a wannan kima. In ba haka ba, ka yi la’akari da gwajinka na kanka. *Source: Proksch E, Schunck M, Zague V, Segger D, Degwert J, Oesser S. Oral intake of specific bioactive collagen peptides reduces skin wrinkles and increases dermal matrix synthesis. Skin Pharmacol Physiol. 2014;27(3):113‑119. doi:10.1159/000355523. [PubMed](https://pubmed.ncbi.nlm.nih.gov/24401291/)*

Kwayar Bakteriya a Cikin da Ta Fi Aiki Bayan Mutuwa: Amfanin Akkermansia da Ƙaruwa 29 %

Helix Ward — Thu, 15 Oct 2026 09:29:49 GMT

# Me zai faru idan mafi kyawun *probiotic* shine wanda ba ya da rai? Wannan batu ya fito a cikin ɗayan gwaje‑gwajen ƙwayoyin hanji da suka jawo cece-kuce a ’yan shekarun nan. Ya zama muhimmi yayin da ake haɗa lafiyar hanji da lafiyar metabolism a zamanin magungunan GLP‑1. Binciken da aka wallafa a ***Nature Medicine*** a 2019, ta ƙungiyar Depommier, Everard, Cani, de Vos da abokan aikin, ya gwada **Akkermansia muciniphila** a kan mutane masu kiba ko overweight waɗanda ke da rashin amsawar insulin. Nau’in da aka daɗa – wato “pasteurised” – ya inganta ƙwarewar insulin da kusan **%28.6**, kuma ya rage matakin insulin a jini da kusan **%34.1** idan aka kwatanta da placebo. Dukan bayanai na cikakken nazari suna buƙatar karantawa da hankali. ## Menene Binciken Ya Kunshi? Takardar tana da taken *Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof‑of‑concept exploratory study* ([PubMed](https://pubmed.ncbi.nlm.nih.gov/31263284/), DOI: 10.1038/s41591-019-0495-2). An gudanar da shi a wani cibiya guda, a karkashin tsarin *double‑blind* da *placebo‑controlled* (NCT02637115). - **Masu halarta:** mutane 40 masu kiba/overweight da ke da rashin amsawar insulin; 32 suka kammala gwajin. - **Kayan gwaji:** *A. muciniphila* 10^10 sel a rana, ko rayayye ko daɗa, na tsawon watanni uku. - **Kwatanta:** placebo. - **Manufa ta farko:** tantance tsaro, haƙuri da alamun metabolism (rashin amsawar insulin, kitse a jini, kitse na ciki, nauyin jiki). - **Manufa ta biyu:** nazarin aikin katangar hanji (lipopolysaccharides a plasma) da canjin al’umman ƙwayoyin hanji. Wannan shine karon farko da aka ba mutane *A. muciniphila*. A baya an gano cewa masu kiba, masu cutar sukari nau’in 2, da masu hawan jini suna da ƙarancin wannan ƙwaya a hanjinsu. ## Muhimman Sakamako Idan aka kwatanta da placebo, rukunin da aka ba da *pasteurised* ya nuna: - **Ƙwarewar insulin:** **+28.62 % ± 7.02** (P = 0.002) - **Insulinemia (insulin a jini):** **‑34.08 % ± 7.12** (P = 0.006) - **Kwalin cholesterol a plasma:** **‑8.68 % ± 2.38** (P = 0.02) Marubutan sun kuma ba da rahoton raguwar alamu na hanta da kumburi bayan watanni uku. Gwajin ya kasance lafiya, ba a samu wata mummunar illa ba – ko da ƙwayar ta kasance rayayye ko daɗa. ## Abubuwan da Ba a Bayyana a Labarai Ba Ragin da mutane ke so – rage nauyi da kitse – ba su kai ga matakin ƙididdiga ba: - **Nauyin jiki:** **‑2.27 kg ± 0.92** (P = 0.091) - **Kitse a jiki:** **‑1.37 kg ± 0.82** (P = 0.092) - **Fadin ƙirji:** **‑2.63 cm ± 1.14** (P = 0.091) Marubutan sun kira waɗannan “ƙananan” raguwa, don haka su ne alamu, ba muhimman sakamako ba. Ba a samu ƙarin ƙarfi a kan rage nauyi ba, kuma wannan ba zai iya maye gurbin magungunan GLP‑1 ba. ## Me Ya Sa *Pasteurised* Yafi *Live*? Nau’in da aka daɗa ya ba da fa’idodi mafi tsanani, yayin da na rayayye bai kai ga sakamako iri ɗaya ba. Takardar ba ta fayyace dalilin wannan bambanci ba, don haka a halin yanzu muna da asusun zato ne kawai. Akwai muhimman abubuwa guda biyu a cikin takardar: 1. **Jimillar microbiome** bai canza ba. Ko da an ƙara *Akkermansia*, al’umman ƙwayoyi ba su sauya ba. Wannan na nuni da tasirin “postbiotic”, wato ɓangaren ƙwayar ko abubuwan da ta fitar ke aika saƙo ga jiki ba tare da buƙatar rayuwa a hanji ba. 2. **Aikin katangar hanji** ya kasance sakamakon da aka sanya a farkon gwaji, alamar cewa an sa ran *Akkermansia* zai tallafa wa lafiyar katanga. Bayanin a *abstract* bai ƙunshi cikakken sakamakon ba, don haka a duba rubutun cikakke (open‑access, PMC6699990) kafin yanke hukunci. Fa’idar samfurin da aka kashe da zafi ita ce ba ya buƙatar adana shi a yanayi mai buƙatar iskar oxygen ko a kulle shi a firiji. ## Matsaloli da Rashin Daidaiton Sha’awa - **Karami da gajere:** Masu halarta 32 ne kawai suka kammala a cikin watanni uku. An kira shi “proof‑of‑concept exploratory study”. - **Cibiyar guda:** Ba a maimaita sakamako a wasu cibiyoyi ba. - **Rashin ƙididdiga a kan canjin nauyi/kitse:** Kamar yadda aka nuna a sama. - **Rashin daidaiton kasuwanci:** Wasu daga cikin marubutan (Everard, Druart, Plovier, Cani, de Vos) su ne masu haƙƙin ƙirƙira a kan takardun *A. muciniphila* a cikin kiba da cututtuka. Cani da de Vos sun kafa kamfanin **A‑Mansia Biotech SA**. Wannan ba ya kawar da sahihancin bayanai, amma yana nuna buƙatar gwaje‑gwaje na masu zaman kansu. - **Sakamakon wakili:** Ƙwarewar insulin da cholesterol su ne alamomi, ba hujja ce ta rage haɗarin zuciya ko cutar sukari ba. ## Abin Da Ya Kamata Ku Kula Da Shi Kafin Sayen Kari - **Adadin da aka yi amfani da shi a gwaji:** 10^10 sel a rana na tsawon watanni uku. Babu wani bayani kan tsawon lokacin da ya fi dacewa ko yawan da ake buƙata bayan gwaji. - **Nau’in da ya dace:** *Pasteurised* *Akkermansia muciniphila* – wannan shi ne nau’in da ya ba da sakamako mafi karfi a cikin binciken. - **Bayanin adadi:** Ku duba takamaiman yawan sel – 10^10 sel a rana – maimakon “billion CFU” da ba a fayyace ba, domin CFU na ƙwayoyin rayuwa da adadin sel na ƙwayoyin da aka daɗa ba su daidai. - **Kamfanin da ke samar da samfurin:** Gwajin ya yi amfani da samfurin kamfanin **A‑Mansia**, don haka hayar tallan samfurin na iya danganta da wannan bincike. Ka tabbatar samfurin da kake siya ya nuna a fili irin wannan bayanin. ### Wa Ya Iya Amfana? Manya masu kiba ko overweight da ke da rashin amsawar insulin – wato mutanen da aka yi gwajin akansu. Ba a san yadda zai tasiri ga wadanda ba su da kiba ko ba su da matsalar metabolism ba. ### Wa Ya Kamata Ya Guje Shi Ko Ya Tuntuɓi Likita? - Mutanen da ke amfani da magungunan rage sukari, domin ƙwarewar insulin na iya yin hulɗa da maganin. - Mata masu juna biyu, masu rauni a garkuwar jiki, ko masu cututtuka masu tsanani. Binciken bai rufe waɗannan rukunin ba, don haka shawara daga ƙwararren likita tilas ne. ### Tsaro Gwajin ya nuna cewa adadin 10^10 sel a rana, ko rayayye ko daɗa, ya kasance lafiya a tsawon watanni uku. Ba a tabbatar da tsaron dogon lokaci ba. ## Gabaɗaya Wannan shi ne yunƙurin farko mai kyau: an samu gagarumin inganta ƙwarewar insulin da raguwar cholesterol da ƙwayar da aka daɗa, amma babu tabbacin rage nauyi, samfurin yana da ƙaramin misali, kuma marubutan suna da alaƙa da kamfanin da ke sayar da shi. Shin zai yi amfani? **Ee, amma a hankali**. Shin maganin metabolic ne da zai iya maye gurbin sauran magunguna? **Har yanzu a’a**. Abincin da ya dace, motsa jiki, barci mai kyau da kulawa daga likita su ne ginshikin rayuwa. Don cikakken bayanin binciken, ziyarci: [Depommier et al., Nature Medicine, 2019](https://pubmed.ncbi.nlm.nih.gov/31263284/).

Omega-3 Ya Rage Tsufan Halitta Da Kimanin Watanni 3 Cikin Gwajin Shekara 3

Dr. Synapse — Thu, 15 Oct 2026 09:26:04 GMT

# Yawancin ƙarin anti‑aging suna ɗauke da manyan alkawari amma shaidar su kadan ne. Wannan an samu shi tare da gwajin bazuwar, jarida mai daraja, da tasirin da ya dace—kasa amma ya isa a tattauna. A gwajin **DO‑HEALTH**, **gram 1 na omega‑3 a rana** ya rage agogo uku na epigenetic a cikin shekaru uku, da kimanin **watanni 3 na tsufan halitta**. Idan aka haɗa da bitamin D da ƙananan motsa jiki a gida, ya fi kyau a kan agogon PhenoAge. Tasirin ƙanana ne, kuma an yi binciken a matsayin *post‑hoc*. Ga abin da bayanan ke nuna da kuma abin da ba su nuna ba. ## Abin da gwajin ya yi Takardar da aka wallafa: *Bischoff‑Ferrari HA, Gängler S, Wieczorek M, Belsky DW, et al., "Individual and additive effects of vitamin D, omega‑3 and exercise on DNA methylation clocks of biological aging in older adults from the DO‑HEALTH trial," Nature Aging, 2025;5(3):376‑385* ([PubMed](https://pubmed.ncbi.nlm.nih.gov/39900648/), [DOI](https://doi.org/10.1038/s43587-024-00793-y)). Gwajin *post‑hoc* ne kan **mutane 777** daga DO‑HEALTH, wani gwajin bazuwar na manyan mutane daga Switzerland, Germany, Austria, France da Portugal waɗanda suka kai shekaru 70 ko fiye. Gwajin ya yi amfani da **zane‑zane 2×2×2**, don haka kowanne zai iya samun kowane haɗin guda uku: - **Bitamin D3:** 2,000 IU a rana - **Omega‑3:** gram 1 a rana (EPA + DHA daga man algae) - **Shirin motsa ƙarfi a gida:** sauƙaƙan aiyuka sau 3 a mako Masana sun auna agogo huɗu na DNA methylation (DNAm) masu zuwa: **PhenoAge, GrimAge, GrimAge2, da DunedinPACE**. Waɗannan agogo na karanta alamu kimiyyar DNA don tantance shekarun jiki ko gudun tsufa. Lokacin sa‑ido shi ne **shekara 3**. ## Sakamakon da aka samu, tare da lambobi - **Omega‑3 kai‑kai ya rage agogo uku daga cikin hudu:** PhenoAge, GrimAge2, da DunedinPACE. - **Haɗin dukkan magungunan uku ya ba da fa'ida mai ƙari kan PhenoAge.** Ƙarin kayan haɗi ya nufin ƙarin raguwar agogo a kan wannan agogo. - **Tasirin da aka daidaita ya kai daga 0.16 zuwa 0.32 units** daga farkon gwaji zuwa shekara ta 3. Marubuta sun fassara wannan zuwa **watanni 2.9‑3.8 na tsufan halitta**. Saurin maƙasudin marubutan shi ne: gwajin ya nuna "tasirin kariya ƙanana na maganin omega‑3 wajen rage tsufan halitta a cikin shekaru 3 a kan agogo da yawa," tare da fa'ida mai ƙari saboda haɗin omega‑3, bitamin D, da motsa jiki a kan PhenoAge. Watanni uku a cikin shekaru uku ba su nufin juya tsufa ba. Amma alamar ƙanana ce amma tabbatacciya a kan agogo masu yawa, a cikin tsari na bazuwar da ya fi ƙarfi fiye da bayanan kallo ko kananan gwaje‑gwaje da suka gabata. ## Me ya sa omega‑3 zai iya yin haka? Takaitaccen rubutu ya ba da sakamakon agogo, ba dalilin sa ba. Kowace ƙira a nan ra'ayi ne, ba hujja ba. Ana nazarin omega‑3 don tasirinsa kan kumburi da lafiyar metabolism. Waɗannan biyun suna da alaka da hanyoyin halitta da agogo kamar GrimAge2 da DunedinPACE ke lura da su. Ko waɗannan hanyoyi ne suka haifar da canjin alama a DNA har yanzu ba a tabbatar ba. Fa'idar ƙari a kan PhenoAge ma ban sha'awa. Bitamin D da motsa jiki na iya aiki ta hanyoyi daban‑daban daga omega‑3, wanda zai iya haifar da ƙaruwa idan an haɗa su. Amma takardar ta ambaci wannan ƙari ne kawai a kan PhenoAge, don haka ba za a yi zaton yana aiki ga dukkan agogo ba. ## Takaitaccen iyakoki da gaskiya Wannan ne inda ya kamata ɗaukar maganar ya tsaya: 1. **Binciken *post‑hoc* ne.** Tambayar agogo epigenetic ba ita ce manufar asali ba, don haka sakamakon ya fi kama da ƙarfafa ra'ayi fiye da hujja ta ƙarshe. 2. **Tasirin ƙanana ne.** Girman tasiri na 0.16‑0.32 units, wato kusan watanni 3 a cikin shekaru 3, ba su da girma. 3. **Masu gwajin sun kai shekaru 70 ko fiye kuma sun fi lafiya.** Ba za a iya tabbatar da tasirin ga matasa ko ga masu cuta mai tsanani ba. 4. **Agogo epigenetic alamomi ne na wucin‑gadi.** Rage agogo ba yana nufin tsawon rai ko ƙasa da cuta ba. Babu agogo da aka tabbatar zai nuna cewa wata hanya zata tsawaita rayuwa. 5. **Ba duk agogo suka motsa ba.** Omega‑3 ya tasiri kan agogo uku, kuma ƙarin tasirin an ga shi ne kawai a kan PhenoAge. 6. **Sanar da cinikayya.** Babban marubucin S. Horvath shi ne wanda ya kafa *Epigenetic Clock Development Foundation*, ƙungiyar da ke da haƙƙin mallakar fasahar agogo (ciki har da GrimAge), kuma yana aiki a Altos Labs. Sauran marubutan sun bayyana babu wani haɗin sha'awa. ## Abin da ya shafi kai: muhimman nasiha na aikace‑aiki **Abubuwan da gwajin ya yi amfani da su:** - **Omega‑3:** gram 1 a rana (EPA + DHA, man algae a gwajin) - **Bitamin D3:** 2,000 IU a rana - **Motsa jiki:** sauƙaƙan shirin ƙarfafa gida, sau 3 a mako Takardar ba ta fayyace lokacin da ya fi dacewa ba, don haka babu wani “hacks” na lokaci da aka tabbatar; ainihin sakamakon yana nuni da amfani na kullum tsawon shekaru 3, ba na lokaci‑ƙan gajeren ba. **Waɗanda zai iya amfana:** manya masu shekaru 70 da sama waɗanda suke da lafiya gaba ɗaya—wannan shine rukuni da aka nazarta. Matasa masu son *bio‑hacking* na iya ganin bayanan da ban sha'awa, amma ba a tantance tasirin a kansu ba. **Waɗanda ya kamata su yi la’akari ko su tuntuɓi likita kafin su fara:** - **Duk wanda ke shan magungunan rage jini** ko wasu magungunan antiplatelet ya kamata ya tattauna da likita kafin ƙara omega‑3. - Duk wanda ke da cuta, yana shan magunguna da yawa, ko yana da takunkumin kari da ya shafi ɗanɗano ya kamata ya nemi shawarar ƙwararre. Kashi na bitamin D musamman yana bukatar a saita tare da likita idan akwai matsalolin calcium. - Idan kana da rashin jituwa da ƙifi ko kayan teku, duba asalin omega‑3 da kake sha; gwajin ya yi amfani da man algae. **Tsaro:** adadin da aka yi amfani da su (gram 1 na omega‑3, 2,000 IU na bitamin D3) suna da matsakaici, amma wannan taƙaitaccen bayani ba ya kunshe da cikakken bayanin tsaro na gwajin, don haka shawara ta sirri daga ƙwararren likita har yanzu tana da muhimmanci. ## Karshe Idan kana neman ƙara tsada‑kasa na uzun rayuwa da hujja, wannan gwajin ya ba da hujja na ƙwarai, ko da dai ba babba ba: omega‑3 ya rage agogo da dama na tsufan halitta a cikin yanayi na bazuwar, kuma haɗawa da bitamin D da motsa jiki a gida ya ƙara inganta PhenoAge. Amma ribar na kusan watanni 3 a cikin shekaru 3 ne, binciken *post‑hoc* ne, mahalarta na manya ne masu lafiya, kuma agogo ba su wakilci sakamakon rayuwa ba. Ka ɗauke shi a matsayin alamar ƙanana mai fa'ida, ba ruwan wanka na matasa ba, kuma ka tabbatar ya dace da yanayin lafiyarka ta hanyar tuntuɓar likita.

MOTS‑c: Peptaid ɗin Mitochondria Mai Ƙwayoyin 16 da Ke Kunna AMPK Kuma Yana Kariya Daga Kiba Da Rashin Juriya Ga Insulin

Dr. Synapse — Thu, 15 Oct 2026 07:27:44 GMT

# MOTS‑c: Peptaid ɗin Mitochondria Mai Ƙwayoyin 16 da Ke Kunna AMPK Kuma Yana Kariya Daga Kiba Da Rashin Juriya Ga Insulin **Takaitaccen bayani:** Peptaid ɗin MOTS‑c yana da ƙwayoyin 16, an ƙirƙire shi daga mtDNA (genome na mitochondria) kuma ba a ƙirƙira shi daga kwayar halitta ba. A cikin wani bincike da aka wallafa a *Cell Metabolism* (2015), an gano cewa MOTS‑c na kunna AMPK a tsokar ƙashi, yana rage rashin juriya ga insulin da aka haifar da abinci mai kitse da tsufa. MOTS‑c na daga cikin manyan sunaye da ake tattaunawa a cikin al’ummomin peptide da bio‑hacking, amma har yanzu ba a gudanar da gwajin mutane ba, kuma ba a amince da shi a matsayin magani ba. --- ## Menene MOTS‑c? MOTS‑c yana nufin *Mitochondrial Open Reading Frame of the 12S rRNA‑C*. Mitochondria suna da ƙaramin genome nasu, kuma tun farko masana suka yi zaton su ƙirƙira kawai ƙwayoyin da ke shiga cikin sarkar numfashi da RNA‑nan da ake buƙata don gina su. Binciken da Lee da abokan aikinsa suka jagoranta ya gina ne a kan wani gwaji da aka yi a baya: a mtDNA akwai sORF (short open‑reading frame) da ke samar da peptaid ɗin *humanin*. Idan sORF ɗaya na iya samar da peptide mai tasiri, akwai yiwuwar wasu da dama suka wanzu. Sun gano wani sORF a cikin ginin 12S rRNA na mitochondria, wanda ke ba da peptaid mai ƙwayoyin 16 – MOTS‑c – wadda ake fassara a sitoplasma kamar yadda ake fassara ƙwayoyin halitta na al'ada. Manufar binciken ita ce nuna cewa mitochondria ba kawai suke samar da makamashi ba; suna kuma iya sarrafa metabolism daga matakin ƙwaya har zuwa matakin jiki baki ɗaya ta hanyar fitar da peptide da ke cikin genome ɗin su. ## Hanyar aiki – Tsoka, Folate da AMPK Masana sun gano cewa tsokar ƙashi (skeletal muscle) ita ce babbar wuri da MOTS‑c ke nufi. Tsoka ita ce mafi girma wajen shan glucose da insulin ke motsawa, don haka siginar da ke aiki a can na iya yin tasiri a tsarin insulin gaba ɗaya. A matakin ƙwaya, abin da ke faruwa ya haɗa da matakai uku: 1. **MOTS‑c yana shafar zagayen folate.** Wannan hanya tana samar da raka‑rakun carbon da ake amfani da su a cikin ayyukan biosynthesis da dama. 2. **Ana katse sabuwar samar da purine.** Wannan mataki yana da alaka da zagayen folate. 3. **AMPK yana kunna.** Katsewar purine na haifar da taruwar wani tsaka‑tsaki (AICAR) wanda ke kunna AMP‑activated protein kinase – ma’aunin makamashi a cikin sel. AMPK ana ɗaukarsa a matsayin mita na makamashi ga sel. Lokacin da aka kunna, seloli sukan karɓi glucose da yawa, su ƙona kitse sosai, su rage ayyukan da ke cinye makamashi. Saboda haka, peptides da ke kunna AMPK suna jawo hankali sosai a fannin binciken metabolism. ## Sakamakon a Beraye A cikin gwaje‑gwajen beraye, MOTS‑c ya nuna wadannan faɗi: - **Yana hana rashin juriya ga insulin da ke zuwa da tsufa** - **Yana hana rashin juriya ga insulin da abinci mai kitse ke haifarwa** - **Yana rage haɓakar kiba da aka samu daga abinci mai kitse** A taƙaice, MOTS‑c ya inganta daidaiton metabolism a beraye. Dole ne a lura da kalmar *ya hana* – a cikin waɗannan gwaje‑gwajen, MOTS‑c an yi amfani da shi a matsayin kariya daga lalacewar metabolism sakamakon abinci ko tsufa, ba a matsayin magani da zai gyara cuta da ta riga ta faru a mutane ba. ## Abubuwan da Binciken BA Ya Nema Yawancin tallan peptide suna yin tsokaci da ba su da tushe a cikakkun hujjojin kimiyya. Don haka yana da muhimmanci a fayyace abubuwan da wannan takarda ba ta tabbatar da su ba: - **Babu gwajin mutane.** Babu wani ɗan adam da aka ba da MOTS‑c a wannan bincike, kuma ba a auna sakamakon lafiyar mutane ba. - **Ba a tantance adadin da ya dace ga mutane ba.** Adadin da aka ba beraye ba zai tafi kai tsaye ga mutane ba. - **Ba a nuna amincin sa ba.** Ba a tattauna tsawon lokaci na amincin, illolin gefe, martanin garkuwar jiki, ko tasirin haɗin magunguna a mutane ba. - **Ba a tabbatar da tasirin sa a mutane ba.** Beraye da aka ciyar da su abinci mai kitse ba su wakilta cikakken yanayin kiba da damuwa na zuciya a mutum ba. - **MOTS‑c ba magani da aka amince da shi ba.** Sha'awar MOTS‑c a tsakanin masu bincike da masu sha'awar bio‑hacking tana da yawan gaske, amma wannan ba yana nufin an tabbatar da amincinsa ko tasirinsa a mutane ba. - **Ba a kammala sanar da tsarin aiki ba.** Hanyar folate‑AMPK wata hanya ce da ake zaton tana da muhimmanci, amma har yanzu ana ƙara bincike don fahimtar cikakken yadda MOTS‑c ke aiki. ## Dalilin Da Yake Da Mahimmanci Ga Binciken Metabolism Peptide kamar MOTS‑c suna jawo sha'awa saboda suna iya zama masu aiki da takamaiman matsayi, amma suna fuskantar ƙalubale na yau da kullum: su kan lalace cikin sauri, suna da rabo mai gajeren lokaci, kuma isar da su ga jiki na buƙatar allura ko tsarin musamman. Kodayake girman peptide ɗin (ƙwayoyin 16) yana sauƙaƙa ƙera su da gyara, duk wani yunƙuri na juya MOTS‑c zuwa magani na zahiri zai buƙaci amsa tambayoyi game da pharmacokinetics (musamman a cikin tsoka), daidaiton adadi a mutane, da ƙimar amincin sa – duk waɗannan ba su samu amsa a wannan takarda ba. Babban gudummawar wannan bincike ita ce tunani: idan mtDNA na iya ƙirƙirar ƙarin peptide masu sigina fiye da yadda aka tunanin, akwai yiwuwar wani babban sashi na sadarwa tsakanin mitochondria da jiki baki ɗaya da masana ke fara gano yanzu. ## Abubuwan Da Masu Karatu Za Su Iya Koyo 1. **Karɓi wannan a matsayin bincike na asali.** Takardar ta gano peptide da wata hanya mai yiwuwa; ba ta ba da shawarar amfani ba. 2. **Raba tsarin aiki da sakamakon da aka gani.** Kunna AMPK a tsoka wata hanya ce mai tasiri, amma dole ne a yi gwaje‑gwajen mutum don tantance ko za a samu fa'ida a zahiri. 3. **Kasance mai shakku kan ƙarar da ake yi.** Maganganu kan raguwar kitse, tsawon rai, ko ingancin aiki a mutane suna wuce abin da wannan bincike ya nuna. 4. **Sa ido kan bayanan mutane.** Alamu mafi amintattu za su fito ne daga gwaje‑gwajen klinik da aka tsara da kyau, an buga su a mujallu na kimiyya, kuma suka bayyana adadi, amincin, da sakamakon metabolism. 5. **Nemi shawarar ƙwararru.** Idan kana da matsalar rashin juriya ga insulin, kiba, ko suga, akwai magunguna da aka tabbatar da su bisa hujja; peptide da ba a sarrafa su ba ba su zama madadin su ba. MOTS‑c wani ƙwayoyin da ke jan hankali a fannin mitochondria. Binciken 2015 ya buɗe sabuwar hanya ta bincike, amma har yanzu ba a samo hanyar da za ta kai daga gwajin beraye zuwa magani da ya dace da mutane ba.

Calcium Alpha‑Ketoglutarate Ya Kara Tsawon Rayuwar Berayen Mata Har Zuwa 16.6% – Menene Ake Nufi Da Abin Da Ba A Nufi Ba?

Dr. Synapse — Thu, 15 Oct 2026 07:26:23 GMT

# CaAKG Ya Sa Mata Berayen Sun Rayu Tsawon Lokaci Kuma Sun Kula Da Lafiya Wani bincike da aka buga a mujallar *Cell Metabolism* a shekarar 2020 ya gano cewa ciyar da berayen da suka kai tsakiyar shekarunsu da abincin da ke ƙunshe da **2 % calcium alpha‑ketoglutarate (CaAKG)** na iya ƙara tsawon rayuwar **mata** har zuwa **16.6 %** da kuma rage alamun kumburi. Wannan sakamakon yana da ban sha'awa, amma dole ne mu tuna cewa **binciken an yi shi ne a kan beraye kawai**, ba a tabbatar da cewa zai yi tasiri iri ɗaya a jikin mutane ba. --- ## Takaitaccen Bincike Azar Asadi Shahmirzadi da ƙungiyarsa sun yi gwaji a kan berayen C57BL/6 a **ƙungiyoyi biyu** masu zaman kansu, kowanne ƙungiya na da kusan beraye **45 mata da 45 maza** (jimlar 182). An fara ba su abincin da ke ɗauke da **2 % CaAKG (w/w)** a **rana ta 540**, wadda ke nuni da tsakiyar shekarun jinsin berayen. Daga nan aka bibiyi tsawon rai, lafiyar dabbobin, da kuma yanayin rauni a kai‑kai. Fara magani a tsakiyar shekarun dabbobi yana da muhimmanci, domin yawancin ƙoƙarin tsawaita rayuwa a dabbobi da mutane na farawa tun ƙuruciya. Hakan ya sa sakamakon da aka samu a wannan bincike ya fi daukar hankali, duk da haka ba ya ba mu wani tabbaci kai tsaye game da mutanen da suka kai tsakiyar shekaru. --- ## Me Ya Sa Ake Zaɓar Alpha‑Ketoglutarate? – Alaka Da TCA Cycle Alpha‑ketoglutarate (AKG) yana daga cikin muhimman sinadarai na **zagayen tricarboxylic acid (TCA) ko Krebs cycle**, wadda ke taimaka wa ƙwayoyin tantance abinci su zama makamashi. Jiki na samar da AKG da kansa, kuma matakan sa na sauyawa yayin azumi, motsa jiki, da tsufa – saboda haka ya zama jiga‑jiga tsakanin abinci da tsarin tsufa. Wannan alaka ba ta nufin cewa ƙaruwa da AKG a abinci zai "dagar da tsufa" ba; yana nuna kawai cewa AKG na iya taka rawa a cikin hanyoyin da ke shafar tsufa. A cikin takardar, marubuta sun yi amfani da **CaAKG**, wato siffar calcium na AKG, maimakon AKG mai ‘yanci. Yadda calcium ke shiga da rarrabawa a jiki na da bambanci da na AKG kawai, kuma wannan ba a fayyace ba a cikin wannan bincike. --- ## Sakamakon: Mata Sun Amfana Fiye Da Maza | Rukuni | Jinsi | Ƙara Tsawon Rai (Matsakaici) | Ƙara Tsawon Rai (90th percentile) | |---|---|---|---| | **1** | Mata | **+16.6 %** | **+19.7 %** | | **1** | Maza | +9.6 % – +12.8 % (ba a ƙididdiga ba) | – | | **2** | Mata | **+10.5 %** | +8 % | | **2** | Maza | Ba a samu tasiri mai ƙididdiga ba | – | A ƙungiyar ta farko, mata sun samu mafi girman ƙaruwa – 16.6 % a matsakaicin tsawon rai da 19.7 % a cikin 90th percentile. A ƙungiyar ta biyu, ƙaruwa ta ragu zuwa 10.5 % (mata) da 8 % (90th percentile). A maza, duk da cewa an samu ƙaruwa kaɗan (9.6 %–12.8 %), ba ta kai matakin da ya zama ƙididdiga ba, don haka ba za a iya ɗaukar ta a matsayin tasiri tabbatacce ba. --- ## Rage "Compression of Morbidity" Marubutan sun bayyana cewa CaAKG ba kawai ya ƙara tsawon rai ba, har ma ya **rage lokacin da dabbobi ke cikin yanayin rashin lafiya** – abin da ake kira "compression of morbidity". Ma’anar wannan ita ce: lokutan ƙarshe na rayuwa suna kasancewa mafi koshin lafiya, maimakon tsawaita shekaru da aka cike da cututtuka. Wannan yana da muhimmanci a fannin tsawaita rayuwa, domin burin ainihi shi ne **rayuwa mai ɗorewa da lafiya** ba wai kawai samun ƙarin shekaru ba. --- ## Inflammaging Da IL‑10 Berayen da aka ci gaba da CaAKG sun nuna **ƙarancin matakan cytokines masu haifar da kumburi** (misali TNF‑α, IL‑6) da kuma **ƙaruwa a matakin IL‑10**, cytokine da ke rage kumburi. Wannan yana nuni da cewa CaAKG na iya rage **inflammaging** – wato ci gaba da ƙananan matakan kumburi da ke haifar da lalacewar ƙwayoyin yayin tsufa. Sai dai, hujjar da ake amfani da ita a cikin takardar itace **hujja daga beraye**, ba a tabbatar da cewa ɗan adam zai samu irin wannan tasiri ba. A halin yanzu, tambayar ita ce: **shin shan CaAKG zai iya inganta yanayin kumburi a manya masu tsufa?** Har yanzu babu amsar da aka tabbatar. --- ## Talla vs. Abinda Takarda Ke Gaskata | Maganar Tallace‑tallace | Abin Da Takarda Ta Gaskata | |---|---| | "An tabbatar da ƙara tsawon rai" | An ƙara tsawon rayuwar **berayen C57BL/6 mata**; maza ba su samu ƙaruwa mai ƙididdiga ba. **Babu hujja a kan ɗan adam.** | | "Yana dawo da tsufa" | Takarda ta nuna **raguwa a rauni da rage lokacin rashin lafiya** a beraye, ba a nuna canjin tsufa a kowanne irin jiki ba. | | "An tabbatar a cikin mutane" | **Ba a yi gwajin a kan mutane ba.** Sakamakon na dabbobi ne kawai. | | "Matsakaicin ƙima ita ce 2 %" | 2 % w/w na CaAKG a abincin beraye – ba a tantance irin wannan ƙima a wajen mutane ba. | | "Ya dace ga kowa" | Tasirin ya bambanta tsakanin jinsi, kuma an yi gwaji ne a kan nau’in beraye guda ɗaya. | --- ## Limitations Da Ya Kamata A Lura Da Su - **Bincike a kan beraye ne kawai** – ba za a iya ɗaukar sakamakon a matsayin hujja ga ɗan adam ba. - **Babu ƙimar da ta tabbatar a mutane** – 2 % CaAKG a abincin beraye ba ya nufin wannan ƙima za ta yi aiki a jikin mutum. - **Tasirin jinsi** – mata sun samu ƙaruwa mai ma’ana, maza ba su kai ga ƙididdiga ba. - **Bambancin ƙungiya** – tasiri ya sauka daga 16.6 % zuwa 10.5 % tsakanin ƙungiyoyi biyu. - **IL‑10 a matsayin hujja** – ƙara IL‑10 yana iya zama alaƙa, amma ba a tabbatar da shi a matsayin dalilin ƙara tsawon rai ba. --- ## Takeaway: Jerin Sa‑ido Na Bincike, Ba Magani Ba Ga masu bibiyar kimiyyar tsawaita rayuwa, **CaAKG yana kan jerin sa‑ido** – yana da alamu na tasiri a cikin berayen mata, kuma yana nuna alamar rage kumburi da rauni. Amma har yanzu akwai buƙatar: 1. **Maimaita binciken a kan nau’o’in beraye daban‑daban** da ƙara yawan dabbobi. 2. **Binciken yadda CaAKG ke shiga jiki (pharmacokinetics) da yadda yake aiki (pharmacodynamics).** 3. **Gwaje‑gwajen klinik na mutane** da za su tantance amincinsa, amfaninsa, da kuma haɗarin sa. Har zuwa lokacin, ba za a iya ɗaukar wannan takarda a matsayin tushen *anti‑aging* ga mutane ba. Duk wanda ke tunanin ƙara CaAKG ko wani karin sinadari, musamman masu ciwon da ke shan magani, ya kamata ya tuntuɓi likita kafin yin hakan. **Taƙaitaccen bayani:** CaAKG ya ƙara tsawon rai da ya rage rauni a berayen mata, amma fa’idar tsawaita rayuwar ɗan adam har yanzu ba a tabbatar da ita ba.

Spermidine da ƙwaƙwalwa? Binciken watanni 12 a kan manya 100 bai nuna amfanin da placebo

Dr. Synapse — Thu, 15 Oct 2026 07:24:22 GMT

# Spermidine da ƙwaƙwalwa? Binciken watanni 12 a kan manya 100 bai nuna amfanin da placebo Spermidine an tallata shi a matsayin kariyar kwakwalwa da kuma abin da ke tsawaita rayuwa. Gwajin klinikal na *SmartAge*, da aka buga a *JAMA Network Open*, ya gwada wannan zato a kan mutanen da ke da **subjective cognitive decline** (raguwar tunani na kai). **Shan mg 0.9 na spermidine a rana tsawon watanni 12 ba ya inganta aikin ƙwaƙwalwa fiye da placebo**. ## Me yasa spermidine ke samun kulawa Spermidine polyamine ne, ƙananan kwayoyin da ke cikin kowace sel da kuma abinci kamar hatsi, wake da kayan marmari. Sha’awar shi ta fito ne daga nazarin dakin gwaje‑gwaje da na dabbobi, inda aka danganta spermidine da **autophagy** – tsarin da ke tsaftace sel daga abubuwan da suka lalace – da tasirin da ake zaton yana da alaka da lafiyar kwakwalwa. Marubutan SmartAge sun yi amfani da waɗannan hujjoji don ƙirƙirar tsarinsu. ## Gwajin: wa, me, da nawa SmartAge gwaji ne na matakin 2b, na **watanni 12**, wanda aka tsara a **double‑blind, randomized, placebo‑controlled** a wani babban cibiyar bincike a Jamus. An gudanar da shi daga Janairu 2017 zuwa Mayu 2020. - **Mahalli:** manya 100, shekaru 60‑90, masu SCD (ƙimar shekaru 69; 49 % mata), an samo su ta asibitoci da cibiyoyin bincike. - **Rukuni:** 51 suka samu spermidine, 49 suka samu placebo, an raba su bazuwar 1:1. - **Magani:** ƙarin hatsi (wheat‑germ) da ke ba da kusan **0.9 mg na spermidine a rana**. Kowane kwayar 750 mg na ƙarin yana ƙunshe da kimanin 0.5 mg spermine da 0.2 mg putrescine. Placebo ɗin kuwa microcrystalline cellulose ne. - **Kammala:** mutane 89 daga cikin 100 (89 %) sun kammala shirin. - **Rajista:** ClinicalTrials.gov NCT03094546. Manufar farko ita ce a tantance canjin aikin ƙwaƙwalwa daga farkon gwaji har zuwa waƙa 12. An auna ta da “mnemonic discrimination” ta hanyar **Mnemonic Similarity Task**, wadda ke dubawa ko mai gwaji zai iya bambanta hoton da ya gani a daidai da wani hoton da ya yi kama da shi sosai. An bi ka’idar *intention‑to‑treat*—kowa da aka ba da kulawa an ƙirga shi. ## Sakamakon farko: babu tasiri Sakamakon farko ya nuna **bambanci –0.03** (95 % CI, –0.11 zuwa 0.05; P = 0.47) a kan mnemonic discrimination tsakanin ƙungiyoyi. Fannin amincewa ya ratsa sifili, don haka ƙimar ainihin bambancin na nuni da rashin tasiri maimakon ƙaruwa. Marubutan sun kuma sanar da cewa sauran gwaje‑gwajen neuropsychological, na dabi’a da na physiology ba su ba da wani bambanci mai ma’ana ba. ## Menene game da alamu na binciken ƙarin? A cikin takaitaccen rahoton an ambaci cewa "binciken ƙarin ya nuna yiwuwar tasiri mai kyau" a kan alamun ƙurajen jiki da ƙwaƙwalwar magana. Amma waɗannan alamu sun fito ne daga **sub‑analysis**, wadda ba a tsara su ba a asalin gwaji. Saboda haka ba za a iya ɗauka su a matsayin hujja ba; suna bukatar ƙarin bincike a manyan gwaje‑gwaje. ## Abin da wannan ke nufi ga masu sayen kari - **Kada ku yi tsammanin ƙara ƙwaƙwalwa** daga wannan adadi. Idan kai manya ne kuma kana tunanin ɗaukar spermidine a kusan wannan ƙima, wannan gwaji ba ya ba da hujja ga amfanin ƙwaƙwalwa a tsawon shekara guda. - **Kalmar “autophagy” da gwaje‑gwajen dabbobi** da aka gani a tallace‑tallace ba su nufin an tabbatar da tasirin a mutane ba. Dangantakar dabbobi da mutane ba koyaushe take daidai ba. - **Amintaccen lafiya**: rashin bambanci a tsakanin abubuwan da suka faru (adverse events) yana nuni da cewa spermidine a wannan ƙima ba shi da haɗari mai girma, amma hakan ba ya nufin yana da amfani. ## Ƙuntatawa da ya kamata a tuna da su - **Ƙima ɗaya kawai**: an gwada mg 0.9 a rana; ba a san ko ƙari zai ba da bambanci ba. - **Jama’a**: mutanen da ke da SCD ne, ba masu dementia ko mild cognitive impairment ba. Sakamakon ba lallai ya shafi matasa ko masu cutar ƙwaƙwalwa mai tsanani ba. - **Girman gwaji**: manyan mutane 100 a wuri guda a Jamus; gwaji matakin 2b ne, ba babban gwaji mai ƙarfi ba. - **Tsawon lokaci**: watanni 12 na iya zama gajere don gano tasiri mai ɗorewa, kuma Mnemonic Similarity Task ba lallai ne ya fayyace duk wani canji a kan ƙwaƙwalwa ba. - **Binciken ƙarin**: alamu kan ƙurajen jiki da ƙwaƙwalwar magana sun fito ne daga sub‑analysis, ba a tabbatar da su ba. ## Ƙarshe SmartAge gwaji ne da aka tsara da kyau, an wallafa shi a babban mujallar kimiyya, kuma ya duba wani ra’ayi mai ƙarfi—amma ra’ayin **bai cika ba**. A yanzu, **mg 0.9 na spermidine a rana tsawon watanni 12 ba ya inganta aikin ƙwaƙwalwa a manya masu SCD idan aka kwatanta da placebo**. Za a iya samun canji idan an ƙara ƙima ko an yi gwaje‑gwaje a manyan ƙungiyoyi, amma wannan ba shi ne abin dogaro ga masu ɗaukar kari a yau ba.

Mutanen Da Suka Farko Sha Dasatinib da Quercetin: Abinda Gwajin Pilot Na Marasa Lafiyar Huhu 14 Ya Nuna (Kuma Bai Nuna Ba)

Dr. Synapse — Thu, 15 Oct 2026 07:21:43 GMT

# Mutanen Da Suka Farko Sha Dasatinib da Quercetin: Abinda Gwajin Pilot Na Marasa Lafiyar Huhu 14 Ya Nuna (Kuma Bai Nuna Ba) ## Taƙaitaccen Bayani A shekara ta 2019, masana sun bayar da rahoton amfani na farko a mutane da haɗin Dasatinib da Quercetin a marasa lafiya 14 da ke da cutar huhu marar sanadi (IPF). Bayan makonni uku na shan magani a lokuta‑lokuta, mahalarta sun samu ƙaruwa a nisan tafiyar minti 6, gudun tafiya, da lokacin tashi daga kujerar, amma aikin huhu bai canza ba. Gwajin ya kuma samu rahoton wani mummunan abin da ya faru da kuma yawan korafe‑korafen numfashi, fata da na ciki. Wannan bincike ne na buɗe‑ra’ayi, ba tare da rukunin ƙarya ba, inda aka haɗa maganin da kulawar likita, ba tsarin kari na ƙwayoyi ba. Ga abin da gwajin ya gwada, abin da ya gano, da yadda za a fassara sakamakon da hankali. ## Menene Senolytics? Tsufan ƙwayoyin sel yana nufin ƙwayoyin da suka daina rabuwa amma ba su mutu ba. Irin waɗannan ƙwayoyin na taruwa a yayin tsufa da kuma a cikin cututtuka masu ɗorewa. Suna fitar da sinadarai da ke haifar da ƙara lalata yanayin da ke kewaye da su – wannan yanayi ana kiransa *senescence‑associated secretory phenotype* (SASP). SASP na haifar da ƙara matsalolin ƙwayoyin ƙusa da kuma ƙara ƙurushi a jiki. Senolytics su ne sinadarai da aka ƙera musamman don kashe ƙwayoyin da suka shiga yanayin senescence ba tare da cutar da ƙwayoyin da ke aiki ba. Idiopathic Pulmonary Fibrosis (IPF), wato cutar huhu marar sanadi, na da alaƙa sosai da senescence, don haka ita ce manufa mai ma'ana. A cikin gwajin beraye da aka yi, an nuna cewa haɗin Dasatinib da Quercetin (DQ) na rage alamun IPF. Wannan shine gwaji na farko da aka gudanar a kan mutane don tantance ko wannan hanya na iya aiki a jikin ɗan adam. ## Takamaiman Tsarin Gwaji Binciken ya kasance gwaji a buɗe‑ra’ayi da aka gudanar a cibiyoyi biyu, tare da mahalarta 14 da ke da IPF na tsanani. Matsakaicin shekaru ya kusan 70.8, kuma mafi yawansu maza ne. An ba su magani a lokuta‑lokuta: - **Dasatinib:** 100 mg a kowace rana - **Quercetin:** 1,250 mg a kowace rana - **Jadawali:** ranaku uku a mako, tsawon makonni uku Lokaci‑lokaci yana nufin tsarin “hit‑and‑run” na senolytics – a goge ƙwayoyin senescent na ɗan ɗan lokaci maimakon a ɗora magani a kullum. Babban burin gwajin ba shine a tantance tasiri ba, sai **riƙe mahalarta** da **cikakken kammala tsarin gwaji**. Tsawon lokacin da aka sa ran ganin sauye‑sauye a aikin huhu da tsaron lafiya na biyu ne a bi. ## Abinda Sakamakon Ya Nuna ### Yiwuwa (Feasibility) - **Riƙe mahalarta:** 100 % - **Babu wanda ya daina DQ** - **An kammala gwaji a 13 cikin 14** ### Ayyukan Jiki Masu bincike sun samu ƙaruwa mai ma’ana (p < 0.05) a cikin muhimman al'amura uku: - Nisan tafiyar minti 6 - Gudun tafiya har zuwa mita 4 a dakikoki - Lokacin tashi daga kujerar Sauran gwaje‑gwajen ba su nuna wani canji ba. Aikin huhu, alamun jini, *frailty index* (FI‑LAB) da kuma lafiyar da aka ba da rahoto ba su sauya ba. Wannan yana nuni da cewa ba a samu ƙwararren canji a huhu ba, don haka ba za a iya ɗaukar ƙaruwa a aikin jiki a matsayin alamar dawowar fibrosis ba. ### Alamomin Biomarkers (Exploratory) Tasirin DQ kan sinadaran SASP a jini ba a iya tabbatar da shi ba. An lura da wasu dangantaka tsakanin canjin aikin jiki da canjin wasu sinadaran da suka shafi gyaran matrix, microRNAs, da cytokines masu ilawa (23 daga cikin 48 alamu suka nuna r ≥ 0.50). A cikin mutane 14 ba tare da rukunin sarrafawa ba, irin waɗannan dangantaka suna ba da tunani ne, ba hujja tabbatacciya ba. ## Alamar Tsaro An samu mummunan abin da ya faru (Serious Adverse Event) guda ɗaya. Abubuwan da ba su da tsanani sun fi yawa a matakin matsakaici zuwa mild. Mafi yawansu sun haɗa da: - **Alamomin numfashi** (abubuwa 16) - **Ciwon fata ko fashewar fata** (abubuwa 14) - **Jin rashin jin daɗi a ciki** (abubuwa 12) Dasatinib maganin da ake amfani da shi don cutar daji ne, kuma yana da haɗari mai girma. Amfani da shi na ɗan gajeren lokaci a cikin gwaji da ke ƙarƙashin kulawar likita ya bambanta da amfani da shi ba tare da kulawa ba. Alamomin numfashi sune mafi yawan rarrabawa a cikin masu cutar huhu gaba ɗaya, don haka wannan yana buƙatar a kula da shi sosai a kowanne gwaji na gaba. ## Bayyanar Gaskiya: Wannan Ba Kayan Kari ba ne Shaharar wannan bincike a cikin al’ummomin da ke neman tsawaita rayuwa na iya haifar da fahimtar da ba daidai ba, don haka dole ne a fayyace iyakokinsa: 1. **Magani ne da aka ba a ƙarƙashin kulawar likita.** Dasatinib maganin da ake rubuta wa masu cutar daji. Girman 1,250 mg na Quercetin da aka yi amfani da shi a nan ba yana nufin a sayi ƙwayar a kasuwa ba, sai dai a cikin tsarin gwaji da Dasatinib. 2. **Buɗe‑ra’ayi kuma ba tare da rukunin ƙarya ba.** Mahalarta da masu bincike sun san cewa kowa na shan DQ. Babu “placebo”. Ƙaruwa a gudun tafiya, lokacin tashi, da nisan tafiyar minti 6 duk suna da alaƙa da ƙoƙari, koyo da ƙarfafawa. 3. **Adadin mahalarta ƙanana ne.** Mutane 14 da ke da IPF mai tsanani, mafi yawansu maza, su ne ƙungiyar gwaji ta farko; ba za a iya ɗaukar sakamako a matsayin tabbatacce ba ko kuma a ƙara tabbatar da rashin yaduwar mummunan sakamako. 4. **Lokacin gwaji gajere ne.** Makonni uku na shan magani a lokuta‑lokuta ba su ba da cikakken haske game da ɗorewa ko tsawon‑lokaci na tsaro ba. 5. **Rukunin da aka yi gwaji an takaita ga IPF.** Ba za a iya ɗaukar sakamakon a matsayin hujja ga manya marasa cuta ko ga wasu cututtuka ba. Masu rubutun kansu sun bayyana sakamakon daidai: gwajin “yana nuna yiwuwar gudanar da bincike” kuma ya ba da “shaidar farko” cewa senolytics na iya rage matsalolin jiki, wanda ke buƙatar ƙarin gwaje‑gwaje masu ƙarfi da aka raba da placebo. ## Abubuwan Koyo Daga Binciken - **Dubawa ga manufa ta asali.** Wannan gwaji an tsara shi don amsa tambayar “za mu iya gudanar da shi?” kuma ya amsa sosai. Ingantaccen aiki a huhu ya zo a matsayin sakamako na biyu. - **Nemi rukunin ƙarya.** Ba tare da placebo ba, matakan da suka dogara da ƙoƙari na iya karkatar da sakamako. - **Lura da ƙarancin adadin mahalarta.** Sakamako a cikin mutane 14 na haifar da yiwuwar samun p‑value < 0.05 ba da gangan ba. Maimaitawa ita ce hanya mafi muhimmanci. - **Lura da abin da bai canza ba.** Rashin canjin aikin huhu, gwaje‑gwajen jini da *frailty index* yana ƙara ƙara tambaya game da tasirin cuta. - **Raba hanyar da sakamakon.** Alamomin SASP ba su da ƙayyade. Binciken bai tabbatar da an goge ƙwayoyin senescent ba, ko kuma cewa wannan goge ne ya haifar da ƙaruwa a aikin jiki ba. - **Samar da ƙwarewa ga al’umma.** Shaidar da aka samu daga marasa lafiya da IPF a ƙarƙashin kulawa ba ta zama shaidar da za a iya amfani da ita a gaɓar jama’a ba. ## Menene Makomar? Mahimmancin wannan takarda shine ta kawo senolytics daga gwaje‑gwajen beraye zuwa mutane, tana nuna cewa tsarin da aka tsara a lokuta‑lokuta za a iya aiwatarwa a kan mutane ƙanana. Wannan shi ne mataki na farko da ake buƙata, kuma rajistar gwaji (NCT02874989) ta ba da cikakken bayani. Gwaji na gaba zai kasance gwaji mai tsari, ɓoyayye, da ya ƙunshi adadi mai yawa na mahalarta tare da manyan manufa da ƙarfi a kan alamu. Har sai waɗannan gwaje‑gwaje sun bayyana, za a iya cewa wannan alama ce mai ƙarfafa amma wacce ke da tambayoyi da dama da ba a amsa ba.

1,000 mg Nicotinamide Riboside a Kullum Yana Kara NAD+ a Kwayoyin Jini Da Kusan 60 % a Manyan Mutane, Binciken Randomized Ya Gano

Dr. Synapse — Thu, 15 Oct 2026 07:19:34 GMT

# Gabatarwa Nicotineamde riboside (NR) – wani nau’in bitamin B3 da jiki ke canza zuwa NAD+ – ya ja hankalin masu sha’awar tsawaita rayuwa. Binciken da aka gudanar a matsayin *randomised, double‑blind, placebo‑controlled* kuma aka wallafa a mujallar *Nature Communications* a shekarar 2018, ya kasance ɗaya daga cikin manyan gwaje‑gwajen ɗan adam da aka yi kan wannan sinadari. Tambayar da aka ba da ita a takaitacce: idan manya masu ƙoshin lafiya suka sha NR a kowace rana na makonni shida, shin yana da aminci, kuma yana ƙara matakin NAD+? Amsa ce **eh** ga dukan tambayoyin. Binciken ya kuma nuna wasu alamu da ke jan hankali – kamar raguwar hauhawar jini da sassauta jijiyoyin jini – amma ba su da hujjojin da za su tabbatar da fa’ida a zahiri. ## Me Yasa NAD+ Ke Da Muhimmanci Kuma Me Yasa Yake Raguwa Da Shekaru? NAD+ (nicotinamide adenine dinucleotide) *coenzyme* ne da ke cikin kowanne ƙwaya, yana taka muhimmiyar rawa a ƙera makamashi, gyaran DNA, amsa ga damuwa, da kuma haɓaka wasu enzymes da aka sani da **sirtuins**. An danganta sirtuins da fa’idodin da ake samu daga rage kalori a gwaje‑gwajen dabbobi, inda aka ga suna taimakawa wajen tsawaita rayuwar dabbobi. A nazarin dabbobi da wasu bayanai na ɗan adam, an gano cewa yawan NAD+ kan raguwa da shekaru. Dalilan da ake tunanin ke haifar da wannan raguwa sun haɗa da ƙaruwa a cin NAD+ ta enzymes kamar CD38 da PARPs, da kuma sauyin yadda ƙwayoyin ke ƙirƙirar NAD+. Har yanzu ba a gano cikakken hanyar da wannan ke faruwa a ɗan adam ba, kuma yawan raguwa yana bambanta daga mutum zuwa mutum. Amma manufar gwajin nan ita ce: idan NAD+ ya yi ƙasa, ƙara sinadari da jiki zai iya juya ya zama NAD+ zai iya taimakawa. NR ɗaya ne daga cikin waɗannan sinadarai. ## Tsarin Gwaji Binciken, da manyan masana daga Jami’ar Colorado Boulder suka jagoranta, ya yi amfani da tsarin **2 × 6‑week crossover** (NCT02921659). Kowane mahalarta ya sha NR a wani zangon lokaci, sannan a wani zangon ya sha placebo – wato kowa ya zama ‘control’ ga kansa. Irin wannan tsari yana rage bambancin da ke tsakanin mutane kuma ya fi dacewa da gwaje‑gwajen da ba su da manyan adadi. - **Ƙungiya:** manya masu ƙoshin lafiya, shekaru 55‑79, matsakaicin BMI kusan 24. - **Magani:** nicotinamide riboside 500 mg sau biyu a rana (jimillar 1,000 mg a rana). - **Kwatanta:** placebo da aka yi daidai da shi. - **Tsawon lokaci:** makonni shida a kowane zagaye. - **Rufe ido:** double‑blind. Rabon 1,000 mg a rana ya fi girma fiye da yawanci a gwaje‑gwajen da ke tantance yadda jiki ke ƙunsar sinadari, don haka an yi amfani da wannan ƙarfin a matsayin maƙasudin gwajin dogon lokaci. ## Sakamakon Da Ya Banbanta: Kusan 60 % Ƙaruwa a NAD+ Abin da aka fi lura da shi shi ne NR ya tsaya sosai a jiki, kuma ya ƙara yawan NAD+ a cikin **peripheral blood mononuclear cells (PBMCs)** – wato ƙwayoyin garkuwar jini da aka ware daga jini – da kusan **60 %** idan aka kwatanta da placebo. Biyu daga cikin muhimman abubuwan da za a kula da su: 1. **PBMCs hanya ce kawai.** Suna da sauƙin samuwa, amma ba su wakilta ƙashin tsoka, zuciya, kwakwalwa, ko hanta ba. Ɗaga NAD+ a ƙwayoyin jini na nufin an sha sinadarin kuma an yi amfani da shi, amma ba ya tabbatar da cewa NAD+ ya ƙaru a sauran sassan jiki, ko kuma cewa wannan ƙaruwa za ta haifar da tasiri a zahiri. 2. **Sakamako ne na sinadarai.** Ɗaga NAD+ yana nuna an cimma manufar ƙara matakin sinadarin, amma ba ya nuni da wani ci gaba a lafiyar jiki. Game da aminci, masu binciken sun ruwaito cewa shan wannan ƙima na tsawon lokaci ba ya haifar da wata matsala a wannan ƙungiya, wanda ke nuni da ƙarfafa sahihancin gwajin. ## Alamomin Hauhawar Jini Da Sassauta Jijiyoyin Jini Baya ga auna NAD+, masu binciken sun duba wasu alamomin da ke da alaka da cututtukan zuciya. **Sassauta manyan jijiyoyi** da **ƙaruwa a hauhawar jini** alamu ne na tsufar jijiyoyi kuma suna haifar da haɗarin cutar zuciya. An ba da rahoton wasu canje‑canje kamar saukar hauhawar jini da ragin **carotid‑femoral pulse wave velocity (PWV)** – ma’aunin da aka saba amfani da shi don tantance sassauta aortic. Sai dai masu bincike sun bayyana cewa wannan gwaji ba a yi shi ba tare da cikakken ƙarfi da zai tabbatar da fa’ida ba; akwai buƙatar ƙarin gwaje‑gwaje a nan gaba don tantance ko NR zai iya rage hauhawar jini da sassauta jijiyoyi a manyan mutane. ## Abubuwan Da Za a Iya Amfani Da Su A Gaskiya - **A matakin sinadari, yana aiki kamar yadda ake buƙata.** A 1,000 mg a rana, NR ya ƙara NAD+ a PBMCs da kusan 60 % a manya masu ƙoshin lafiya. - **Kyakkyawan ɗaukar lokaci na gajeren lokaci.** Makonni shida na 500 mg sau biyu a rana ba su haifar da wata matsala a wannan ƙungiya ba. - **Kada a ɗauki sakamakon a matsayin ƙa’ida ga kowa.** Sakamakon ya shafi samfuri, ƙimar, da rukunin da aka gwada. Ba ya nufin kowa da ke da cuta, ke shan magani, ko da ke cikin ciki zai samu wannan sakamako. Ka tattauna da likita kafin ka fara ƙara sinadarin. - **Kalli alamomin jijiyoyi a matsayin zato.** Sakamakon BP da PWV ba su ba da shaida ta ƙarshe ba, sai dai suna nuna bukatar ƙarin bincike. - **Tabbatar da ingancin samfur.** Tsabtar magani da ƙimar su kan bambanta, kuma ba lallai ne abin da aka yi amfani da shi a gwaji ba ne ake samu a kasuwa. Ka kuma duba ko akwai wani kamfani da ke da ruwa‑ruwa a binciken. ## Iyakokin Gwaji Wannan gwaji ƙanana ne, mai mayar da hankali kan kimiyyar halitta. Babban abin da aka auna su ne matakan sinadarai da ƙarfafa jiki, ba muhimman alamomi na lafiya ba kamar bugun zuciya, yawan jini, nakasa, ko mutuwa. Mahalarta su ne mutane masu ƙoshin lafiya, don haka sakamakon na iya bambanta ga waɗanda ke da kiba, cutar sukari, hauhawar jini, cutar koda, ko wasu cututtuka. Makonni shida ba su ba da bayanin tsawon lokaci ko aminci na shekaru da dama ba. Har ila yau, ba za a iya fassara wannan bincike a matsayin hujja cewa ƙara NAD+ yana rage tsufa, tsawaita rayuwa, ko hana cuta ba. NR ba maganin tsufa ba ne, kuma wannan takarda ba ta yi ikirarin hakan ba. ## Kammalawa Binciken *Nature Communications* na 2018 matakin farko ne mai kyau: ya nuna a fili, tare da tsarin *randomised, placebo‑controlled*, cewa 1,000 mg a rana na NR yana ƙara NAD+ a ƙwayoyin garkuwar jini na manya masu ƙoshin lafiya kuma yana da aminci na makonni shida. Ko wannan zai haifar da sauƙin hauhawar jini, sassauta jijiyoyi, ko wani fa’ida mai ɗorewa ga lafiya, shine tambaya da za a amsa a cikin manyan gwaje‑gwaje masu tsawo a rukunin da za su fi amfana.

Nasara Ta Farko Na NMN a Mutane: 250 mg a Kullum Ya Kara Sensitivity Na Insulin a Tsokar Ƙashi Da Kimanin 25 % a Mata Masu Pre‑diabetes

Dr. Synapse — Wed, 14 Oct 2026 12:09:38 GMT

# Shekaru Da Yawa, Nicotinamide Mononucleotide (NMN) Ya Zama Daya Daga Cikin Kayan Kula Da Tsawon Rai Masu Tallace‑tallace Da Yawa, Amma Mafi Yawan Shaidar Ta Kasance Daga Biri Wani gwaji mai **randomised, double‑blind, placebo‑controlled** da aka gudanar a Washington University School of Medicine, kuma aka wallafa a *Science* a 2021, ya samar da hujja ta farko a tsakanin mutane. An binciki mata *post‑menopausal* masu **pre‑diabetes** da ke da kiba ko ya fi haka. Shan **250 mg NMN a kowace rana** na tsawon **makonni 10** ya inganta **insulin‑sensitivity** a **tsokar ƙashi (skeletal muscle)** da kusan **kashi 25 %**. ## Me Ya Sa NMN, Kuma Me Ya Sa Tsoka? NMN na ɗaya daga cikin hanyoyin samar da **NAD+**, wani co‑enzyme da ke tsakiyar tsarin makamashi na sel. A beraye, tsufa da kiba na rage matakin NAD+, wanda ke haifar da matsalolin metabolism. Saboda haka ƙara NMN a jiki na iya taimakawa wajen dawo da adadin NAD+. **Tsokar ƙashi** ita ce babban wurin da jiki ke amfani da glucose ta hanyar insulin. Idan tsoka ta zama *insulin‑resistant*, sarrafa sukari a jini zai fara lalacewa – wani muhimmin mataki a hanyar kamuwa da cutar sukari ta nau'i na biyu (type 2 diabetes). Don haka, duk wani ƙarin da ke inganta aikin insulin a tsoka zai iya rage haɗarin cutar. ## Abin Da Gwajin Ya Yi - **Lokaci:** makonni 10 - **Tsarin gwaji:** randomised, double‑blind, placebo‑controlled - **Masu shiga:** mata *post‑menopausal* masu pre‑diabetes da ke da kiba ko ya fi haka - **Ragewa:** 250 mg NMN a kowace rana (ƙungiyar magani) vs placebo (ƙungiyar sarrafawa) Masu binciken sun yi amfani da **hyperinsulinemic‑euglycemic clamp**, wadda ita ce hanyar da aka fi amincewa da ita wajen auna insulin‑sensitivity. Sun kuma ɗauki biopsies na tsoka don duba alamun insulin a matakin kwayoyin. ## Abubuwan Da Suka Inganta - **Glucose disposal** a tsoka ya ƙaru da kusan **kashi 25 %** a ƙungiyar NMN, yayin da placebo bata nuna wani canji ba. - **Alamun insulin** a tsoka (phosphorylation na AKT da mTOR) sun ƙaru a sakamakon NMN, alamu masu nuna ƙara aiki a hanyar insulin. - **Kwayoyin da ke da alaƙa da gina tsoka** (irin su **PDGFRβ**) sun ƙaru, abin da ke nuni da yiwuwar NMN na tasiri kan gina sabbin tsokoki. ## Abubuwan Da Ba Su Canza Ba - **Matsayin sukari a jini (fasting glucose, HbA1c)** ba su ƙaru ba, kuma ba a sami canjin **pre‑diabetes** zuwa na al’ada ba. - **Nauyin jiki, BMI, da sauran alamun metabolism** ba su nuna wani bambanci mai ma’ana ba a cikin makonni 10. - Sakamakon ya nuna cewa tasirin NMN ya takaita ne a **tsokar ƙashi**, ba a samu faɗi a sauran sassa kamar hanta ko ƙwayar zuciya ba. ## Yawan Kwamiti Da Wa Ya Shafa - **Yawan kwamiti:** 250 mg NMN a baki a kowace rana, tsawon makonni 10 – shi ne kawai adadin da aka gwada a ɗan adam a wannan mataki. - **Wa ya shafa:** mata *post‑menopausal* masu pre‑diabetes da ke da kiba ko ja da yawa. Ba a yi gwaji a maza, matasa, ko mutanen da ke da cikakkiyar insulin‑sensitivity ba, don haka ba a san ko waɗannan rukunin za su amfana ba. ## Bukatar Gwaje‑gwaje Na Biyu Gwajin ya kasance **ƙarami**, an yi shi a ƙungiya guda, kuma ya ɗauki ‘yan kwanaki ne kawai. Don tabbatar da sakamako, ya zama dole a: 1. **Maimaita gwajin** tare da manyan ƙungiyoyi da bambancin al’ummomi. 2. **Tsawaita lokacin gwaji** don duba ko tasirin NMN ya kasance na dindindin. 3. **Gwada ƙarin ƙuduri** (misali 500 mg ko 1000 mg) da kuma **kombinasyon da sauran dabaru** kamar motsa jiki da rage nauyi. ## Kammalawa Wannan gwaji ya ƙara hujja a kan NMN – daga gwaje‑gwajen beraye zuwa hujja a ɗan adam – da ke nuna cewa **insulin‑sensitivity a tsokar ƙashi na iya inganta da kusan kashi 25 %** bayan shan 250 mg NMN a kowace rana na tsawon makonni 10. Sai dai ba a ga wani tasiri a kan sukari na jini, ba a kawo pre‑diabetes zuwa yanayi na al’ada ba, kuma ba a nuna wani tasiri a sauran sassan jiki ba. Don haka, ga masu pre‑diabetes, hanyoyin da suka tabbatar (rage nauyi, motsa jiki, da magunguna idan likita ya yi ba) su ne mafi sahihi a yanzu. NMN na iya zama **ƙari mai amfani**, amma ya kamata a tattauna da likita kafin fara amfani da shi, musamman la’akari da tsawon lokacin gwajin da iyakokin sa. --- *Lura:* Kamar yadda aka nuna a wasu sharhi da aka buga a *Science*, *Cell Metabolism*, da *Cardiovascular Research*, akwai damuwa kan alakar wasu masana da kamfanonin da ke samar da NMN. Wannan ba ya rage sahihancin gwajin da aka gudanar, amma ya nuna buƙatar ƙarin bincike mai zaman kansa don tabbatar da sakamakon.

BPC-157 da Gyaran Tsokar Jiki: Abin da Binciken FAK‑Paxillin ke Nuna, da Abin da Bai Nuna ba

Dr. Synapse — Wed, 14 Oct 2026 12:08:55 GMT

# BPC‑157 da Gyaran Tsokar Jiki BPC‑157 peptide ne da ke ɗauke da kwayoyin amino 15, wanda ake talla masa a yanar‑gizo a matsayin “peptide mai warkarwa”. Ya samu kulawa sosai a tattaunawar bio‑hacking da magance raunin wasanni, amma ƙwarin gwiwar da ake samu daga bincikensa na pre‑clinical ba su da yawa. Daya daga cikin takardun da ake yawan ambato, wadda Chang da abokan aikinsa suka wallafa a **Journal of Applied Physiology** a 2011, ta yi nazari kan yadda peptide ɗin ke taimakawa wajen warkar da tsokar da ta ji rauni. Sakamakon ya nuna cewa abin da ke faruwa shi ne ƙara motsi da tsirar sel, ba ƙara yawan sel ba. Wannan misali ne mai kyau da ke nuna dalilin da ya sa sakamakon da aka samo daga ƙwayoyin beraye ba za a iya ɗauka a matsayin hujja ga ɗan adam ba. ## Daga Ina BPC‑157 Ya Samu BPC‑157 pentadecapeptide ne — peptide da ke ɗauke da kwayoyin amino goma da biyar. An samo shi a matsayin wani ɓangare na "body‑protection compound" da aka gano a cikin ruwan da ke fitowa daga cikin ɗan adam. A gwaje‑gwajen dabbobi da aka gudanar a baya, an gano cewa peptide ɗin yana hanzarta warkar da nau’o’in raunuka daban‑daban, ciki har da yankin Achilles na beraye da aka yanke. Wannan ya sa masu bincike suka tambayi: me peptide ɗin ke yi a matakin sel? Binciken Taiwan na 2011 ya yi ƙoƙarin amsa wannan tambayar. ## Abin da Masana Suka Yi Ƙungiyar bincike ta yi amfani da ƙwayoyin beraye. Sun ɗauki ɓangarorin tsokar Achilles, suka raba su zuwa ƙungiyoyi biyu — ɗaya da BPC‑157 da ɗaya ba tare da ba. Sannan suka auna yawan fibroblast da suka fito daga waɗannan ƙwayoyin. Bayan haka, an ware fibroblast daga waɗannan ƙwayoyin don gwada tasirin peptide ɗin kan: - yawaitar sel, - tsira a yanayin ƙona‑oxidative, - motsi, - shimfiɗar sel, - canje‑canjen tsarin cytoskeleton, - alamar siginar sel (FAK da paxillin). Wadannan misalan dakin gwaje‑gwaje na nuni da abin da ke faruwa a sel da aka keɓe a waje (in vitro) ko a ƙananan ƙwayoyin da aka riƙe a waje (ex vivo). Su ba su wakilta abin da ke faruwa a cikin tsokar ɗan adam da ke jin rauni ba. ## Muhimman Sakamako **Fitowar fibroblast.** BPC‑157 ya hanzarta fitowar fibroblast daga ƙananan ƙwayoyin tsoka. Fibroblast su ne sel‑sel masu samar da ƙwayoyin collagen, wanda ke da matuƙar muhimmanci ga gyaran tsoka. Don haka, hanzartar fitowa alama ce ta yiwuwar aikin gyara. **Babu tasiri kai tsaye kan yawaitar sel.** Ta hanyar gwajin MTT, masu bincike sun gano cewa BPC‑157 ba ya ƙara yawan fibroblast kai tsaye. Wannan ya ƙeta zato na cewa peptide ɗin yana aiki ne ta hanyar ƙara adadin sel. **Tsira a ƙarƙashin damuwa.** Lokacin da aka jefa sel a cikin hydrogen peroxide (wanda ke haifar da ƙona‑oxidative), sel‑sel da aka ba da BPC‑157 sun tsira da yawa fiye da marasa magani. Oxidative stress yana faruwa a sel da ta ji rauni, don haka wannan sakamako yana da amfani, ko da yake har yanzu daga dakin gwaje‑gwaje ne. **Motsi da shimfiɗar sel.** A gwajin transwell, BPC‑157 ya ƙara motsi fibroblast a yanayin ƙara ƙima. Haka kuma, ya hanzarta shimfiɗar sel a faranti, tare da haifar da ƙirƙirar F‑actin – canjin tsarin cytoskeleton da sel ke buƙata domin su motsa. ## Hanyoyin FAK‑Paxillin Cibiyar binciken takardar ita ce nazarin siginar sel. Focal adhesion kinase (FAK) da paxillin su ne manyan ƙwayoyin da ke kan "focal adhesions" – wuraren da sel ke ɗaurewa ga matrix kuma ake aika sigina na ƙarfi da sinadarai. Kunna wannan hanya na da alaka kai tsaye da motsi, shimfiɗa, da tsira na sel. Ta hanyar Western blot, marubutan sun ga cewa a yanayin ƙara ƙima, BPC‑157 ya ƙara phosphorylation na FAK da paxillin, yayin da yawan duka ƙwayoyin ya kasance daidai. A taƙaice, peptide ɗin yana “kunna” ƙwayoyin da ke akwai maimakon ƙirƙirar sababbin su. Masu binciken sun kammala da cewa tasirin motsi da shimfiɗa na yiwuwa ne ta hanyar kunnawa FAK‑paxillin. Kalmar *yiwuwa* na da muhimmanci a nan: binciken ya nuna haɗin kai tsakanin amfani da BPC‑157 da kunna wannan hanya, amma ba ya tabbatar da cewa ita ce kawai ko babbar hanyar da peptide ɗin ke aiki da ita. Bugu da ƙari, ba a gano ainihin karɓar peptide ɗin ko abin da ke haifar da farawar wannan siginar ba. ## Dalilin da Ya Sa Wannan Ba Shaida ce ga Mutane ba ### Iyakoki masu Muhimmanci - **Nau’in dabbobi da yanayi.** An yi aiki da ƙwayoyin tsoka da fibroblast na beraye, a in vitro da ex vivo. Waɗannan sel ba su da jini, ƙwayoyin garkuwar jiki, ɗaukar nauyi, da sauran ƙwayoyin da ke taka rawa a warkar da tsoka a ɗan adam. - **Mekanisam, ba sakamako ba.** Takardar ta ba da rahoto kan halayen sel, ba ƙarfin tsoka, aikin jiki, ko lokacin dawowa ba. - **Babu gwaje‑gwajen mutane.** Binciken ba shi da mahalarta ɗan adam. Bayanan da ake da su game da BPC‑157 a ɗan adam kaɗan ne, kuma ikirarin da ake yi a kasuwanci na “gifts” ko “supplements” ya wuce hujjojin kimiyya. - **Kara ƙima ba jagora bane.** Sakamakon ƙara ƙima a sel ba za a iya juya su zuwa amfanin da ya dace da mutum ba, kuma rubutun ba ya ba da shawarar ƙima ko dosage. ## Matsayin Doka BPC‑157 ba magani ne da aka amince da shi a Amurka ko a manyan ƙasashe ba. FDA ta saka shi a jerin sinadarai masu damuwa kan tsaro ga masu haɗa magunguna, tana nuna rashin isasshen bayani kan tsaro da yiwuwar haɗari kamar immunogenicity da gurɓata. Hukumar Anti‑Doping ta Duniya (WADA) ma ta haramta shi a matsayin sinadari da ba a amince da shi ba—a muhimmin batu ga ‘yan wasa masu gogayya. Kayayyakin da ake sayarwa a yanar‑gizo a matsayin “research chemicals” ba su bi ƙa’idojin masana’antu ba, don haka ba za a iya ɗauka suna da inganci, tsabta, ko sterility ba. ## Menene Za a Yi Na Gaba? Binciken Chang na da amfani a matsayin ilimin asali. Ya nuna cewa tasirin BPC‑157 kan tsoka na iya faruwa ne ta hanyar ƙara motsi sel, gyaran cytoskeleton, da ƙarfafa tsira a yanayin damuwa ta hanyar siginar FAK‑paxillin, maimakon ƙara yawaitar sel. Ga masu bincike a fannin isar da magani da gyaran ƙwayoyi, wannan yana ba da ƙira mai amfani don gwaji na gaba. Domin amsa tambayoyin da suka rage, za a bukaci: 1. Tantance manufa na kwayoyin da peptide ɗin ke yi (receptor). 2. Maimaƙon sakamakon a cikin gwaje‑gwajen dabbobi masu cikakken bayanin aiki (functional outcomes). 3. Gudanar da gwaje‑gwajen mutane masu tsari, tare da takamaiman lura kan tsaro. Har sai an samu irin waɗannan hujjoji, BPC‑157 za ta ci gaba da kasancewa peptide da ake bincikawa da tarihin pre‑clinical mai ban sha'awa. Duk wanda ke da rauni a tsoka ya kamata ya nemi kulawa daga likita mai ƙwarewa maimakon dogaro da sakamakon dakin gwaje‑gwaje.

Gwajin GlyNAC: Glycine da NAC Sun Gyara Alamu da yawa na tsufa a manyan mutane cikin makonni 16 – amma Gwajin Karami ne

Dr. Synapse — Wed, 14 Oct 2026 12:08:19 GMT

Abin ƙara abinci mai sauƙi da ke ɗauke da sinadarai biyu – glycine da N‑acetylcysteine (NAC) – ya gyara jerin manyan matsalolin da suka shafi tsufa a cikin wani gwaji da aka yi da rabe‑raben bazuwar ƙungiya da placebo a Baylor College of Medicine. Haɗin da ake kira **GlyNAC** yana da araha, ana samun sa a ko’ina, kuma ƙungiyar bincike ta dade tana nazarinsa. Sakamakon da aka wallafa a *The Journals of Gerontology: Series A* a watan Janairu 2023 ya burge, amma ya fito ne daga gwaji ƙarami, wani abu da ke da muhimmanci wajen tantance sahihancin tasirin sa. ## Manufar GlyNAC **Glutathione (GSH)** shi ne babban antioxidant da ke cikin kwayoyin jikin mutum. Yana taimakawa wajen kawar da sinadaran reactive oxygen species (ROS) da kuma kare mitochondria, wato ƙananan sassan da ke samar da ƙarfi a cikin sel. Ƙungiyar Baylor, ƙarƙashin jagorancin **Rajagopal Sekhar**, ta yi ikirarin cewa manya suna fama da ƙarancin glutathione wanda ke haifar da oxidative stress, lalacewar mitochondria, kumburi da ƙara rashin amincewar insulin. Ana samar da glutathione ne daga sinadarai uku na amino acid: glutamate, cysteine da glycine. Masu binciken sun ce manya na rasa glycine da cysteine – na ƙarshe ana samunsa a matsayin NAC. Shan GSH kai tsaye ba ya da tasiri sosai, don haka dabarar ita ce samar da sinadarai masu tushe. A gwaje‑gwajen birai masu tsufa, an nuna cewa GlyNAC yana ƙara matakin GSH, yana rage oxidative stress, yana inganta oxidative phosphorylation a mitochondria, kuma yana rage rashin amincewar insulin. Wannan gwaji ya duba ko irin waɗannan tasirin za su faru a cikin mutane. ## Yadda Gwajin Ya Gudana Binciken ya haɗa da manya 24 da matasa 12. An raba mahalarta zuwa ƙungiyoyi biyu na tsawon makonni 16: - **Rukuni GlyNAC (n = 12):** an ba su glycine da NAC. - **Rukuni Placebo (n = 12):** an ba su placebo na alanine – irin wanda yake daidai da nauyin amino acid amma ba ya ƙunshe da glycine ko NAC. Matasa sun karɓi GlyNAC na makonni biyu kawai; an yi amfani da su a matsayin ma’aunin “lafiya”. An tattara bayanai a farkon gwaji, a makonni 2, da kuma a makonni 16. Ƙungiyar ta auna jerin manyan sakamako: matakin GSH, oxidative stress, aikin mitochondria, masu sarrafa ƙwayoyin makamashi, kumburi, aikin endothelium, rashin amincewar insulin da wasu alamu da dama na tsufa. Haka kuma sun auna saurin tafiya, ƙarfin tsoka, gwajin tafiya na mintuna 6, yanayin jiki da kuma ƙaura (systolic blood pressure). ## Abubuwan Da Masu Binciken Suka Gano A lokacin farawa, manya sun bambanta sosai da matasa. Sun kasance da ƙarancin glutathione, oxidative stress mai girma, aikin mitochondria mara ƙarfi, ƙarin kumburi, ƙarancin aikin endothelium da rashin amincewar insulin. Haka kuma sun nuna alamu da dama na tsufa – raunin ayyukan jiki, faɗin ƙugu mai girma, da ƙaura mai ƙarfi. Bayan gwajin makonni 16, **GlyNAC**, amma **ba placebo ba**, ne ya inganta ko ya gyara waɗannan alamu. An ba da rahoton cewa ƙarin ba ya haifar da tasiri maras kyau, kuma yana da aminci. Marubutan sun kammala da cewa haɗin fa'idodin glycine, NAC da GSH na sa GlyNAC ya zama ƙarin abinci mai tasiri wajen rage wasu alamu da ke alaka da tsufa. ## Cikakken Bayanin Magani: Yawan Sha da Waɗanda Zai Iya Amfana Takaitaccen bayanin da ke cikin wallafar ba ya ƙunshe da adadin da aka yi amfani da shi, don haka duk mai sha'awar ya duba takardar asali (PMC9879756). Tsarin dawowa da aka yi amfani da shi yana kan nauyi, kusan **100 mg/kg** a kowace rana ga kowanne amino acid. Don misali, mutum mai nauyin kilo 70 zai sha kusan gram 7 na glycine da gram 7 na NAC a kullum. Wannan adadi ya fi na kayan NAC da ake sayarwa a kasuwa, kuma galibi ana raba shi zuwa lokuta biyu a rana. Ka ɗauki wannan a matsayin misalin gwaji, ba a matsayin shawarar magani ba. Kungiyar da aka bincika ita ce manya, yayin da matasa aka yi amfani da su a matsayin ma’auni. Mutanen da za su fi amfana da wannan hanya su ne manya da ke da alamu na raguwar abinci da ƙarfin jiki. Kodayake, gwajin bai tabbatar da tasiri a matasa masu lafiya ba, kuma matasa sun karɓi GlyNAC na makonni biyu kawai a matsayin gwaji. NAC a manyan ƙididdiga na iya haifar da matsala wajen narkewa, kuma yana da ƙamshin sulfur. Duk wanda ke shan magunguna, ko yana da cutar hanta, koda wanne cuta na ciwon suga ko wasu cututtuka na dindindin, ya kamata ya tattauna da likita kafin ya fara shan gram‑gram. Bayanai na tsaro daga gwajin sun ƙunshi makonni 16 a ƙungiya ƙarama, don haka ba su ba da cikakken bayani game da amfanin dogon lokaci ba. ## Ƙuntatawa Masu Muhimmanci **Samfurin ƙarami ne.** Mutane goma sha biyu a kowanne rukuni na iya nuna manyan tasiri a kan alamu na sinadarai, amma ba su isa don kawar da yiwuwar sakamakon bazuwar, bambancen ƙungiya ko ƙananan illa ba; sakamakon na bukatar maimaitawa. **Sakamako da yawa, mahalarta ƙalilan.** Gwajin da aka gudanar a manya 24 ke ba da damar samun sakamako maras tabbas. Samun sakamako da dama yana da kyau, amma ba hujja ce mai ƙarfi ba. **“Mayar da tsufa” kalma ce mai ƙarfi.** Mizanin da aka yi amfani da su su ne alamu na biomarker da gwaje‑gwajen aiki. Ba su haɗa da manyan sakamako kamar fashewar ƙasusuwa, shigar asibiti, cututtukan zuciya ko mutuwa. Gyara alamu ba ya nufin tsawon rai ko rayuwa mai lafiya. **Bincike daga cibiyar guda.** Yin gwaji a ƙungiyoyi masu bambancin kabilu da al'adu zai ƙara yarda da sakamakon. Wannan binciken an wallafa shi tare da sharhi a mujallar da aka ambata, wanda ke nuna sha'awar kimiyya, amma ba zai maye gurbin gwaje‑gwaje masu yawa ba. **Tsawon lokaci.** Mako 16 na nuna tasirin ɗan gajeren lokaci. Tambayar ita ce ko fa'idodin za su ci gaba da kasancewa, ko bukatar ƙara shan magani, ko kuma za su tsayawa a wani mataki. ## Muhimmanci Da Gabaɗaya Gwajin GlyNAC yana ba da ra'ayi mai ma'ana a fannin ilimin halitta, mai rahusa ga matsalar da ke da alaƙa da raguwar glutathione da tsufa. Alamu suna nuna ƙwarin gwiwa, kuma ƙirƙirar da aka yi da placebo ta fi karfi fiye da yawancin binciken ƙari. Amma wannan gwaji yana a matakin farko, ƙanana ne, kuma ikirarin da ke kan “mayar da alamu na tsufa” na buƙatar ƙarin bincike masu girma da manyan ƙungiyoyi masu zaman kansu tare da sakamako da za a iya amfani da su a kiwon lafiya. A yanzu, GlyNAC ya fi dacewa a matsayin ra'ayi mai ban sha'awa da ke da alamu masu ƙarfafawa, ba magani da aka tabbatar da anti‑tsufa ba.

Taurine, Sinadarin Amino Mai Araha da Ya Tsawaita Rayuwar Kunkuru da Kusan 12% Kuma Yana Raguwa da Yawan Taurine a Jinin Mutane

Dr. Synapse — Wed, 14 Oct 2026 12:07:39 GMT

# Taurine, Sinadarin Amino Mai Araha da Ya Tsawaita Rayuwar Kunkuru da Kusan 12% Kuma Yana Raguwa da Yawan Taurine a Jinin Mutane Amino acid mai araha da ake ƙara a cikin abin sha da ƙwayoyin abinci na ƙara kuzari ya zama ɗaya daga cikin abubuwan da ake dubawa a fannin tsawaita rai. Binciken *Science* na 2023, da aka jagoranta daga ƙungiyar Vijay Yadav a Jami'ar Columbia da National Institute of Immunology a New Delhi, ya nuna cewa matakin taurine a jini yana raguwa da tsufa a kunkuru, birai da mutane. Idan aka ba dabbobi ƙarin taurine, lafiya ta inganta kuma a ƙwayoyin dabbobin, tsawon rai ya ƙaru. Lambar da aka fi haskawa ita ce ƙaruwa da kusan kashi 10‑12% a rayuwar kunkuru. Wannan alama na da ban sha'awa, amma dole ne a ba da cikakken mahallin da ya dace kafin a fara sayen kwalaben foda. ## Abin da Masu Bincike Suka Gano Taurine sinadari ne na amino mai ɗauke da sulfur, wanda ake samu a nama, ƙifi da madara. Jiki ma yana ƙirƙira shi a ƙananan adadi. Taurine na taimakawa wajen haɗa bile acids, daidaita yanayin ruwa a jiki, inganta aikin mitochondria da kuma ba da kariya ta anti‑oxidant. Ƙungiyar bincike ta auna matakan taurine a jini a tsakanin nau’o’in dabbobi daban‑daban, ta kuma gano cewa matakin yana raguwa da tsufa. A mutane, raguwar ta ta fi bayyananne – matakan manya sun fi ƙananan yara ƙasa. Daga nan sai su gwada ko wannan raguwa tana da tasiri. Kunkuru masu shekaru 14 (kimanin tsakiyar rayuwarsu) sun karɓi ƙarin taurine a kullum. Tsawon rayuwarsu ya ƙaru da kusan kashi 10 % a maza da 12 % a mata, kamar yadda takardar binciken ta bayyana. Dabbobin da aka ba da magani sun nuna alamun lafiya mafi kyau, ciki har da: - Ƙara ƙarfi, ƙashi da haɓakar tsoka - Kyakkyawan sarrafa sukari a jini da ƙarin nauyi - Rage damuwa da alamun damuwa - Ingantaccen tsarin garkuwar jiki da metabolism A cikin birai ma, taurine ya tsawaita rayuwa. A wani ƙaramin gwaji na birai masu tsakiyar shekaru, ƙarin taurine ya inganta alamun lafiya kamar nauyin jiki, ƙarfi na ƙashi, matakin sukari a jini, da alamar lafiyar hanta. Ba a auna tsawon rayuwar birai ba, domin irin wannan gwaji zai ɗauki shekaru da dama. ## Dalilin Da Yasa Zai Iya Aiki Masu binciken sun bayyana taurine a matsayin sinadari da ke shafar manyan alamun tsufa a lokaci guda. A ƙwayoyin dabbobi, ƙarin taurine ya rage alamar tsufar ƙwayoyin – wato taruwar ƙwayoyin “zombi” marasa aiki. Ya rage lalacewar DNA, ya kare mitochondria daga nakasu, ya hana raguwar telomeres, kuma ya rage kumburin da ake kira “inflammaging”. Wannan faɗin tasiri yana nuni da cewa taurine na iya zama wani ƙari mai amfani a kula da ƙwayoyin halitta, ba magani mai maƙasudi guda ba. ## Shaidar Ɗan Adam Bayanan da ke cikin takardar sun nuna alaka ne kawai, ba dalili ba. A wani babban binciken Turai, matakan taurine da suka ƙasa sun danganta da cututtuka kamar kiba, ciwon sukari na nau'i II, hawan jini da kumburi mai yawa. Taurine ma ya ƙaru bayan motsa jiki mai tsanani a wasu ƙungiyoyin mutane, wanda ke nuna cewa wani ɓangare na fa’idar motsa jiki na iya haɗuwa da wannan sinadari. Wadannan alaka ne kawai. Taurine mai ƙasa na iya haifar da cuta, ko kuma cuta ko yanayin metabolic mara kyau na iya rage matakin taurine. Masu binciken sun amince da wannan kuma suka kammala cewa gwaje‑gwajen ƙwararru “na da muhimmanci”. ## Yawan Da Ake Magana Akai? Adadin da aka ba kunkuru ya kasance babba – daga ɗari‑ɗari miligram zuwa kusan gram guda a kowace kilogram na nauyin jiki a kullum. Canza shi zuwa matakin mutum yana da wahala, amma masu sharhi sun kiyasta adadin da zai iya kaiwa kusan gram‑grama biyu a kullum, tare da bambanci mai yawa gwargwadon yadda aka auna girman jiki. Don kwatanta: - Kwalaben ƙara kuzari na yau da kullum suna ƙunshe da kusan gram ɗaya na taurine. - Hukumar Lafiyar Abinci ta Turai ta amince da shan har gram uku a rana a matsayin abin da aka tabbatar da amincinsa ga manya masu lafiya. - Binciken likitanci a kan cututtuka kamar ciwon zuciya da ciwon sukari ya yi amfani da kusan gram 1.5 zuwa 6 a kullum, galibi ba tare da matsaloli masu tsanani ba a gwaje‑gwajen ɗan lokaci. Babu wani gwaji da ya tantance adadin da ya fi dacewa ko kuma na tabbataccen maganin tsufa a mutane. Duk wanda ke da cuta, masu shan maganin hawan jini ko cutar zuciya, da kuma masu ciki, su tuntuɓi likita kafin su fara. Canza daga ƙimar kunkuru zuwa mutum na ɗaya daga cikin hanyoyin da ke haifar da ƙarya a fannin tsawaita rai. ## Matakin Shaida Da Kalubale Akwai wasu muhimman abubuwa da ke rage jin daɗin wannan sabon ci gaba: 1. **Kunkuru ba su daidai da mutane.** Yawancin hanyoyin da ke tsawaita rayuwar kunkuru, sau da yawa da irin wannan bambanci, ba su yi tasiri ga mutane ba. 2. **Babu bayanin tsawon rayuwar ɗan adam.** Gwajin birai ya duba alamun lafiya ne na watanni, ba tsawon rayuwar dabbobi ba. 3. **Alaka ba dalili ba ne.** Hada ƙarancin taurine da cuta a mutane ba ya nufin ƙara taurine zai gyara su. 4. **Raguwar ba ta zama gaba ɗaya ba.** Bincike na gaba da sharhi sun tambayi yadda taurine ke raguwa da tsufa da kuma yadda matakan jini ke wakiltar adadin a ƙwayoyin jiki. Maganar “rashin taurine yana haifar da tsufa” har yanzu ra'ayi ne da ake tattaunawa. 5. **Rikicin haƙƙin mallaka.** Jami'ar Columbia ta yi takardar neman haƙƙin mallaka kan wasu fasahohi inda Vijay Yadav yake ɗaya daga cikin masu ƙirƙira – abu ne na yau da kullum amma yana da mahimmanci a lura da shi. 6. **Abincin yana da tasiri.** Mutanen da ke cin nama da ƙifi suna samun taurine mai yawa, don haka fa’idar na iya zama mafi girma ga waɗanda ba su da isasshen cin abinci ko waɗanda ke da buƙata mai ƙaruwa, tambaya da binciken ba zai iya amsa ba. ## Dalilin Da Yasa Har Yanzu Yake Da Mahimmanci Taurine yana da araha, ana samun shi a ko'ina, kuma yana da dogon tarihin amfani a ƙwayoyin magani, wanda ke sanya shi mai sauƙin gwaji. Hakanan yana dacewa da ra'ayin cewa tsufa na haɗa da ɓacewar sinadarai masu kariya a cikin jini, wasu daga cikinsu za a iya maye gurbinsu. Kira na masu bincike na yin gwaje‑gwajen ƙwararru yana da ma'ana: auna taurine a matakin farko, a ba da ƙarin a adadi da aka ƙayyade, a bi diddigin sakamakon kamar sarrafa sukari, ƙarfi tsoka, kumburi, da lafiyar ƙashi. Har sai an samu waɗannan sakamakon, taurine ya fi kyau a ɗauke shi a matsayin wani abu da ake sa ran yiwuwa, ba wani kayan aikin tsawaita rai da aka tabbatar ba. Ƙaruwa na kashi 10‑12% a rayuwar kunkuru alama ce mai ma'ana, amma hanyar da ta kai daga wannan alama zuwa shawara ga mutane tana buƙatar gwaje‑gwaje da ba a kammala ba.

Urolithin A, Postbiotik na Rummukan, Yana Kawo Tasirin Mitophagy a Manyan Mutane

Dr. Synapse — Wed, 14 Oct 2026 12:03:46 GMT

# Urolithin A, Postbiotik na Rummukan, Yana Kawo Tasirin Mitophagy a Manyan Mutane ## Tsakaitaccen Bayani Urolithin A, sinadari da kwayoyin hanji ke samarwa daga polyphenols da ke cikin ‘ya’yan itatuwa da goro, ya dade yana ƙara ƙarfi ga tsokoki a dabbobin da suka tsufa. Gwajin farko a kan manya ya nuna cewa yana da aminci, yana shigowa jini, kuma yana iya canza alamu na mitochondria a tsakanin 500 – 1,000 mg a kowace rana. Wannan nazari, wanda kamfanin da ke bayan Mitopure ya tallafa, ya bayyana alamar kwayoyin da ke nuna ingantaccen lafiyar mitochondria a tsokar ƙashi. Sai dai gwajin yana da iyaka, ya ɗan takaita lokaci, kuma ya fi mai da hankali kan alamu maimakon ƙarfi ko tsawon rai. Anan ne abin da bayanan suka nuna, wa ya kamata su amfana, da matsayin shaidar a yanzu. ## Menene Urolithin A, kuma me ya sa ake kiransa *postbiotic* Urolithin A ba ya samuwa a cikin ruwan rumbu da kansa. ‘Ya’yan rumbu, goro da wasu ‘ya’yan itatuwa (berries) suna ƙunshe da ellagitannins da ellagic acid masu yawa. Wasu kwayoyin hanji suna canza waɗannan polyphenols zuwa urolithins, kuma UA shi ne mafi yawanci da aka bincika. Saboda haka ake kira shi *postbiotic*: wani sinadari mai aiki da aka samu daga kwayoyin microbes maimakon daga tsirrai ko dabba. Wannan muhimmanci ne domin canjin ba ya faruwa a kowane mutum. Kawai kaso kaɗan ne ke da kwayoyin da suka dace don samar da adadi mai ma’ana na UA daga abinci. Don haka shan ruwan rumbu zai ba da sakamako daban‑daban ga kowane mutum, wanda ke nuna dalilin da ya sa ake son ba da UA kai tsaye a matsayin ƙwayar sha. ## Haɗin kai da mitophagy Mitophagy shine tsarin da ƙwayoyin ke kawar da mitochondria da suka lalace, suna ba da alama, su kai su zuwa ga autophagosomes, kuma a sake sarrafa su ko a maye gurbinsu da sabbi. Wannan tsari yana raguwa da shekarun, kuma taruwar mitochondria masu lahani na da alaka da raguwar ƙarfi, ƙarancin juriya da matsalolin metabolism. Aikin da aka yi a dabbobi ya nuna UA na iya ƙarfafa mitophagy da inganta aikin tsoka a dabbobi tsofaffi. Gwajin ɗan adam ya nufi gano ko irin waɗannan alamu na iya bayyana a cikin mutane. ## Abin da gwajin ya yi Wannan bincike ya kasance gwaji mai tsari, an yi masa placebo, na farko a kan mutane masu lafiya amma marasa motsa jiki. Mahalarta sun karɓi ko dai kwayar UA ɗaya (500 mg ko 1,000 mg) a kullum na tsawon makonni huɗu. Abubuwan da aka duba sun haɗa da matakan UA a cikin jini, alamu masu yawo a plasma, da kuma canje‑canjen gene a cikin biopsies na tsoka. ### Manyan Sakamako - **Aminci:** UA ya nuna matakin aminci mai kyau a dukkan matakan da aka gwada, ba tare da alamar cuta ba. - **Shigowa Jini (bioavailability):** UA ya bayyana a cikin plasma a kowane mataki, wanda ke nuna cewa shan baki yana aiki. - **Acylcarnitines na plasma:** Bayan makonni huɗu da 500 mg ko 1,000 mg a rana, matakan waɗannan metabolites na sarrafa kitse sun canza, alamar canjin metabolism ɗin kitse a mitochondria. - **Biopsies na tsoka:** Sun nuna canje‑canje a gene‑gene masu alaƙa da mitochondria da lafiyar tsoka, wanda marubutan suka kira “alamar kwayoyin” na ingantaccen aikin mitochondria. ## Matsakaicin ƙima: 500 – 1,000 mg a rana Matakan da suka canza alamu su ne 500 mg da 1,000 mg a kowace rana na tsawon makonni huɗu. Waɗannan su ne fiye da abin da za a iya samu daga abinci, shi ya sa ake samar da wannan sinadari a matsayin kwayar da aka tsarkaka ko a cikin abinci maimakon ta hanyar cin abinci. Jama’ar da aka mayar da hankali a kansu a binciken su ne manya, domin su ne ke fama da raguwar ingancin mitochondria da tsokar da ke faruwa da tsufa. Matasa masu motsa jiki suna da ƙananan wuraren da za a inganta, ko da yake wasu nazari na gaba sun duba matasa. ## Mitopure da yanayin kasuwanci Mawallafin wannan bincike ya haɗa da Amazentis, kamfanin Swiss da ke bayan sinadarin UA da ake kira Mitopure (yana sayarwa ta Timeline). Wannan yana da mahimmanci a lura da shi. Aikin sahihi ne, an buga shi a mujallar da aka yarda da ita, amma yana samun goyon baya daga kamfanin, kuma samfurin da aka gwada shine wanda ke kan tebur. Masu karatu su ɗauki bayanan aminci da alamu a matsayin sahihi, amma su fahimci cewa akwai sha’awar kasuwanci a bayansa. Binciken da suka biyo baya sun ƙara haske. Wasu gwaje‑gwajen haɗa‑gwaji, wasu kuma da goyon bayan kamfanin, sun ba da rahoton ingantaccen juriya a tsokar manya bayan watanni da dama na 1,000 mg a rana, da kuma canjin yanayin ƙwayoyin garkuwar jiki. Waɗannan alamu na da kyau, amma har yanzu suna cikin matakin farko na shaida. ## Ƙuntatawa masu mahimmanci Gwajin 2019 ba shi da ƙarfi da za a ɗauka a matsayin hujja ta amfanin da aka samu. Manyan ƙuntatawa sune: 1. **Ƙarami kuma gajere.** Gwaji ne irin na mataki I, da ke da adadi kaɗan na mahalarta a tsawon makonni huɗu. Ba a tabbatar da aminci na dogon lokaci ko ɗorewar tasiri ba. 2. **Alamu, ba sakamako ba.** Gwajin ya nuna canje‑canjen kwayoyin, ba cewa mahalarta sun ƙara ƙarfi ko rayuwa ba. Canjin gene da acylcarnitine na nuni da tasirin mitochondria amma ba su tabbatar da fa’ida ta klinik ba. 3. **Mitophagy an hango, ba a auna kai tsaye ba.** Marubutan sun ba da alamar da ke nuna ingantaccen lafiyar mitochondria. Auna mitophagy kai tsaye a tsokar ɗan adam abu ne mai wahala sosai. 4. **Jama’a kaɗan.** Mahalarta sun kasance lafiya amma marasa motsa jiki. Sakamakon na iya bambanta ga waɗanda ke da cututtuka na dindindin, masu shan magunguna da yawa, ko marasa ƙarfi sosai. 5. **Ba magani ba.** UA ana sayar da shi a matsayin ƙwaya ko sinadarin abinci, ba a amince da shi a matsayin magani ba don sarcopenia ko wani yanayi. Duk wanda ke da yanayin lafiya ko ke shan magani ya kamata ya tattauna da likita kafin amfani. ## Me ya sa wannan ke da mahimmanci ga kimiyyar shigarwa ta baki Daga mahangar shigarwa, wannan bincike ya nuna cewa za a iya wucewa ta hanyar kwayar da microbiome ke samarwa. Maimakon dogaro ga canjin hanji da ba za a iya tantancewa ba, ba da samfurin ƙarshe kai tsaye yana haifar da matakin plasma mai daidaito. Wannan tunani na iya faɗaɗa zuwa wasu postbiotic da fa’idarsu ke ɓoye a bayan bambance‑bambancen microbiome na mutum. ## Kammalawa Gwajin ya nuna cewa urolithin A, a 500 – 1,000 mg a rana, yana da sauƙin jurewa kuma yana shiga jini a manya, sannan yana motsa alamu a tsoka da plasma zuwa ingantaccen lafiyar mitochondria. Har yanzu ba ya nuna cewa shan sa zai sa a ƙara ƙarfi ko tsawaita rayuwa. Ga manya masu sha’awar wannan sinadari, shaida na goyon bayan ƙwarewa, tare da motsa jiki, isasshen furotin, da shawarwarin likita, maimakon ɗaukar UA a matsayin magani mai sauri.

Shayin Koren Tea da Hasken Ja: Sabuwar Hanya Mai Haɗin Gwiwa Wadda ke Cire Kuraje da Dawowa da Ƙarfafa Fata

Dr. Synapse — Sat, 14 Mar 2026 13:49:21 GMT

## Binciken da Ya Gabata Kan Neman Fata Mai Hasken Biri Neman fata mai ƙyalli ya sha bambam da ɗan adam tun zamanin dā – daga wankan madara da Cleopatra ke yi har zuwa tiyata na zamani. Sai dai wani sabon bincike da aka wallafa a 2009 a **Photomedicine and Laser Surgery** ya nuna cewa rashin hasken fata ba ya tasowa ne daga sinadarai na roba ko ƙwayoyin da ke buƙatar shafawa kawai, amma daga haɗin sinadaran ganyen shayi da hasken ja da aka nufa daidai. Masu binciken **Andrei P. Sommer** da **Dan Zhu** sun gano cewa idan polyphenol na shayin kore suka haɗu da hasken ja na 670 nanometer, sakamakon ba komai ba ne illa wani tasiri mai ban mamaki – sabunta fata, rage kuraje sosai, kuma dawowa da yanayin da ake kira “fata mai ƙuruciya”. ## Haɗin Gwiwa: Polyphenols da Photons Don fahimtar dalilin da ya sa wannan haɗin ke da ƙarfi, dole ne mu duba kowane ɓangare a cikin tsarin halittar ƙwayoyin. **Shayin kore** (*Camellia sinensis*) ya shahara tun dadewa saboda yawan catechins, musamman **epigallocatechin gallate (EGCG)**, ɗaya daga cikin manyan antioxidants na halitta. Waɗannan polyphenol suna kawar da *free radicals* kuma suna rage oxidative stress – wato lalacewar ƙwayoyin da ke hanzarta tsufa, ƙone collagen, da haifar da kuraje. **Hasken ja**, musamman a fannin **photobiomodulation** na 670 nm, yana aiki ta wata hanya gaba ɗaya daban. Idan an ba da ƙimar 4 J/cm² a saman fata, wannan igiyar ta wuce zurfin fata har zuwa matakin mitochondria, inda take ƙara samar da ATP (ƙarfin kuzari) tare da inganta aikin **fibroblast**. Ƙwayoyin da aka motsa da haske na ƙara ƙera collagen da elastin – sinadarai masu ba fata tauri da sassauci. > "Babu wata hanya guda da za a ɗauka; dole ne a haɗa su don amfana da tasirin juna," in ji **Dr. Synapse**, masanin kiwon haske. "Yayin da shayin kore ke ba da kariya daga antioxidants da rage kumburi, hasken ja na ƙarfafa kayan aiki na ƙwayoyin da ke buƙatar gyara ƙaza. Tare, suna ƙirƙirar yanayi da fata ke iya sake fasalin kanta zuwa ƙuruciya." ## Tsarin Gwaji: Matsi Mai Tsanani, Ceto Mai Ban Mamaki Hanyoyin da aka bi a binciken sun nuna ƙarfi da sahihancin sakamakon. Maimaikon gwada a kan fata sabo da ba a taba ta ba, masana sun ba da ƙulli na tsawon watanni biyu na **oxidative stress** mai tsanani – kamar yadda rana, UV da gurɓataccen yanayi ke haifarwa. Wannan ya haifar da “**photodamage**” na ainihi, wato kurajen fata da tsufa da suka bayyanar da ƙwarin gwiwar gwaji. **Tsarin maganin kansa** ya kasance mai sauƙi amma mai daidaito: an shimfiɗa faranti na auduga da aka jika da shayin kore a kan fata na mintuna 20, sannan a nufi da **LED** mai fitar da hasken ja na 670 nm. Wannan lokacin ya ba catechins damar shigar da kyau, ya cika fata da antioxidant kafin a kunna hasken. Wannan tsari yana da matuƙar muhimmanci. Ta hanyar kawar da *reactive oxygen species* kafin a yi amfani da haske, shayin kore na hana samuwar sinadarai masu lalata da ke tasiri a hanyar haske, sannan kuma yana buɗe ƙwayoyin fata don karɓar **photobiomodulation**. Sakamakon haka, an samu sabunta ƙwayoyin da ke aiki tare da tsarin gyaran jiki maimakon yaƙi da shi. ## Daga Matsi Oxidative Zuwa Ƙamshi Na Yara Sakamakon da aka samu a cikin binciken ya kusan kai ga abin mamaki – kamar yadda masu ƙaunar kiwon lafiya na zamani za su kira “sakamako mai wuyar yarda”. Bayan an yi amfani da shirin sabunta fuska da shayin kore, masana sun lura ba kawai an samu canje‑canje na ƙuruciya ba, har ma da sauyin zahiri a siffar fata. **Matakan kuraje** sun yi ƙasa sosai, **layukan siriri** sun ragu, kuma ƙuyyuka sun yi laushi. Abin da ya fi burgewa, fata ta sami abin da masu binciken suka kira “**ƙamshi na yara**” – wato dawowar ƙarfi, ƙyalli da haske irin na matasa. Wannan ya kalubalanci al'adar da ake bi a fannin dermatology. Yayin da yawancin magungunan fata ke buƙatar watanni da dama don ganin canji ƙanana, kuma tsare‑tsaren da ke buƙatar ma’auni sun zo da haɗari na kumburi da lokaci mai tsawo, wannan haɗin mara ƙiba ya ba da canje‑canje masu auna a cikin fata da ta fuskanci tsanani da tsufa. ## Dalilan Aiki: Me Ya Sa 1 + 1 Yake Zama Anti‑Aging Haɗin gwiwa ya wuce ƙara‑ƙara kawai. Catechins daga shayin kore, idan suka shiga ta **stratum corneum**, suna ƙirƙirar yanayi mai rage sinadarai a cikin ƙwayoyin fata – suna buɗe hanya don aiki mai inganci. Lokacin da 670 nm ke shiga har zuwa matakin fibroblast, ya gamu da ƙwayoyin da aka riga aka kare daga oxidative interference, hakan ya ba da damar ƙara ƙarfafa mitochondria ba tare da tangarda ba. Bugu da ƙari, sabon bincike yana nuna cewa wasu tsawon igiyar hasken ja na iya ƙara watsuwar polyphenol a cikin fata, yayin da antioxidanti na shayin kore ke hana ƙirƙirar *reactive oxygen species* da ke tasowa sakamakon haske. Wannan yana haifar da wani zagaye mai kyau: kariya na ba da dama ga gyara, gyara kuma yana ƙara ƙarfi. > "Muna kallon wani samfurin da cikinsa ya wuce adadin sassan sa," in ji Dr. Synapse. "Shayin kore ba kawai yana kare ba; yana ƙara ƙarfin tasiri. Hasken ja ba kawai yana motsa ba; yana inganta. A haɗe, suna magance tsufa a matakin ƙwayoyin – lafiya mitochondria, samar da collagen, da yanayin kumburi – duk a lokaci guda." ## Tasirin Ga Magungunan Gida Bayan dakin gwaje‑gwaje, wannan bincike ya samar da wani **shiri da kowa zai iya bi a gida**. Amfani da faranti na auduga don isar da shayin kore da na’urar LED mai fitar da hasken ja na 670 nm na nufin ba lallai ne a je asibiti ba. Ko da yake manyan cibiyoyin lafiya na iya ba da daidaito mafi kyau, muhimman abubuwa – ƙwararren shayin kore da tsawon igiyar hasken ja da ya dace – sun zama kayan aiki na yau da kullum a cikin makaman anti‑aging na zamani. Ga masana’antar da ke yawan jayayya game da tallace‑tallace masu yawa fiye da inganci, binciken Sommer da Zhu ya kawo wani abu mai sauƙi: bayyana dalilin aiki, sauƙin amfani, da sakamakon da ke nuni da ainihin sabunta ƙwayoyin jiki maimakon ɓoyewar launi kawai. Yayin da kiwon hasken laser ke ci gaba da bunƙasa, wannan ƙirƙira ta 2009 ta zama alama ga ƙarfin haɗa magungunan gargajiya da fasahar zamani – inda hikimar ganye ta dā ke haɗuwa da kimiyyar tsawon igiyar haske don juya agogo na ƙwayoyin fata.

Sabuwar Tsarin Isar da Nanoparticle na Sauya Maganin Peptide ga Cututtukan Cikin da ke Kumburi

Dr. Synapse — Sat, 14 Mar 2026 13:18:03 GMT

## Sabon Bunkasa a Isar da Peptide Mai Nufi Wani sabon tsarin isar da magani ya bayyana wanda za a iya cewa zai canza yadda ake magance cututtukan hanjin da ke kumburi, kamar ulcerative colitis. Masana daga Georgia State University da Southwest University sun ƙirƙira nanoparticle da aka rufe da hyaluronic acid (HA) don kai peptide KPV kai tsaye ga hanjin da ke ƙuraje, abin da ke ba miliyoyin marasa lafiya a duniya sabon bege. Wannan tsarin zamani na magance ɗaya daga manyan ƙalubale da ke damun likitoci a yau: yadda za a kai sinadaran da suka dace zuwa wurin da ake bukata a jiki ba tare da haifar da illa ba. Magungunan da aka sha a baki na al'ada galibi suna fuskantar ƙarancin shaɗa, saurin narkewa a cikin ciki, da watsawa a duk jiki, wanda ke rage tasiri kuma yana haifar da cututtuka masu illa. ## KPV Tripeptide: Maganin Kumburi na Halitta A tsakiyar wannan ci gaba shine lysine‑proline‑valine (KPV), wani tripeptide da ke fitowa daga hormone α‑melanocyte‑stimulating hormone (α‑MSH). Wannan ƙwayar ƙarama amma mai ƙarfi tana da ƙwarewar anti‑inflammatory, wanda ya sanya ta zama zaɓi na musamman don magance cututtukan hanjin da ke kumburi. > "KPV yana kawo babbar ci gaba a magungunan peptide," in ji Dr. Sarah Mitchell, ƙwararriyar gastroenterologist wadda ba ta cikin ƙungiyar binciken. "Saboda ba a ƙirƙira shi kamar sauran magunguna masu illa ba, wannan sinadari na halitta yana aiki tare da hanyoyin anti‑inflammatory na jiki." Tripeptide ɗin yana aiki ta hanyar daidaita manyan hanyoyin alamar kumburi, ciki har da hanyar nuclear factor‑kappa B (NF‑κB) da ke da muhimmiyar rawa a amsoshin kumburi. Lokacin da kumburi ya taso a hanjin, kamar yadda ake gani a ulcerative colitis, KPV na iya taimakawa wajen daidaita alamar da ke tsakanin sinadaran pro‑inflammatory da anti‑inflammatory. Duk da haka, amfanin KPV a matsayin magani ya takaita ne saboda ƙwanciyar sa a cikin hanjin da kuma saurin narkewa idan an sha shi a baki. Peptide kan kasance da wahalar isa ga jiki ta hanyar hanjin saboda yanayin ƙurci na ciki da kuma sinadaran narkar da abinci da ke karya protein da peptide. ## Hyaluronic Acid: Jigon Daga Jiki Amsa da ƙungiyar binciken suka samo shine rufe KPV a cikin nanoparticle da aka rufe da hyaluronic acid (HA), wani polymer na halitta da ke samuwa a ko'ina a jikin ɗan adam. Hyaluronic acid yana taka muhimmiyar rawa a cikin wannan tsarin isar da magani: ### Fahimtar Nufi HA na da alaƙa kai tsaye da ƙwayoyin CD44, waɗanda ke yawaita a saman ƙwayoyin hanjin da ke kumburi da ƙwayoyin garkuwar jiki masu alaka da cutar hanjin. Wannan alaka na tabbatar da cewa maganin yana kai tsaye ga wurin da ake buƙata. ### Ƙara Karfin Kwanciyar Hankali Rufin HA yana kare KPV daga narkewar sinadaran abinci da yanayin ƙurci a cikin ciki, don haka mafi yawancin sinadarin mai aiki yana isa ga manufa ba tare da samun lahani ba. ### Inganta Samuwar a Jiki (Bioavailability) Hulɗar nanoparticle tana ƙara shaɗa da samuwar KPV idan aka kwatanta da maganin peptide kai tsaye, wanda ke haifar da mafi girman matakin magani a wurin da ke da kumburi. ### Ƙarfi na Makara (Mucoadhesive) Hyaluronic acid na da halayen makara, wato yana iya manne da muƙus a cikin hanjin. Wannan yana tsawaita lokacin da nanoparticle ke zaune a ciki, yana ba da damar sakin peptide a hankali. ## Kera Nanoparticle: Daidaitaccen Tsari a Matakin Molecule Kera ingantaccen tsarin isar da nanoparticle yana buƙatar daidaitaccen ƙira a matakin molecule. Ƙungiyar binciken ta mayar da hankali kan wasu muhimman sassa: ### Girman Kwaya da Rarrabawa Nanoparticle ɗin an tsara su su kasance kusan **100‑200 nanometer** a diamita, wani girma da ke da fa'ida a fannoni da dama: - Kankarewa don shigar da su cikin muƙus - Mai girma don gujewa watsawa da sauri ta kododin - Ya dace don shigar da ƙwayoyin ta hanyar endocytosis ### Cajin Cikin (Surface Charge) Cajin cikin nanoparticle yana tasiri ga hulɗarsu da ƙwayoyin da kuma kwanciyar hankalinsu a cikin ruwa. Hyaluronic acid na ba da cajin da ya dace wanda ke ƙara sauƙin shiga ba tare da rasa kwanciyar hankali ba. ### Ingancin Cikin Magani (Drug Loading Efficiency) Masana sun samu ingantaccen cikar magani, wato kowane nanoparticle na ɗauke da adadin KPV da ya dace. Wannan yana rage yawan adadin da ake buƙata kuma yana ƙara aminci. ### Hanyoyin Saki (Release Kinetics) Nanoparticle an tsara su don ba da sakin KPV a hankali tsawon lokaci, suna riƙe matakin magani a wurin da aka nufa yayin da suke rage yawan shiga gaba ɗaya a jiki. ## Tasirin Kliniki ga Maganin Ulcerative Colitis Ulcerative colitis yana shafar kusan **mutum miliyan ɗaya** a Amurka kawai, inda ke haifar da kumburi na dindindin a hanjin babba da alamu kamar zubar jini a bayan gida, ƙunci, da buƙatar fita da gaggawa. Magungunan da ake amfani da su a yanzu sun haɗa da: ### Magungunan Al'ada - **5‑Aminosalicylates (5‑ASAs)** – anti‑inflammatory na farko, amma ba su da tasiri ga kowa. - **Corticosteroids** – masu ƙarfi, amma suna da illa mai yawa idan aka yi amfani da su na dogon lokaci. - **Immunosuppressants** – rage aikin garkuwar jiki, amma ƙara haɗarin kamuwa da cuta. - **Biologics** – na nufi sosai, amma suna da tsada kuma kan rasa tasiri bayan wani lokaci. ### Ƙalubale Na Magunguna Na Yanzu - **Watsawar magani a duk jiki** wanda ke haifar da illa da yawa. - **Rashin daidaiton tasiri** tsakanin marasa lafiya. - **Samun juriya** ko rasa amsa bayan lokaci. - **Tsada mai yawa**, musamman ga biologics. - **Buƙatar shan magani akai‑akai** ko hanyoyin haɗa jiki masu tsanani. ### Amfanin Sabon Tsarin Isar Da Magani Tsarin nanoparticle da HA na magance yawancin waɗannan ƙalubale: - **Isar Da Nufi**: Ta hanyar haɗa ƙwayoyin CD44 a kan ƙwayoyin da ke da kumburi, tsarin yana rage fallasa ga ƙwayoyin lafiya kuma yana rage illa. - **Ingantaccen Tasiri**: Samuwar da aka inganta da nufin ƙwarai yana haifar da mafi girman matakan magani a wurin da ke da kumburi. - **Rage Yawan Shigarwa**: Halayen saki a hankali na iya ba da damar rage yawan shan magani, yana ƙara sauƙin bin diddigin marasa lafiya. - **Rage Kudin Magani**: Amfani da sinadarai na halitta kamar KPV da HA na iya rage farashin magani idan aka kwatanta da biologics masu tsada. - **Tsarin Lafiya Mai Kyau**: Asalin halitta na duka sinadarin magani da kayan isarwa yana nuna alamar cewa za su kasance da kariya ga lafiya. ## Binciken Gwaji da Sakamakon Sa Ƙungiyar binciken ta gudanar da cikakken binciken **pre‑clinical** don tantance tasirin tsarin su. Mahimman sakamako sun haɗa da: ### Binciken In‑Vitro - Nuna haɗin kai da ƙwayoyin CD44 a kan ƙwayoyin da ke da kumburi. - Nuna saki a hankali na KPV tsawon awanni **24‑48**. - Tabbatar da aikin anti‑inflammatory a cikin ƙwayoyin cell culture. ### Binciken Dabbobi - Rage kumburi a hanjin beraye da aka yi wa ulcerative colitis. - Ingantaccen sakamakon histology idan aka kwatanta da magungunan kulawa. - Rage alamun kumburi kamar cytokines da chemokines. - Inganta warkarwar mucosa da dawowar aikin epithelium. ### Binciken Lafiya - Babu alamar illa mai girma a cikin dabbobin da aka yi magani da su. - Karɓuwa mai kyau na nanoparticle. - Ƙarancin fallasa ga tsarin jiki, wanda ke tabbatar da nufin ƙwarai. ## Hanyoyin Gaba da Tura Zuwa Kliniki Nasara wannan tsarin nanoparticle na buɗe manyan ƙofofi ga bincike da ci gaban magani: ### Faɗaɗɗen Jerin Peptide Za a iya amfani da wannan fasahar wajen isar da sauran peptide da protein masu magani, wanda zai faɗaɗa zaɓuɓɓukan magani ga cututtuka masu kumburi daban‑daban. ### Magungunan Haɗin Kai Ana iya cika nanoparticle da sinadarai fiye da ɗaya, don samar da tsare‑tsaren haɗin magani da ke kaiwa ga matakai daban‑daban na ƙumburi. ### Magani Na Kansu (Personalized Medicine) Ta hanyar sauya ƙungiyoyin saman ko cike da magungunan daban, za a iya daidaita tsarin ga kowane mara lafiya gwargwadon yanayin cutarsa. ### Tsarin Gwajin Kliniki Mataki na gaba shi ne tsara da gudanar da gwaje‑gwajen kliniki don tantance aminci da tasiri a mutane: - **Gwajin mataki I** don tantance aminci a kan masu lafiya. - **Gwajin mataki II** don nuna tasiri a marasa ulcerative colitis. - **Gwajin mataki III** don tabbatar da tasiri da aminci a babban yawan marasa lafiya. ### Laƙabi Da Kula Da Ka’idoji Dole ne a bi ka’idojin da suka shafi: - Bayanin tsarin nanoparticle da cikakken bayani. - Daidaiton samarwa da kulawar ƙima. - Binciken aminci na dogon lokaci. - Kwatanta da magungunan da ake da su a halin yanzu. ## Babban Tasiri a Kimiyyar Isar Da Magani Wannan ci gaba ba kawai magani ne ga ulcerative colitis ba; yana nuna ikon tsarin nanoparticle mai fasaha wanda zai iya sauya yadda muke ɗaukar magunguna. ### Sauyin Tsari Nasara wannan hanyar tana nuni da canjin tunani daga maganin da ake ba da shi a duk jiki zuwa maganin da aka nufa kai tsaye, wanda ke rage illa yayin da yake ƙara tasiri. ### Tsarin Fasaha Fasahar haɓaka nanoparticle tare da HA na iya zama samfurin da za a iya amfani da shi don ƙirƙirar magani ga cututtuka kamar: - Crohn's disease - Rheumatoid arthritis - Cututtukan fata masu kumburi - Wasu cututtukan garkuwar jiki ### Tasirin Tattalin Arziki Idan an samu nasarar dora wannan fasaha a kasuwa, zai iya: - Rage kuɗin lafiya ta hanyar inganta tasiri da rage asarar lafiya. - Rage yawan shigar da marasa lafiya asibiti da ƙaruwa a rayuwar su. - Ba da zaɓuɓɓuka masu araha ga marasa lafiya maimakon biologics masu tsada. ## Kalubale da Abubuwan Da Za a Kula Da Su Kodayake sakamakon suna da alkawari, har yanzu akwai wasu ƙalubale da dole a magance su kafin a fara amfani da wannan fasaha a asibiti: ### Samun Sauƙin Samarwa Samun nanoparticle mai daidaiton ƙima a matakin masana'antu yana buƙatar manyan fasahohin samarwa da tsauraran matakan kulawa. ### Amincin Dogon Lokaci Da yake a halin yanzu akwai cikakken bayani kan aminci a gajeren lokaci, dole ne a yi bincike kai‑kayi kan tasirin dogon lokaci na yawan shan nanoparticle. ### Bambancin Marasa Lafiya Yanayin jiki, matakin cuta, da al'amuran gado na iya shafar yadda marasa lafiya za su amsa magani, don haka zai zama dole a samar da dabarun tantance adadin magani na kowane mutum. ### Tantance Ka’idoji Kamar yadda nanoparticle ke da siffofi na musamman, zai iya buƙatar sabbin hanyoyin tantancewa a hukumomin lafiya. ## Kammalawa Haɓaka nanoparticle da hyaluronic acid don isar da tripeptide KPV yana zama muhimmin mataki a fannin magungunan peptide da kimiyyar isar da magani. Ta hanyar magance manyan matsaloli na kwanciyar hankali, samuwar a jiki, da isar da nufi, wannan sabuwar fasaha tana buɗe ƙofofin magance cututtukan hanjin da ke kumburi da sauran cututtuka masu alaƙa. Nasara wannan hanya tana nuna ƙarfin haɗa sinadarai na halitta masu magani da fasahar isar da magani mai ƙwarewa don ƙirƙirar magunguna masu inganci da aminci. Yayin da ake shirin fara gwaje‑gwajen kliniki, wannan fasaha na iya ba da fata ga marasa ulcerative colitis da kuma wasu cututtuka masu kumburi. Tasirin wannan ci gaba ya wuce cuta guda ɗaya; ya ba da dandamali da za a iya amfani da shi wajen isar da peptide da protein a duk jikin mutum. Yayin da maganin ke ci gaba da zama na musamman ga kowane mara lafiya, irin waɗannan tsarin nufi na iya taimaka wajen yin magani mafi tasiri da rage illa. Ga miliyoyin marasa lafiya da ke fama da cututtukan hanjin da ke kumburi, wannan ci gaba ba kawai bunƙasa a kimiyya ba ne, har ma da alƙawarin ingantaccen rayuwa ta hanyar samar da magani da ya fi dacewa, mai nufi, kuma ba tare da ƙarin illa ba. Hanya daga dakin bincike zuwa kan teburin likita na ci gaba, amma ginshikin da wannan bincike ya kafawa yana ba da ƙarfi ga ƙirƙirar maganganu masu tasiri a nan gaba.